corporate responsibility report corporate responsibility report content download corporate responsibility report overview research practice corporate responsibility gsk patient need emerge technology message ceo cloning technology stem cell research responsibility matter gsk genetic research benchmarking animal research datum summary human tissue research principle mantaine confidentiality research participant corporate responsibility governance medical governance stakeholder engagement conduct clinical trial engagement planning approval audit assurance work healthcare professional risk management inform consent report posttrial treatment clinical trial develop world access medicine clinical trial child train auditing approach public disclosure clinical research hivaid viiv healthcare patient safety research development patient safety governance framework open innovation collecting report safety datum pipeline update collaboration patient safety vaccine flexible pricing ethical conduct develop country middleincome country key policy develop country privacy portfolio expansion acquisition diligence advocacy marketing product future plan grant donation healthcare organisation payment healthcare professional directtoconsumer advertising training awareness lead example training awareness performance monitor compliance monitor sale marketing reporting channel monitor compliance performance corporate responsibility report content supply chain people supplier standard inclusion diversity human right clause employee engagement choose supplier development training monitoring engagement develop leader supply chain performance reward recognition supplier diversity restructuring sustainable source health safety wellbee security supply health safety culture counterfeiting address key health safety risk health wellbeing programme environmental sustainability health safety performance evironmental sustainability strategy human right manage environmental sustainability plan target employee stakeholder engagement supplier awareness recognition community lifecycle assessment supply chain society climate change energy activity embargo country propellant facility public policy transport travel patient advocacy climate change energy performance water approach external affair environmental stewardship public policy activity potential hazard advocacy healthcare reform mass efficiency advocacy healthcare disease prevention waste advocacy research practice packaging advocacy patient safety emission air advocacy intellectual property right datum audit assurance political contribution lobbying expenditure datum summary patient advocacy internal audit transparency external assurance understand patient gsk response assurance advocacy work communitie global programme local programme community investment plan target corporate responsibility report home overview overview approach corporate responsibility find issue cover online report corporate responsibility gsk strong value central business success place great importance achieve achieve responsible business mean connect business decision society healthcare need operating way reflect value commit transparency respect people demonstrate high integrity conduct patient focus value underpin principle outline standard gsk commit corporate responsibility committee nonexecutive director provide highlevel guidance approach accountability responsible management gsk sit ceo member corporate executive team know research development manufacture sale product raise ethical issue aim open tackle understand important communicate stakeholder seek understand view transparent setback experience progress read approach gsk section access medicine provide access healthcare societys press social challenge want increase access medicine vaccine patient irrespective live ability pay believe right thing know contribute business success strive meet societys healthcare needs build trust business helps safeguard licence operate long term access strategy focus area difference core business activity skill resource particular mean initiative improve affordability conduct encourage investment develop world achieve pursue flexible pricing strategy refocus activity reflect need develop country seek innovative partnership try reach people access medicine vaccine read access medicine research practice investment new medicine vaccine core business focus effort area great patient need advance science offer good opportunity discover new medicine generate commercial return aim new treatment provide value currently available treatment patient payer patient safety priority evaluate benefit risk medicine stage research new product approve sale commit transparency disclosing result clinical research essential meet consistently high quality ethical standard part business market operate enable protect safety clinical trial participant patient use medicine obtain regulatory approval new medicine vaccine maintain trust patient healthcare professional recognise biomedical research raise ethical concern include related animal research use emerge technology stem cell research clinical trial standard aim address open approach regularly engage stakeholder issue read research practice ethical conduct build strong ethical culture gsk develop robust policy recruit right people equip information need ethical decision put patient core principle ethical healthcare company employee understand stand policy procedure underpin approach comply code conduct set fundamental standard follow employee guide business conduct help employee ethical decision emphasise company value internal compliance system design support ethical behaviour decision make employee identify address breach code read ethical conduct supply chain patient depend uninterrupted supply medicine manufacture high quality standard effective responsibly manage supply distribution system essential high quality product right place right time meet patient need protect complex supply distribution chain disruption ensure product store correctly handle carefully distribution destination aim source company maintain high standard quality labour environment protect employee human right standard explain party code conduct eh human right clause supplier contract approach include regular supplier performance review audits training measure place detect prevent counterfeiting product endanger patient health lead loss revenue read supply chain environmental sustainability integrate environmental sustainability business responsibility contribute meeting environmental challenge opportunity focus carbon dioxide emission contribute climate change water use environmental stewardship cover use material generation waste conduct life cycle assessment key product identify reduce environmental footprint set ambitious environmental sustainability goal reduce impact operation value chain raw material product disposal longterm goal value chain carbon neutral short term set demand target reduce carbon footprint water use read environmental sustainability people employ people country worldwide want gsk know great place work employer choice talented people background employment practice help create right workplace culture gsk employee feel value respect empower inspire important element approach include commitment inclusion diversity support flexible working practice regular twoway communication employee respectful fair treatment employee change company leader set tone employee role play maintain culture ask adopt company value behaviour work return aim provide great employee experience gsk include highquality training development opportunitie competitive reward package keep employee contractor healthy safe priority rigorous management system reduce risk harm people working gsk help remain healthy productive energised read people human right work hard protect human right sphere influence include employee supplier local community society broadly direct control human right operation commit uphold universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization signatory global compact voluntary global standard human right labour environment anticorruption maintain high standard human right benefit business help good employee support relationship community near site ensure supplier contract run smoothly provide reliable supply highquality product protect reputation read human right public policy patient advocacy public policy activity work legislation policy encourage scientific innovation balance interest business stakeholder work patient group professional group help member voice healthcare debate believe conduct advocacy work responsibly valuable contribution debate issue impact business particularly relate research development use pharmaceutical healthcare aim increase stakeholder trust gsk transparent lobby public policy work address concern stakeholder pharmaceutical industry exercise inappropriate influence government publish key element annual public policy activity website report trade association membership federal institution lobbying expenditure publish information work patient group include detail funding provide gsk political contribution read public policy patient advocacy work community invest community partnership programme seek improve access medicine healthcare world create opportunity education economic development aim real difference community work partner find innovative solution healthcare challenge programme include global initiative design tackle disease develop world multiple country support local programme tailor specific need challenge different market support include donation time money expertise medicine encourage employee involve volunteer programme benefit organisation charity support contribute employee personal development read work community corporate responsibility report home gsk introduction gsk strong value central business success place great importance achieve achieve responsible business mean operating way reflect value include treat stakeholder respect connect business decision society healthcare need seek minimise negative impact maximise benefit business approach guide corporate responsibility principle mission value mission improve quality human life enable people feel well live long value underpin commit transparency respect people demonstrate high integrity conduct patient focus read embed value ethical culture organisation people ethical conduct section medicine vaccine consumer healthcare product improve people life valuable contribution society know research development manufacture sale product raise ethical issue aim open transparent tackle seek understand respond view stakeholder subject establish management process help advance progress principle ensure identify manage responsibility reputational risk business cost disease contribution matter ill health expensive individual society result poverty cause poverty patient mean loss quality life loss earning shorten life expectancy place great burden family instance need care sick relative reduce attendance school work government employer taxpayer mean increase healthcare cost loss workforce productivity disease effect social economic development world poor country research develop medicine vaccine consumer healthcare product real difference patient live important responsibility issue gsk aim improve efficiency focus closely need patient healthcare payer partner accelerate development new treatment enhance research neglect tropical disease increasingly important focus area gsk contribution product limited accessible affordable commit increase access medicine vaccine corporate responsibility report home gsk message ceo message ceo transform gsk competitive efficient company company build strong value deep commitment excellence company employee customer society work proud continue run business responsible way central transformation separate responsible business strategy commitment responsible valuesbase business underlie mean lead value principle transparent work respond need stakeholder especially put patient decisionmake thoughtful communicate compromise ethical standard generate real value patient business build strong culture decision guide value commit transparency respect people demonstrate high integrity conduct patient focus access medicine commit increase access medicine patient irrespective live ability pay embed range flexible pricing model deliver medicine vaccine people need possible right thing contribute business success example cap price patent medicine develop country charge develop country introduce flexible pricing develop country challenge work early stage result initiative far promising indicate price reduction extend access patient provide sustainable return gsk year create specific operating unit dedicate increase access medicine develop country success judge profit contribution increase access medicine believe approach take define gsk company healthcare provider patient trust combine commitment quality ethical business practice help stand business truly commit patient neglect tropical disease continue significant commitment work neglect tropical disease partnership area progress gsk rtss malaria vaccine candidate phase iii trial go vaccine malaria potential save live million children africa commit price rtss responsibly seek ensure price barrier access set price cover cost generate small return reinvest development generation malaria vaccine product disease develop world announce donate albendazole medicine protect schoolage children africa intestinal worms intestinal worm cause ill health schoolage child infection major positive health impact add albendazole donate global alliance eliminate lymphatic filariasis mean donate billion tablet year year significant commitment environmental sustainability strengthen commitment environment set new ambitious target goal reduce environmental impact value chain raw material product disposal carbon neutral achieve reduction nearly greenhouse gas emission hope give good foundation build come year reduce water use exceed annual reduction target operating integrity continue work resolve number longstanding legal matter light case fundamentally change procedure compliance marketing sell farreache policy procedure place guard inappropriate promotion healthcare professional seek ensure breach regulation occur report government truly embe value need willing change work invest resource demonstrate leadership change make year reward sale team example historically sale team reward accord volume prescription area practice common industry new incentive system assess sale representative scientific business knowledge feedback customer region overall performance business unit focus provide information support customer want generate prescription act good interest patient healthcare practitioner true partner deliver good possible care patient view strong value differentiate great company mediocre one live value achieve result good society good gsk report demonstrate continue important exciting change look forward update progress year andrew witty chief executive officer corporate responsibility report home gsk responsibility matter gsk responsibility matter gsk responsible business practice underpin value align principle essential business success help respond concern stakeholder successfully implement business strategy strategy strategy focus priority diversify business deliver product value simplify operation design help respond effectively challenge business environment include loss patent protection unprecedented number product grow demand healthcare payer costeffective healthcare annual report information element responsible business directly relate achievement strategy example effort increase access medicine help create right condition expansion business emerge market responsible business practice help respond societys change expectation today stakeholder expect business play great role tackle world social environmental challenge meet everhigher standard ethical conduct particularly true gsk healthcare company reflect support strategy culture company evolve understand responsive stakeholder need open transparent way operate help build trust company create product real value patient healthcare payer deliver strategy responsibly meet change expectation stakeholder believe effective successful business business case corporate responsibility ultimately believe responsible business good society good gsk help operate efficiently gain trust stakeholder create product patient healthcare payer need foster right condition expansion business operating demonstrate practice ethical support licence operate ability improve people live product build trust gsk product enhance ability attract retain motivate talented people increasingly important few young people major market choose sciencebase career support constructive engagement stakeholder help prevent avoidable conflict identify innovative approach benefit gsk wide society facilitate great access market ability influence healthcare policy improve relationship regulator healthcare payer work government increase access medicine resolve healthcare challenge particularly important help anticipate prepare legislative change remain competitive helps maintain support intellectual property system find innovative way increase access medicine reduce cost increase environmental efficiency efficient use resource key responsibility issue consider follow responsibility issue significant relevant material gsk contribution health research development manufacture sale medicine vaccine consumer healthcare product increase access medicine make product accessible affordable raise ethical standard research development sale marketing environmental impact particularly relate climate change number factor influence materiality assessment include business strategy risk management process stakeholder interest include investor feedback change business operation example type product produce location operate exist propose legislation public opinion medium coverage corporate responsibility report home gsk responsibility matter gsk benchmarke benchmarke gsk receive follow rating benchmarking organisation index organisation access medicine index access medicine foundation riskmetric gsk rank access medicine index second successive time june index assess rdbased pharmaceutical company seven generic company performance seven criterion management influence pricing patenting capability philanthropy gsk rank high seven category read organisation dow jones sustainability index rating gsk continue member dow jones sustainability index cover sustainable company sector gsk award bronze class distinction survey publish organisation ftsegood rating gsk include ftsegood index benchmark company corporate responsibility parameter include environmental sustainability stakeholder relationship human right supply chain labour standard business ethic organisation business community communitymark rating gsk company manufacture company award new communitymark follow independent assessment outstanding community investment company award mark threeyear period monitor ensure continue commitment excellence gsk retain communitymark organisation carbon trust standard rating gsk achieve global certification company report organisation sustainability global reporter benchmark rating report score percent improvement previous year average pharmaceutical company benchmarke sustainability strength identify include comprehensive account gsk strategic priority clear alignment responsibility activity business strategy focus reporting material issue impact strong commitment external engagement collaboration deliver strategic priority transparent account public policy initiative relationship internal strategy area suggest improvement include provide evidence business case activitie development metric target corporate responsibility report home gsk responsibility matter gsk datum summary datum summary corporate responsibility datum summary access medicine metric number combivir epivir tablet ship millions number generic arvs supply licence gsk millions combivir notforprofit price day voluntary licence grant generic manufacturer gsk arvs cumulative total value product donate gsk patient assistance program million cost wholesale price wac research development metric expenditure billion number trial publish gsk clinical study register cumulative total ethical conduct metric number employee complete certification gsk code conduct number contact ethic compliance channel employment metric woman management grade ethnic diversity people colour ethnic diversity ethnic minority reportable injury illness rate hour work environment metric total climate change impact thousand tonne equivalent climate change impact energy operation transport climate change impact patient use inhaler energy operation transport million gigajoule environment metric water use million cubic metre wastewater chemical oxygen demand cod thousand tonne nonhazardous waste dispose thousand tonne hazardous waste dispose thousand tonne volatile organic compound emission thousand tonne community investment metric total community investment expenditure million cost wholesale price wac value albendazole donation million cost wholesale price wac number albendazole tablet donate prevention lymphatic filariasis million reportable injury illness rate hour work datum relate viiv healthcare gsk datum include arvs sell notforprofit discount price include freight delivery cost mdecin san frontires pricing report list average cost generic equivalent restate figure reflect value cost average cost good wholesale acquisition price wac year value donation way believe accurate reflection true cost gsk transparent figure remain wac include contact line manager compliance officer confidential integrity helpline offsite post office box climate change impact calculate equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review factor update datum year appropriate corporate responsibility report home gsk principle principle corporate responsibility principle underpin value identify key responsibility issue provide guidance employee standard gsk commit access medicine continue research develop medicine treat disease develop world find sustainable way improve access medicine disadvantaged people seek partnership support activity read approach access medicine standard ethical conduct expect employee meet high ethical standard aspect business conduct activity honesty integrity adhere principle comply applicable law regulation read ethical conduct research innovation undertaking research innovating explore apply new technology constructively engage stakeholder concern arise ensure product subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulation legal standard applicable research development product read research practice product customer promote product line high ethical medical scientific standard comply applicable law regulation read marketing ethic caring environment operate environmentally responsible manner systematic management environmental impact measurement performance set challenging performance target improve efficiency activity minimise material energy use waste generate aim find opportunity use renewable material recycle waste read environmental sustainability employment practice treat employee respect dignity encourage diversity ensure fair treatment phase employment provide safe healthy work environment support employee perform potential responsibility performance reputation business read employment practice human right commit uphold universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization expect standard supplier contractor business partner work gsk behalf read approach human right leadership advocacy establish challenging standard corporate responsibility appropriate complexity specific need business build external guideline experience share good practice seek influence remain competitive order sustain business read approach public policy patient advocacy engagement stakeholder want understand concern interest corporate responsibility issue engage range stakeholder communicate openly address issue way aim meet need different group allow pursue legitimate business goal read stakeholder engagement community investment positive contribution community operate invest health education programme partnership aim bring sustainable improvement underserve people develop develop world read work community corporate responsibility report home gsk corporate responsibility governance corporate responsibility governance corporate responsibility committee crc nonexecutive director provide highlevel guidance approach ceo member corporate executive team cet accountable responsible management business participate crc meeting committee member sir christopher gent chair stephanie burn james murdoch daniel podolsky committee meet time year review policy progress committee review performance principle annually access medicine standard ethical conduct research innovation employment practice community investment principle discuss year committee report finding board augment engagement stakeholder opinion sophia tickell appoint independent external adviser corporate responsibility committee march sophia cofounder director meteo direct pharma future series aim align well societal shareholder value sit expert review committee access medicine foundation member european healthcare innovation leadership network management corporate responsibility crc review gsk activity number area principle include access medicine access pricing medicine middleincome develop country standard ethical conduct embed ethical value organization research innovation policy use animal research development research integrity transparency governance research conduct external supplier collaborator treatment rare condition disease develop world potential stem cell science regenerative medicine product customer disclosure payment healthcare professional caring environment environmental sustainability strategy management environmental risk manufacture employment practice employment practice include diversity inclusion lead develop employee employee relation include consultation arrangement realignment pay performance strategy management health safety risk manufacture community investment community partnership investment humanitarian donation committee review sign annual performance information publish report website management structure cover diverse range issue believe manage business function relevant subject expert work crossfunctional team representative key business area oversee development implementation communication policy include responsibility element gsk member senior manager direct access corporate executive team small central team coordinate policy development reporting specifically respect communicate socially responsible investor stakeholder measure performance establish metric key performance indicator track performance responsibility issue corporate responsibility report home gsk stakeholder engagement stakeholder engagement stakeholder engagement dialogue enable touch view opinion society operate help identify important issue shape response interest shareholder wide society regular engagement mean well inform emerge current issue change societal expectation provide opportunity voice approach responsibility issue obtain important feedback build trust discussion take place normal course business provide training help manager market communicate local stakeholder approach responsible business transparency way engage stakeholder example provide report stakeholder engagement method healthcare professional hcp sale representative meeting interaction clinical trial engagement professional organisation patient meeting gsk scientist patient focus patient initiative work patient advocacy group market research understand patient need government regulator lobby public policy work advocacy key issue access medicine investor meeting investor responsible investor participation carbon disclosure project employee regular employee survey consultation employee representative change business participation carbon disclosure project local community interaction site level range issue community investment programme specialists environment health safety stakeholder panel multilateral agency engagement access medicine public health nongovernmental organisation engagement issue relate access medicine community investment public policy animal welfare scientific community participation academic collaboration participation scientific debate supplier global regional supplier review meeting meeting diverse supplier peer company pharmaceutical industry organisation meeting joint project pharmaceutical supply chain initiative corporate responsibility report home gsk stakeholder engagement engagement engagement discussion stakeholder focus responsibilityrelated issue example include engagement investor meet investor responsible investment analyst year respond number investor survey analyst attend briefing broad investor relation programme responsibility issue raise investor include governance transparency remuneration audit internal control risk management animal testing welfare clinical trial ethic include trial develop country stem cell biodiversity use genetically modify organism ethic compliance sale marketing code ethical issue healthcare professional payment supplier contract related ethic environment issue bribery act impact gsk operation whistleblowe procedure culture competition policy access medicine access medicine index develop country rare disease pricing issue formation develop country market access operating unit environment environmental performance climate change profile gsk business travel transport emission alternative propellant water pollution treatment management relate process water management pharmaceutical environment renewable raw material environmental impact packaging disposal drug human right human right policy system activity embargo country human capitalemployee restructure training development collective bargaining productrelate question include avandia seroxatpaxil synflorix ingredient gsk product engagement employee important employee know commitment corporate responsibility understand responsibility uptodate progress employee inform connectgsk intranet site spirit internal quarterly magazine article responsibility issue publish spirit cover issue viiv healthcare deliver commitment tackle hiv gsk open innovation strategy increase access medicine launch global strategy inclusion diversity employee volunteer pulse assignment programme distribute copy quarterly edition online version available intranet distribute corporate responsibility highlight spirit magazine directly corporate executive team gsk board senior manager site director communication staff news article icon intranet site guide user directly report read approach embed ethical culture gsk biennial employee survey engage employee environmental issue engagement access medicine engagement issue relate access medicine cover access medicine section hold number formal engagement process subject relate access medicine report detail report corporate responsibility report home gsk audit assurance audit assurance assess aspect responsibility performance internal external assurance process audit assurance department responsibility independently assess sample basis process control place comply law regulation company standard gsk audits focus key business risk area gsk audit function centralised department independent business unit allow function holistic view risk manage company report finding audit risk committee direct reporting line board help ensure significant issue escalate timely manner audit department include approximately audit professional group manufacture internal audit include environment health safety sustainability research development internal audit commercial financial internal audit information technology internal audit audits range duration week simple activity scope limit month audit involve complex highly technical process audit team supplement external expert specific technical skill use guest auditor business issue identify audit team recommend improvement gsk manager develop action plan address cause noncompliance address gap internal control audit assurance department track plan completion report result senior management audit risk committee supplement traditional audit programme strategic risk evaluation sre quantify strategic emerge risk develop appropriate mitigation strategy approach design evaluate area gsk incomplete understanding risk enable development implementation appropriate mitigation plan read assurance internal audit risk management corporate governance section annual report external assurance report environment health safety reporting externally assure sgs independent external assurer assurance process include verification key environment health safety datum site visit telephone call ehs professional review system process collect collate analyse interpret datum read assurance statement assure section report year bureau verita provide assurance ethical conduct section report read respond recommendation report report information access medicine externally assure read response report corporate responsibility report home gsk risk management risk management nonfinancial reputational risk include core risk management process risk oversight compliance council rocc coordinates management significant business risk oversee internal control ensure compliance applicable law regulation gsk policy rocc meet regularly review assess significant risk mitigation plan chair gsk corporate compliance officer include corporate executive team cet member head department internal control risk management assurance audit compliance responsibility cet member responsible establish appropriate risk management structure business unit identify mitigate significant risk business unit review significant risk year include operational risk legal compliance risk risk achievement strategic goal objective ensure significant risk connect change management direction external environment identify business unit corporate function require present risk management compliance approach rocc audit risk committee annually provide balanced assessment status internal control key risk highlight significant compliance issue allocate audit resource ensure sufficient attention pay area high risk significant risk follow significant risk face gsk risk deliver commercially successful product intellectual property protection risk substantial adverse outcome litigation government investigation governmental payer regulatory control risk interruption product supply taxation treasury antibribery corruption risk concentration sale wholesaler global political economic condition environmental liability accounting standard protection electronic information asset alliance acquisition attraction retention implement gsk strategic priority risk factor section annual report provide detail alliance acquisition diligence acquire new business line strategic priority grow diversified global business growth business undermine commitment high quality ethical environmental workplace standard diligence process design identify risk pose new business acquisition include ethical social environmental risk diligence usually manage relevant manager corporate development department conjunction regional business development manager oversight provide head corporate development chief strategy officer depend nature deal technical scientific expert involve work improve skill involve diligence process share good practice business read corporate responsibility report home gsk report reporting report performance annually website commitment open transparent business activity online report include overview section summarise approach key issue cover report useful tool search function glossary term option download report resource download section year publish review provide overview approach performance key responsibility area information corporate responsibility include annual report brand name appear italic report trademark own andor license gsk associate company datum datum relate worldwide operation calendar year state datum environment health safety section independently assure sgs information approach external assurance provide audit assurance section reporting standard use external guideline inform report relevant base report global reporting initiative gri guideline produce gri index element guideline cover report aid comparison company report join global compact provide index report line global compact expectation corporate responsibility report home access medicine introduction access medicine provide access healthcare societys press social challenge year million world poor people die curable preventable infectious disease suffer unnecessary ill health access basic healthcare service include essential medicine vaccine cost healthcare barrier access patient develop world particularly people healthcare insurance want increase access medicine vaccine country believe right thing know contribute business success strive meet societys healthcare needs build trust business help safeguard licence operate long term pursue progressive policy world develop country ldcs focus increase access medicine develop country help build business increasingly important commercial market brazil china india indonesia russia past majority revenue country come sell medicine vaccine higherincome sectors society achieve sustainable growth need highincome sector increase access affordability patient lowerincome level country world gsk extend access develop world view short story gsk extend access medicine develop world develop innovative pricing strategy world gsk review year access strategy focus area difference core business activity skill resource particular mean initiative improve affordability conduct encourage investment develop world achieve pursue flexible pricing strategy refocus activity reflect need develop country seek innovative partnership try reach people access medicine vaccine leadership access medicine gsk rank access medicine atm index publish second time index publish index produce access medicine foundation financial analyst riskmetric provide independent assessment company effort improve access medicine index assess rdbased pharmaceutical company seven generic company gsk rank high seven category please progress recognise know continue consider recommendation atm index carefully review approach corporate responsibility report home access medicine approach approach access medicine global problem require global commitment barrier access vary significantly country depend poverty income level coverage quality healthcare infrastructure political commitment resource allocate healthcare tailor approach different need develop country ldc develop country develop world detail expand access develop country diagram show disease priority differ poorer wealthy sector society broad representation disease affect regardless economic status disease cancer heart disease affect affluent urgent healthcare priority low income sector society tend infectious disease improve access medicine core gsk overall strategy prioritise high level company ceo andrew witty closely involve access effort speak publically commitment view set article global health issue publish january lead journal health affairs president gsk emerge market asia pacific region lead access effort develop country review corporate executive team gsk senior executive management team corporate responsibility committee board establish develop country market access dcma operating unit july aim increase patient access gsk medicine vaccine expand presence help build sustainable business develop country country manager gsk business ldcs report new unit enable consistent integrate approach increase access country unit work gsk country manager develop country increase access flexible pricing approach dcma unit aim increase availability gsk medicine broaden portfolio relevant people country price increase access unlock demand contribute education awareness expand distribution supply chain capability possible work partnership company governments international agency academic institution patient group ngo community provide expertise resource medicine vaccine improve healthcare infrastructure availability medicine work achieve patient dcma unit focus enhance exist partnership establish new collaboration develop country help improve healthcare availability infrastructure conduct strategic review approach combat malaria review conduct crossfunctional team report directly ceo case study article global health issue andrew witty publish lead journal health affair develop country ldcs challenge increase access medicine particularly difficult world develop country approach country include investment new medicine vaccine neglect tropical disease encourage research outside gsk open innovation strategy progressive pricing policy encourage investment healthcare infrastructure pricing strategy ldc include cap price patent medicine set notforprofit price hivaid medicine viiv healthcare tiere pricing vaccine broaden portfolio medicine vaccine ldc make relevant people country include register wide range gsk medicine country available partnership reddys aspen ensure gsk presence important therapy area invest profit sale pharmaceutical consumer healthcare product ldc project strengthen healthcare infrastructure country support number disease prevention community healthcare programme announce new fiveyear commitment expand donation medicine albendazole treat schoolage child africa risk intestinal worm soiltransmitted helminth add donation global alliance eliminate lymphatic filariasis increase commitment donate albendazole billion tablet year read community partnership activity community investment section report currently supply medicine vaccine directly quarter ldcs look opportunity expand presence country africa partnership ngo organisation example recently relaunche gsk angola establish reliable sustainable supply chain somalia open innovation strategy neglect tropical disease focus ldc middleincome country middleincome country mic brazil china india indonesia thailand large affluent middle class offer significant business opportunity gsk mic large number people live extreme poverty healthcare demand outstrip available resource challenge bad increase incidence chronic disease asthma diabete mic represent increasingly important customer industry present significant access challenge past majority revenue mic come sell medicine vaccine higherincome sectors society achieve growth need highincome sector increase access patient low income level believe business growth sustainable deliver great access medicine lowerincome group mic benefit neglect tropical disease open innovation strategy research unit dedicate make product portfolio well suited use develop country continue implement flexible pricing strategy medicine vaccine affordable segment society mic abbas hussain president gsk emerge market asia pacific region say aim reduce price time increase volume return supply medicine patient low price patient high price well society well gsk easier say happen far reduce price end inlicense joint venture acquisition expand portfolio middleincome country well reflect local disease burden demographic profile market transfer manufacture research expertise key market support community programme number middleincome country develop country develop country patient afford medicine need healthcare budget strain develop range value riskshare pricing model reflect commitment work government stakeholder support effort medicine vaccine available people possible mean develop country formulate pricing access policy tend use grouping overlaps develop country ldc country subsaharan africa ssa lowincome country middleincome countries gsk use term develop country include grouping consider ldc country identify low middleincome country use world bank classification corporate responsibility report home access medicine hivaids viiv healthcare hivaid viiv healthcare approach accord late estimate million people worldwide live hiv twothird new infection child subsaharan africa progress million aidsrelated death new infection day discrimination stigmatisation remain people struggle access antiretroviral arv medicine healthcare support need onethird million people live hiv need therapy receive gsk significant history develop medicine treat hiv offer hivaids medicine notforprofit nfp price develop country ldc subsaharan africa partnership pfizer launch viiv healthcare pharmaceutical company wholly focus hiv viiv healthcare specialist company dedicate development innovative medicine partnership improve access care gsk pfizer hiv medicine market viiv healthcare creation viiv healthcare intend accomplish people life affect hiv gsk pfizer achieve bring commercial benefit company viiv healthcare share commitment increase access medicine core objective address lack suitable treatment formulation specific group people live hiv child take case expand access policy legacy company viiv healthcare publish update approach increase access medicine short summary performance provide research viiv healthcare commit development new molecule target unmet medical need hiv include treatment child problem drug resistance complex treatment regimen age hiv effect associate current treatment pricing viiv healthcare offer complete arv portfolio nfp price ldc world bank lowincome country subsaharan africa cover people currently live hiv explore flexible pricing solution middleincome country increase access medicine meet commercial objective voluntary licence viiv healthcare extend voluntary licensing policy adopt gsk enable generic company manufacture sell version product country royaltyfree cover people currently live hiv community investment viiv healthcare support community impact hivaids positive action programme positive action child fund positive action community grant performance research development treatment child hivaid viiv healthcare commit million seed funding support publicprivate partnership research development new hivaids medicine formulation specifically child partnership support early detection hiv access therapy hivpositive infant young child viiv healthcare launch new partnership treat asia bangkokbase programme run american foundation aids research amfar viiv healthcare donate million year help treat asia strengthen paediatric hiv programme collaborative network clinician investigator healthcare worker provide care treatment child affect hiv partnership focus research medical education identify share good practice treatment child hiv viiv healthcare support hiv collaborative research trial crt evaluate strategy prevention mothertochild transmission hiv paediatric treatment resourcepoor country research new hiv treatments secondgeneration integrase inhibitor promise new class compound treatment hiv help address issue drug resistance dose complexity shionogiviiv healthcare joint venture follow encourage result phase iib clinical trial novel oncedaily unbooste investigational hiv integrase inhibitor sgsk know take compound fix dose combination trii epzicemkivexa phase iii clinical trial information gsk vaccine research hiv hiv collaborative research trial crt viiv healthcare support international hiv crt resourcepoor setting trial sponsor external organisation uks medical research council national institutes health focus public healthrelate issue prevention mothertochild hiv transmission paediatric adult treatment strategy start treatment hivtb coinfection viiv healthcare donate arvs andor financial support scientific input life study end trial underway plan involve patient twentynine trial involve african country paediatric study provide significant clinical datum efficacy safety pharmacokinetic viiv healthcares nrti score tablet resourcepoor set notforprofit pricing combivir viiv healthcare lead arv sell patient year develop country ldc compare introduce preferential pricing significant improvement affordability price affordable world poor community significant additional healthcare resource viiv healthcare ship million tablet notforprofit nfp combivir epivir develop country compare million decline supply viiv healthcare arvs expect number voluntary licence scale outweigh growth nearly volume supply licensee supply million tablet version epivir combivir african country figure include syrup formulation conservative estimate arv treatment ship preferential price viiv healthcare continue look new customer nfp arvs regularly review nfp price license able produce firstline arvs low cost continue increase share business supply combivir epivir tablet viiv healthcare viiv healthcare licensees chart datum relate gsk datum relate viiv healthcare figure include syrup formulation conservative estimate arv treatment ship preferential price patient receive treatment difficult estimate number patient treat result preferential pricing agreement control healthcare provision total unaid estimate million people live hiv low middleincome country access hiv therapy thirteenfold increase middleincome country pricing viiv healthcare negotiate preferential pricing arrangement hivaid medicine middleincome country casebycase basis price lower pay develop country need notforprofit price paid develop country approach sustainable bilaterally dialogue government number potential technology transfer agreement discussion country right local technological capacity read gsk approach pricing middleincome country voluntary licensing viiv healthcare extend policy voluntary licence consider request genuine partner casebycase basis grant royaltyfree voluntary licence entire current future arv portfolio use country people hiv live includes develop country lowincome country subsaharan africa allow licensee combine viiv healthcare arvs company right viiv healthcare partner shire pharmaceuticals shionogi agree waive right royalty payment country order improve access product develop collaboration viiv healthcare grant voluntary licence arvs increase company form licensee supply million tablet version epivir combivir african country represent growth viiv healthcare welcome trend give customer subsaharan africa great choice improve affordability contribute well security supply note figure include syrup formulation conservative giving estimate arv treatment ship preferential price community investment viiv healthcare recognise significant role community play response hivaid epidemic committed support community affect disease positive action establish gsk support community grant vulnerable group new positive action child fund community grant local operating company positive action project include research education prevention care treatmentrelate activity detail current recent project find viiv healthcare website positive action child fund establish commit million year support global effort virtually eliminate mothertochild transmission hiv grant award june support project seven african country india second proposal announce december target area great need mothertochild transmission hiv support grassroots communitybase organisation care support woman affect genderbased sexual violence democratic republic congo viiv healthcare commit million year support elizabeth glaser pediatric aids foundation work increase early detection hiv improve access lifesave care treatment infant child hivaid partnership aim improve hiv testing care infant young child lesotho malawi swaziland viiv healthcare launch positive action southern initiative collaborative communityfocuse programme design improve care treatment adherence african americans latinos live hivaid state alabama georgia louisiana mississippi black americans latinos disproportionately affected hivaid compare caucasians rate new infection time great african american male time great african american females hall acquir immune defic syndr medicine patent pool foundation end medicine patent pool foundation formally establish board director unitaid medicine patent pool mpp international community response meet challenge improve access treatment care people live affect hiv aid establishment viiv healthcare active dialogue unitaid medicine patent pool foundation medicine patent pool write viiv healthcare pharmaceutical company work hiv early december ask join formal discussion pool viiv healthcare meet early january continue lead discussion mpp key development communicate viiv healthcare mpp create section website update engagement company meantime important viiv healthcare continue focus broad deep approach meeting challenge access care people live hiv set rest report corporate responsibility report home access medicine research development research development urgent need new well medicine vaccine neglect tropical disease treatment disease suitable use develop country longstanding commitment research development disease develop world ddw portfolio include project number disease particular relevance develop country include bacterial meningitis chagas disease chlamydia dengue fever hivaid human african trypanosomiasis leishmaniasis malaria pandemic flu pneumococcal disease ambitious recognise challenge complex address organisation partnership essential pursuing open innovation approach work industry academia ngo government open innovation gsk include sharing expertise resource scientist world tre canto open lab share intellectual property knowhow pool open innovation neglect tropical disease open datum ddw research help stimulate research outside gsk explain detail follow section develop world research unit aim integrate research develop world pharmaceutical vaccine organisation specific group focus disease develop world include neglect tropical disease ntds significant portion develop world drug discovery work take place tre canto site spain campus link gsk scientist organisation include research decision prioritise socioeconomic public health benefit commercial return similar group active vaccine organisation belgium complement discovery effort create new unit focus drug development patient emerge market focus late stage clinical product match need patient emerge market aim champion need patient gsk operation specifically unit work adapt gsk product well meet need patient emerge market include regionalspecific indication dose requirement presentation group look develop affordable form medicine accessible people country create fixeddose combination generic offer improve clinical outcome affordable price partner research institute government emerge market innovative research understand longterm healthcare priority unit currently asset clinical development therapeutic area respiratory dermatology urology cardiovascular clinical development portfolio broaden coming year include infectious disease neurology oncology different research develop world gsk scientist work ddw research need prioritise aspect affect access new medicine start process research new ddw treatment consider factor heat humidity resistance product able survive hot climate refrigeration facility available ease use easy use setting limit healthcare facility example onceaday tablet take home preferable injectable medicine administer hospital clinic affordability price important factor look molecule formulation straightforward manufacture expensive produce corporate responsibility report home access medicine research development open innovation open innovation new well medicine vaccine urgently need fight neglect tropical disease give scale task need think differently conduct find new way industry academia ngo government work pursue open innovation strategy help speed disease develop world include flexible intellectual property provide access knowhow resource share datum research community position intellectual property read position paper tre canto open lab create open laboratory tre canto medicine development campus spain stimulate research new treatment disease develop world open lab space visit scientist university notforprofit partnership research institutes come site work project learn expertise share worldclass facility set notforprofit foundation initial investment million support visit scientist research project govern board lead scientist field provide strategic direction foundation research support project support open lab foundation contribute research helps discover new medicine disease develop world project involve collaboration scientist home laboratory gsk tre canto open access facility build partnership approach take tre canto site establish work closely publicprivate partnership group medicine malaria venture mmv global alliance drug development alliance drug discovery effort scientist work centre post fund partner result collaboration detailed pipeline section read publicprivate partnership pool open innovation neglect tropical disease helped establish independent knowledge pool gsk available patent knowledge stimulate research treatment neglect tropical disease ntds know pool open innovation neglect tropical disease point january independently administer bio venture global health bvgh nonprofit organisation aim accelerate development drug vaccine diagnostic meet global need term point medicine treatment ntds develop pooled patent intellectual property available develop country royaltyfree basis contribute patent patent application pool cover small molecule formulation direct treatment delivery technology ntds response feedback scientific research community commit consider request access knowledge experience example review request information try result specific area work overcame particular challenge organisation company contribute patent pool biotechnology group alnylam massachusetts institute technology medicine malaria venture university california berkeley caltech believe creation point appointment bvgh administrator help foster constructive discussion group include pharmaceutical company area organisation grant access asset point include emory institute drug discovery ithemba pharmaceutical company base south africa work support south african government information pool administration visit pool open innovation neglect tropical disease bio venture global health website share research information ddw commitment open innovation commit share research finding demonstration publish lead scientific journal nature research finding help identify potential new treatment malaria research result yearlong screening process gsk scientist review million compound gsk chemical library seek inhibit malaria parasite normally screen automate take week process hand give nature screen danger work malaria parasite research cofunde gsk medicine malaria venture process identify compound show great activity molecule proprietary gsk time available wide research community datum chemical structure available online european bioinformatics institute emblebi national institutes health pubchem resource collaborative drug discovery value information enhance research tool available site researcher cost researcher access download datum ask report finding site create open worldwide collaboration aim expand collective knowledge speeding development new medicine hope stimulate new research lead new antimalarial therapeutic strategy new way fight malarial infection information view online european bioinformatics institute emblebi national institute health pubchem resource collaborative drug discovery wwwcollaborativedrugcom franciscojavier gamo thousand chemical starting point antimalarial lead identification nature vol issue doi nature publicprivate partnership biomedical costly risky timeconsuming activity disease disproportionately affect develop world affect develop country market treatment exist hivaids case incur cost risk involve expectation market well country return investment disease develop world return investment expect pursue new way work solution publicprivate partnership ppp model business public sector work ppps work commercially viable sharing risk cost involve ppp company gsk provide technology manufacturing distribution expertise academic institution provide research disease area knowledge public sector partner government organisation bill melinda gates foundation help fund development delivery cost ensure medicine vaccine people need fund usually channel organisation medicine malaria venture mmv help coordinate global activity ppps increasingly important transform landscape development medicine vaccine disease develop world ppps work different way example partnership centre dedicated disease develop world discovery centre tre canto global vaccine business headquartered belgium gsk provide facility medicinal drug discovery meet run cost half scientific post tre canto subsidise partner organisation mmv global alliance drug development drug neglect disease initiative compound clinical development gsk provide clinical regulatory manufacturing expertise resource global supply network clinical trial conduct support partner reduce cost development get new product patient fast research programme oversee joint steering committee representative gsk partner term agreement new treatment result ppps available diseaseendemic country affordable price corporate responsibility report home access medicine research development pipeline update pipeline update section contains update key research project develop world cover medicine vaccine gsk company research new vaccine treatment world health organization priority infectious disease hivaid malaria tuberculosis information hivaid research include section viiv healthcare read develop world research unit integrate research develop world pharmaceutical vaccine organisation medicine develop world malaria work malaria treatment include tafenoquine pyridone gsk tafenoquine develop tafenoquine potential new treatment radical cure vivax malaria partnership medicine malaria venture mmv malaria parasite vivax cause acute infection red blood cell dormant infection liver cell lead malaria symptom recur time radical cure completely eliminate malaria parasite body include dormant parasite liver tafenoquine offer potential oneday treatment course significantly shorter current day standard care course primaquine tafenoquine like primaquine class medicine know cause acute haemolytic anaemia condition red blood cell destroy people inherit disorder know glucosephosphate dehydrogenase gpd deficiency gpd deficiency common area malaria prevalent result issue initial study underway understand haemolytic risk tafenoquine subject gpd deficiency study begin interim result expect addition phase clinical study assess efficacy safety different dose tafenoquine schedule begin pyridone gsk pyridone new class compound potential highly effective drugsensitive drugresistant strain falciparum vivax malaria mosquito stage parasite develop pyridone gsk partnership mmv enter time human clinical trial early safety concern preclude development molecule novel inhibitor target investigation tuberculosis tuberculosis medicine research tre canto conduct partnership global alliance drug development alliance partnership aim discover new medicine novel combination treatment susceptible drugresistant contribute overall shortening treatment time lead project look mycobacterium gyrase inhibitor enzyme involve key step growth multiplication bacterium focus develop suitable compound affect enzyme research translate preclinical datum potential clinical finding help predict early stage patient respond treatment significantly speed research currently effectiveness new drug determine month completion treatment collaborate european union framework innovative medicine initiative issue visceral leishmaniasis sitamaquine compound development affordable day oral treatment visceral leishmaniasis potentially fatal parasitic disease spread sand fly rationale develop sitamaquine provide accessible treatment patient represent significant advance available therapy phase study demonstrate sitamaquine unlikely offer significant advance hope extensive external consultation policy maker major stakeholder endemic country take decision discontinue development sitamaquine ground gsk continue carry drug discovery effort treatment partnership brazil oswaldo cruz foundation drug neglect disease initiative dndi new alliance announce new collaboration brazil oswaldo cruz foundation fiocruz direct develop innovative medicine malaria tuberculosis chaga disease leishmaniasis alliance build vaccine work fiocruz enable scientist fiocruz gsk tre cantos facility openly share new research idea knowhow agreement initially concentrate chagas leishmaniasis experience fiocruz area severe burden unmet medical need patient living disease explore opportunity join force notforprofit organisation drug neglect disease initiative dndi discovery new compound treat neglect disease include human african trypanosomiasis sleep sickness chaga disease vaccine develop world malaria gsk working malaria vaccine decade candidate vaccine call rtss develop partnership path malaria vaccine initiative mvi currently phase iii study site seven african country trial schedule february enrol planned infant child initial result phase iii study expect late month group late week group final analysis expect late rtss malaria vaccine candidate design primarily africa effective successful vaccine human parasite notably rtss vaccine development spearhead extended team researcher organisation span globe include gsk mvi bill melinda gates foundation scientist africa europe north america phase study show rtss reduce clinical episode malaria month age group month period follow vaccination addition rtss show promising safety tolerability profile alongside world health organization standard infant vaccine price rtss vaccine cover cost generate small return reinveste research development secondgeneration malaria vaccine product disease develop world vaccine information gsk joe cohen coinventor rtss vice president advisor malaria vaccine project comment go year today vaccine start give weekold child fantastic achievement mvi executive director christian loucq note development half mission partner commit ensure vaccine reach need hope international community respond starting prepare day go vaccine available distribution use current plan rtss submit regulatory authority use child month age follow later submission use infant week age age range child current childhood vaccination expand programme immunisation epi gsk collaborate develop nextgeneration malaria vaccine build success rtss sign agreement crucell begin earlystage testing malaria vaccine candidate combine rtss crucell adenovirus advac technology gsk working mvi army preliminary research potential vaccine target vivax second malariacausing parasite tuberculosis despite widespread use yearold bacillus calmetteguerin bcg vaccine tuberculosis remain world second lead cause mortality morbidity work partner vaccine development programme include aeras global vaccine foundation tuberculosis vaccine initiative candidate vaccine demonstrate positive early result date conduct phase trial tbnave tbinfecte bcgvaccinated adult hiv positive adult take combination antiretroviral phase trial african infant ongoing hivaid involve aids vaccine research decade pursue separate vaccine strategy successful aid vaccine combine approach gsk hiv vaccine candidate fas currently phase clinical trial hivinfecte subject evaluate safety efficacy fas vaccine candidate combine recombinant adenovirus vector collaboration international aids vaccine initiative iavi gsk work pasteur institute paris partner develop aids vaccine fusing gene hiv virus measle vaccine vector phase clinical trial start collaborative discovery programme aim identify hiv envelopebase protein vaccine capable produce broadly neutralise antibodie hiv infection conduct multiple partner dengue fever joint initiative fiocruz develop vaccine dengue fever continue scientist gsk fiocruz work facility brazil belgium partnership enhance brazilian capacity corporate responsibility report home access medicine vaccine vaccine approach vaccine play major role prevent disease acknowledge world health organization costeffective health investment estimate million death prevent child save disability vaccine year gsk world large vaccine producer grow vaccine portfolio key element business strategy aim increase access vaccine investment vaccine research tiere pricing develop country partnership help build local healthcare infrastructure manufacturing capacity include technology transfer effort need vaccine underuse country estimate live million child save year exist vaccine accessible need require sustained financing development innovative vaccination programme tiere pricing vaccine year entire vaccine portfolio available preferential price develop country tiered pricing system price link gross national income define world bank size order length particular supply contract sell vaccine large volume longerterm contract able significantly reduce price individual dose develop world price little tenth develop country model work vaccine demand relatively predictable centralised bulk purchasing group unicef introduce flexible pricing vaccine sell directly government customer strategic alliance number joint venture technology transfer arrangement gsk vaccine help increase supply affordability vaccine enable develop country develop research manufacturing capability increase market access gsk read approach technology transfer position paper arrangement include new agreement sign binnopharm russia help russia modernise national immunisation calendar add additional vaccination highly prevalent infection human papillomavirus hpv rotavirus streptococcus partner brazil oswaldo cruz foundation fiocruz manufacture vaccine public health priority brazil include polio haemophilus influenzae type hib measle mump rubella rotavirus recently pneumococcal disease local manufacturing technology transfer deal generate sale gsk vaccine help brazil strengthen research manufacturing capability china joint venture shenzhen neptunus develop manufacture influenza vaccine collaboration agreement biotech company walvax develop manufacture paediatric vaccine include measle mump rubella vaccine vaccine portfolio pipeline vaccine approve marketing address medical need develop develop country cover lead cause childhood mortality vaccine protect follow disease cervical cancer chickenpox diphtheria hepatitis haemophilus influenzae type meningitis hib influenza seasonal measle meningitis mumps otitis medium respiratory pneumococcal disease polio rotavirus rubella tetanus typhoid whoop cough pertussis scientist work vaccine research gsk vaccine pipeline recognise large industry potential new vaccine onethird vaccines pipeline target disease particularly prevalent develop world ehreth global value vaccination vaccine gsk receive award recognise vaccine pipeline scrip award annual vaccine industry excellence awards performance vaccine include immunisation campaign country worldwide billion vaccine dose ship billion go develop country include develop middleincome country vaccine include government vaccination programme develop country example rotarix rotavirus vaccine include government vaccination programme newborn baby brazil salvador mexico panama venezuela supply close million dose vaccine vast majority go develop country supply million dose pandemic influenza vaccine worldwide include million dose donate use develop country malaria vaccine candidate want maximise access vaccine case tiere pricing appropriate try different approach example malaria vaccine candidate know rtss currently latestage clinical trial africa successful expect position initial submission regulatory authority approval vaccine exclusively african child market develop country offset cost unlike virtually vaccine tier price seek ensure price barrier access commit set price cover cost make small return reinveste fully generation malaria vaccine product disease develop world take approach consultation partner bill melinda gates foundation path malaria vaccine initiative believe helpful launch malaria vaccine notforprofit price create expectation follow product similarly price major disincentive investment malaria organisation essential unintended consequence provide guidance actual price well idea cost structure likely demand vaccine addition price commitment donate million dose path malaria vaccine initiative synflorix march gsk manufacturer sign agreement gavi alliance speed access pneumococcal vaccine synflorix respiratory pneumococcal disease major global health issue leading cause death child develop country year streptococcus pneumoniae respiratory infection estimate kill million child year age worldwide distinct strain serotype pneumococcus cause vast majority invasive disease young child new financing mechanism advance market commitment amc supply million dose synflorix gavieligible country price cost develop market help protect million child year amc seek close vaccine gap year delay experience vaccine launch develop world accessible develop country synflorix approve use europe introduce africa kenya january synflorix uganda november gsk criticise humanitarian organisation mdecin san frontire msf claim company sell pneumococcal vaccine synflorix private market uganda price unaffordable align gsk state pricing policy develop country ldc msf understand synflorix sell dose claim attract medium attention result negative article gsk take criticism extremely seriously immediately conduct internal review gsk establish tiere pricing policy vaccine recognise government ngos world health organization tiere pricing mean poor country pay fraction cost develop country vaccine sell year develop country bring attention msf vaccine price small private market align wide access strategy ldcs increase access medicine people living country acknowledge mistake conduct review ldc ensure compliance company bring new pricing policy vaccine small private market ldc set price western european average issue clear guidance local operating company ensure compliance new policy maximum retail price synflorix private market country set dose apply provide price price offer agency gavi alliance unicef purchase large volume world poor child offer gsk low price january dose synflorix administer advance market commitment amc mechanism mean hundred million child africa vaccinate streptococcus pneumoniae respiratory infection price marginally cost good expect african family pay vaccine vast majority fund donate western government detail amc gsk recognise important campaigning role ngo msf play grateful attention meet regularly work issue respond concern write face face meeting continue pilot project explore number different approach increase access vaccine develop country include project egypt mexico develop network new clinic people easily obtain immunisation local community example egypt join force borg chain private pathology laboratory find cost effective way help adult access vaccine new initiative use borgs branch cold chain infrastructure housecall customer service system deliver vaccine offer reduced price affordable section society partnership launch borg branch seasonal flu vaccine accompany training branch manager physician technician receptionist agent centre staff specialist agents flu hotline vaccine query establish far people receive vaccine centre look expand programme partnership laboratory network egypt africa cervarix vaccine cervical cancer partner major international nongovernmental organisation distribution network develop country cervical cancer death occur result pilot programme launch south america encouraging read flexible pricing section involve project improve infrastructure childhood immunisation programme india millions mother child receive basic immunisation strategic alliance russia launch new alliance russian company binnopharm gsk provide technology expertise enable binnopharm manufacture fill pack number innovative gsk vaccine accordance international current good manufacturing practice standard russia efficient system universal mass vaccination cover approximately population gsk combine pneumococcal vaccine supply binnopharm trademark brazil technology transfer agreement fiocruz rotarix vaccine protect rotavirus cause gastroenteritis continue year gsk fiocruz sole supplier million dose rotavirus vaccine brazil deal benefit gsk fiocruz help ensure million baby brazil protect gsk rotarix year fiocruz produce rotarix brazilian domestic market manufacture rotarix gsk contract export gsk provide fiocruz access technology synflorix vaccine protect lifethreatening infection pneumonia meningitis bacteraemia brazilian government incorporate vaccine national immunisation programme corporate responsibility report home access medicine flexible pricing flexible pricing pricing factor impact access medicine vaccine adopt range flexible pricing model reflect commitment work government stakeholder deliver medicine vaccine people need possible world gsk innovative approach pricing view short story gsk extend access medicine develop world develop innovative pricing strategy world gsk review year develop country ldc offer substantially reduce pricing patent medicine viiv healthcare offer notforprofit price hivaid medicine country subsaharan africa offer tiere pricing gsk vaccine worldwide poor community middleincome country face barrier access medicine ability offer notforprofit highly preferential price world poor country sustainable continue adequate return medicine vaccine betteroff market middleincome country grow market gsk represent important source future business industry explore range pricing approach balance commercial objective need increase access medicine market afford pay include flexible tiere preferential pricing model tailor product local source manufacture arrangement develop country patient lack access medicine particular problem uninsured patient seek price medicine fairly country level reflect value patient payer patient assistance program discount saving card provide access gsk medicine uninsured patient minimal cost flexible pricing challenge price complex multidimensional issue factor new product introduction reaction competitor price change impact gsk ability improve access medicine example seek evolve business model company low cost base able supply low price gsk price reduction lead competitor reduce price improve affordability benefit patient mean price reduce point profit business market unsustainable reduce price medicine guarantee patient able access able generate increase volume need sustainable time cut price need increase investment marketing distribution factor include diversion product sell low price betteroff group country country possible betteroff country seek price reduction ability pay great take factor account continue review price medicine private public purchaser country ensure competitive profitable medicine available wide number people reasonably afford corporate responsibility report home access medicine flexible pricing develop country develop country approach commit significantly reduce price patent medicine develop country ldc aim reduce price price france product sell ensure cover manufacturing cost offer sustainable commitment apply patent product gsk sole supplier market response feedback physician extend price reduction offpatent product extend commitment vaccine small private market ldc set price western european average apply provide price price offer agency gavi alliance unicef purchase large volume world poor child offer gsk low price continue look opportunity price reduction country manager gsk business ldcs report new develop country market access operating unit enable consistent integrate approach increase access country focus register wide range product ldc approach include longestablished practice tiere pricing vaccine viiv healthcare notforprofit pricing hivaid medicine product diversion notforprofit preferentially price medicine illegally ship sale betteroff country deny treatment patient poor country particular risk diversion ldc market betteroff country east west africa share supply chain lack stringent border control reduce risk introduce price reduction nonldc market world gsk innovative approach pricing view short story gsk extend access medicine develop world develop innovative pricing strategy world gsk review year performance patent product april reduce price develop country ldc gsk patent brand individual product line formulation country register price reduce average apply follow brand seretide asthma chronic obstructive pulmonary disease copd avamys rhinitis flixotide asthma malarone malaria avodart benign prostatic hypertrophy avandia type diabete avandamet type diabete fraxiparine anticoagulant ultiva anaesthetic arixtra venousthromboembolism vte zeffix hepatitis case price reduce price france product sell case possible reduce price level cover manufacturing cost instance reduce price possible look opportunity introduce reduction sale volume majority product increase significantly follow price decrease believe increase access patient chart focus launching brand ldc reduce price patent expiry price reduction continue apply launch new gsk patent product ldc price line reduce pricing policy medicine cover price reduction product gsk sole supplier know product meet priority health need general population ldc explore way expand access gsk product sponsor research assess current reach gsk respiratory product fully understand barrier access different urban area ldc use finding form partnership ngo healthcare provider professional patient respiratory group tackle barrier deliver well treatment price reduction gsk brand product east africa chart show average price patient combine number pack sell follow gsk patent product avamys avandamet avodart flixotide malarone seretide east africa price reduce average quarter number pack sell increase fourfold end price reduction gsk brand product francophone west africa chart show average price patient combine number pack sell follow gsk patent product avamys avandia flixonase flixotide seretide francophone west africa price product reduce average quarter number pack sell increase fourfold average end sale growth region slightly erratic political climate market impact civil war natural disaster difficult distribute medicine reduction offpatent product feedback local physician indicate need lowerpriced antibiotic give high incidence infectious disease response early reduce cost augmentin francophone west africa augmentin zinnat east africa details augmentin price reduction francophone west africa chart show average price patient number pack sell augmentin francophone west africa cost augmentin reduce early number pack sell increase twothird month follow price reduction average end believe peak volume mid onset winter market price reduction augmentin zinnat east africa chart show average price patient number pack sell augmentin zinnat east africa prices augmentin zinnat reduce average east africa early see twofold increase number pack sell end read profit pricing arvs viiv healthcare ensure patient benefit country government control markup case middleman pass price reduction patient work pharmaceutical distribution network ensure price reduction pass patient work government medium ensure patient aware benefit reduction beginning sale volume increase country receive feedback physician indicate patient medicine patient compliance prescribe dose improve case corporate responsibility report home access medicine flexible pricing middleincome country middleincome country approach middleincome country mic brazil china india indonesia thailand large affluent middle class offer significant business opportunity gsk country large number people live extreme poverty strategy grow business mic increase volume product sell increase number patient income level receive achieve need flexible approach pricing medicine right circumstance price reduction enable sell product significantly increase access patient possible single pricing approach mic difference economic status demography healthcare infrastructure pricing regulation market access pricing team work local operating company establish right pricing approach mic market include optimise price reflect market ability pay poor country pay medicine betteroff country introduce differential pricing structure market reach new sector population include business public sector organisation market previously deal private sector work closely mic health authority payer agree innovative pricing programme medicine support example disease awareness campaign help improve patient access closely monitor price compare local competition ensure price reduction pass patient appropriate commercial team collaborate manufacture organisation reduce cost good generate high sale volume improve efficiency explore local source manufacturing arrangement help reduce price establish number tool process enable regional country team share information good practice market access help maximise opportunity minimise risk include webcast online training virtual tutorial dedicated website good practice sharing explore create right condition differential pricing country expect commence number pilot project feasibility study work closely group distribution chain medicine transparency alliance meta ensure price reduction pass patient expect launch pilot project country meta active approach include longestablished practice tiere pricing vaccine voluntary licence preferential pricing hivaid medicine form commercial partnership patient access medicine bring product country time discount card introduce discount card number country ukraine vietnam enable lowincome patient chronic disease asthma obtain prescription medicine discount price world gsk innovative approach pricing view short story gsk extend access medicine develop world develop innovative pricing strategy world gsk review year performance quarter introduce flexible pricing innovative medicine vaccine mic new reduce price closely link countrys gross national income ability pay challenge work early stage result initiative far promising indicate price reduction extend access patient provide sustainable return gsk avamys avamys fluticasone furoate oncedaily nasal spray treat allergic rhinitis reduce price avamy average mic country avamys launch launch future introduce price line reduction follow reduction find increase number pack sell offset impact lower price mean treat patient profit chart avamys launch mexico reduce price market leader chart show market share avamys mexico launch january price low market leader avamys achieve market leadership month launch market establish competitor product hold market share number pack sell end illustrate impact flexible pricing increase affordability choice patient time increase market access gsk avamys maintain market leadership despite previous market leader provide twoforone offer follow launch avamys avodart reduce price avodart dutasteride treatment benign prostatic hyperplasia bph average mic number pack sell increase significantly russia treatment bph cover reimbursement programme compliance treatment low patient stop therapy month treatment reduce price avodart russia volume pack sell increase suggest patient initiate stay treatment long chart avodart price reduction russia chart show increase number pack sell follow price decrease april rapid uptake follow price decrease increase pack volume see december tyverb india reduction price breast cancer treatment tyverb result double number new patient receive treatment increase number unit sell month trend encourage confident able expand access patient new price cervarix reduce price cervarix cervical cancer vaccine average mic significantly increase uptake example monthly sale cervarix increase significantly philippine reduce price vaccine settle time volume vaccine sell price reduction introduce similar result achieve indonesia vietnam sixfold increase number woman vaccinate chart mic introduce measure alongside price reduction help increase uptake cervarix sure vaccine available woman example philippine support number women health education programme disease awareness activity include tour hope charity bike tour raise money philippine general hospital provide lowcost cervical cancer screening increase access cervarix low middleincome woman alternative channel corporate institutional local government programme work local provincial government cervarix volume price reduction southeast asia note chart baseline mean volume dose month prior launch reduce pricing fast period indonesa rate vaccination decline stock issue vietnam delay visa renewal chart show increase sale volume cervarix introduction price reduction philippine indonesia launch vietnam reduce price volume increase significantly settle time volume vaccine sell price reduction introduce price reduction relate direct sale government customer read tiere pricing system vaccine distribute multilateral agency new centre increase access cervarix mexico find price reduction lead increase uptake medicine vaccine case need work partner introduce price reduction alongside measure example reduce price cervarix mexico woman afford vaccine fee charge doctor immunisation tackle join force nongovernmental organisation lead chain clinical laboratory set new vaccination centre centre charge fee administer vaccine mean woman receive cervarix vaccine affordable price initiative sustainable important gsk vaccination centre small profit ngo cover cost achieve need reduce cost sure sufficient number patient attend clinic work closely ngo raise awareness cervical cancer advertise vaccination centre general public reduce cost introduce direct delivery system cut middleman wholesaler distributor donate dose vaccine initiative start year initiative woman vaccinate centre partner borg chain laboratory egypt expand access vaccine read vaccine section nonpatente product take step establish competitive private market pricing nonpatente brand countrybycountry basis example brazil sale volume antibiotic augmentin substantially increase reduce market price prescribe presentation half march country initiative september gsk indonesia introduce sehat terjangkau affordable health initiative reduce price half medicine cover offpatent patent product treatment disease hivaid asthmachronic obstructive pulmonary disease copd hepatitis epilepsy gastrointestinal disease benign prostatic hyperplasia bph antibiotic follow model establish gsk philippine expand access programme look way reduce barrier access country patient pay prescription cost reimbursement coverage low example china people pay weekly launch small sevenday pack heptodin antiviral treatment hepatitis help patient able access medicine early extend orange card programme cover breast cancer treatment tyverb ukraine corporate responsibility report home access medicine flexible pricing develop country develop country approach access medicine issue develop world develop country limit public health provision patient afford medicine need particular problem people health insurance information patient assistance program pap discount saving card develop age population rise incidence chronic disease mean healthcare budget strain develop country government balance desire healthcare equality need manage limited financial resource aim price medicine fairly market price new product price newly approve medicine determine countrybycountry basis country price negotiate directly government payer example sickness fund private health insurer manufacturer free set price subject kind government control seek ensure price new product reflect clinical value patient term improve efficacy well safety few effect value provide healthcare system payer high risk associate need fair return investment national price regulation balance act manage public healthcare budget enable patient access reward innovation ensure continue investment sell medicine wholesaler pharmacy directly patient intermediary add price markups pharmaceutical product addition dutie tariff impose import product affect price pay end customer example national health service hospital patient approach europe europe statefunde healthcare system experience budgetary constraint achieve good result patient public budget industry believe work genuine partner government help find solution bring value healthcare system support costmanagement country europe require demonstration value new medicine example clinical effectiveness costeffectiveness reach decision reimbursement government possible want demonstrate value medicine evidencebase datum time introduce new medicine allow fair price set reflect medicine prove value affordable customer sustainable gsk balance requirement challenge complex example case level uncertainty exist relation new medicine uncertainty aspect evidence provide launch expect financial impact new medicine case innovative approach price setting need support patient access medicine gsk work regulator policy maker innovative pricing programme balance fair reward gsk maintain efficient fast patient access country demonstrate value research believe change need current system drug discovery development improve productivity deliver increase value medical system patient shareholder gsk found member active contributor european healthcare innovation leadership network ehiln new collaboration bring industry regulator health technology assessment organisation healthcare payer patient group medical association academic europe ehiln seeks improve understand different stakeholder group constitute medicine value explore research process improve generate evidence need effectively demonstrate medicine value involve number pilot project explore stakeholder consultation improve research process gsk receive advice range stakeholder pipeline product offer potentially new mechanism help manage diabete find process useful feedback shape development strategy product pilot plan hope consultation routine way drug develop future programme patient assistance program pap discount saving card provide prescription medicine uninsured patient free minimal cost gsk operate programme include commitment access cover cancer treatment bridge access cover medicine outpatient patient selfenrol bridge access simple application apply telephone help advocate gsk access provide extra help lowincome senior disabled patient enrol medicare programme provide free medicine eligible patient spend prescription medicine current year meet income requirement base federal poverty level federal poverty level single person couple family member access industry programme give uninsure citizen discount medicine gsk seven pharmaceutical company programme open people earn time federal poverty level nearly million americans enrol access work government employer find new way address problem chronic disease reduce healthcare cost approach call triple solution healthy america focus prevention intervention innovation performance pricing europe explore flexible approach pricing example contractual pricing patient access scheme launch launch parkinson medicine requip extended release result trial available extend release form product achieve well result exist immediate release form requip gsk france agree french health authority launch requip low price exist version price barrier access patient submit additional study datum demonstrate requip superior requip base new clinical datum french authority agree increase price explore similar solution oncology medicine arzerra france italy spain votrient oncology medicine recommend use national health service uks national institute health clinical excellence nice order votrient accessible patient quickly gsk offer innovative patient access scheme include discount list price potential partial rebate future link outcome headtohead trial current standard care sunitinib headtohead study sunitinib comparz currently underway report advanced kidney cancer difficult treat malignancy effect treatment big impact quality life different treatment option available different sideeffect profile allow patient physician choice wait result headtohead trial gsk propose innovative flexible approach pricing enable patient clinician choice access votrient soon possible gsk confident evidence trial demonstrate value votrient pay partial rebate nhs world gsk innovative approach pricing hear general manager innovative patient access scheme votrient world gsk review year seek approval breast cancer medicine tyverb gsk offer patient access programme patient able receive tyverb combination capecitabine programme gsk cover cost tyverb week treatment national health service pay treatment week patient continue benefit uks national institute health clinical excellence nice conclude tyverb meet require costeffectiveness threshold national process ongoe work number local primary care trust set similar patient access programme enable increase patient access tyverb oncology medicine arzerra implement contractual discount scheme european country explore option france italy spain discount card develop orange card scheme country bulgaria lithuania provide discount certain group patient senior citizen disabled people able afford copayment element prescription medicine program patient receive gsk medicine worth million programme value medicine calculate average cost good wholesale acquisition cost approach value medicine accurately reflect true cost gsk transparent believe pharmaceutical company adopt practice value wholesale acquisition cost value medicine million year patient receive day prescription gsk medicine access programme give patient discount inception access give million patient saving totalling million wide range product viiv healthcare launch new patient assistance programme replace gsk bridge access programme hiv medicine extend coverage patient increase household income threshold enrolment federal poverty level viiv healthcare pilot membership welvista programme nonprofit programme facilitates access hiv medication individual currently wait list aids drug assistance program welvista patient access hiv medicine different company patient assistance programme make easy obtain medicine need viiv healthcare continue offer patient saving card programme year initiative come effect january help maintain access hiv medicine lowincome patient affect economic downturn launch programme provide adult vaccine free charge eligible lowincome individual insurance coverage vaccine gsk vaccine access program enable eligible adult receive fdaapprove vaccine hepatitis hepatitis tetanus diphtheria pertussis eligible woman age able receive cervical cancer vaccine programme start february patient receive assistance corporate responsibility report home access medicine portfolio expansion portfolio expansion growth develop country achieve strategic alliance acquisition deal help bring big range affordable innovative medicine wide population alliance acquisition access highquality competitively price pipeline brand pharmaceutical product allow broaden product portfolio sure well suited need patient develop country focus quality secure supply chain mean collaboration provide reliable highquality choice patient country pursue joint venture technology transfer agreement develop country agreement benefit gsk give access new market benefit develop country expand supply essential medicine vaccine support development local research manufacturing capability vaccine alliance current alliance include partnership aspen license collaboration aspen africa lead healthcare company give access portfolio lowcost quality brand product license product sale gsk emerge market asia pacific region combine commercial activity gsk aspen subsaharan africa collaboration use gsk commercial infrastructure help bring aspen extensive product portfolio pipeline patient region gsk acquire shareholde aspen demonstrate commitment investing region donga sign alliance donga south korean company portfolio proprietary generic pharmaceutical product lead consumer healthcare brand collaboration help gsk increase accessibility product patient korea grow business country world large pharmaceutical market reddys agreement reddys laboratory enable license brand pharmaceutical sale emerge market asia pacific region product cover therapy area cardiovascular diabete oncology gastroenterology pain management gilead enter agreement gilead develop launch hepatitis treatment viread china japan saudi arabia gilead commit increase access medicine patient asia bring new way address burden chronic hepatitis need new product launch file regulatory application product partnership aspen reddys broaden product portfolio launch product country africa latin america commonwealth independent states cis antiinfective cardiovascular oncology therapy area acquisition acquisition include laboratorios phoenix lead argentine pharmaceutical business focus development manufacturing marketing sale brand generic product phoenixs broad portfolio enable bring medicine value patient argentina increasingly important emerge market expand local manufacturing base acquire nanjing meirui pharma company lead chinese pharmaceutical business portfolio urology allergy product expand portfolio manufacturing base china fastestgrowe pharmaceutical market report detail previous acquisition corporate responsibility report home access medicine advocacy advocacy appropriate lobby government policy maker encourage change policy environment help increase access healthcare sustainably particular support approach encourage adequate investment healthcare infrastructure support innovation support differential pricing adequate financing mechanism gavi global fund fight aid malaria factor critical sustainably improve access long term advocacy advocacy work area include urge continue make healthcare develop world major agenda item support development pilot advance market commitment pneumococcal vaccine participate mmvs malaria donor forum support secretary general ban kimoon effort develop launch global strategy womens children health millennium development goal summit september work government global health issue cochaire uks industry government forum access medicine present event access medicine parliament discuss intellectual property innovation funding government ngos foundation stakeholder attend executive board meeting world health assembly present commonwealth health minister meet playing lead role major global health initiative example gsk sit board gavi alliance participate roll malaria board meeting participate partner forum government global health strategy meeting secretary general special envoy malaria engage intergovernmental meeting pandemic influenza preparedness participate meeting access issue european parliament sponsor meeting business ngo attend deputy secretary general bob orr secretary state international development andrew mitchell discuss role private sector improve maternal child health mmvs malaria donor forum uks industry government forum access medicine engage expert ensure success strategic review approach combat malaria believe gsk uniquely place key player fight malaria research expertise facility promise malaria vaccine pipeline extensive operation malariaendemic country review approach combat malaria develop comprehensive malaria vision strategy company vision world malaria long barrier human health development prosperity review conduct crossfunctional team report directly ceo team consult range stakeholder inside outside company gain well understand priority view current treatment prevention effort gsks approach feedback essential development new strategy external expert partner spoke include medicine malaria venture head national malaria control programme affect country world health organization global malaria programme bill melinda gates foundation office ray chamber special envoy malaria feedback cover range issue respect vaccine candidate rtss stakeholder tell gap local advocacy expertise affect rollout vaccine advise use health economic datum demonstrate vaccine potential impact encourage gsk focus discovery effort generation medicine artemisinin invest diagnostic malaria gpd deficiency common gene deficiency affect choice malaria treatment suggest align community investment malaria example support use rapid diagnostic test fund diagnostic education local surveillance effort critical fighting malaria expert business include employee involve disease develop world seek view maximise potential malaria lesson learn development launch product align global malaria strategy stress importance view malaria research core business increase coordination integration different part gsk work malaria government relation gsk aim support work constructively government effort strengthen develop sustainable healthcare system globe read example activity area engage human right health read response review gsk policy practice special rapporteur right health report improve access medicine responsibility improve access healthcare develop country require holistic approach embrace prevention treatment effort fundamentally strengthen health system stakeholder need contribute pharmaceutical company include gsk medicine affordable possible people world poor community sustainable manner invest research disease develop world new prevention tool treatment urgently need work find innovative solution deliver medicine vaccine people need wealthy nation continue generous development assistance welcome new funding come global fund fight aids malaria bill melinda gates foundation pepfar president emergency plan aid relief unitaid fund inadequate need predictable sustainable fund research strengthen health system purchase medicine vaccine support disease prevention develop country genuine political commitment prioritise healthcare national budget address stigma improve affordability remove import tariff medicine middleincome country support tiere pricing approach base partly ability pay seek low price offer world poor country make return betteroff country able offer low price poor country read response review gsk policy practice special rapporteur right health report corporate responsibility report home access medicine future plan future plan pleased progress believe contribute effort increase access medicine creation develop country market access operating unit bring increase focus effort expand access medicine people live ldc drive initiative go forward continue deliver objective develop product portfolio suit disease burden suffer patient develop country continue plan introduce flexible pricing strategy work increase access middleincome country seek partnership encourage scientist work research centre disease develop world tre canto spain encourage consider innovative approach intellectual property noncompetitive setting contribute pool open innovation neglect tropical disease similar mechanism seek reduce price patent medicine ldc continue reinvest profit sell medicine ldc help strengthen healthcare infrastructure country encourage consider similar scheme retain focus neglect tropical disease look way increase access treatment noncommunicable disease ncds diabetes cancer prevalent improvement tackle childhood infectious disease lead people live long ncds represent disease burden develop country measure daly daly disabilityadjuste life year accept measure disease burden daly equivalent lose year healthy life chart increase access medicine ncds particularly challenging cost provide longterm lifelong care september general assembly hold special session ncds gsk commit work relevant stakeholder help tackle grow problem global burden disease disabilityadjuste life year dalys accept measure disease burden daly equivalent lose year healthy life global burden disease report disabilityadjuste life year corporate responsibility report home research practice introduction research practice investment new medicine vaccine core business focus effort area great need advance science offer good opportunity discover new medicine essential meet consistently high quality ethical standard part business market operate enable protect safety clinical trial participant patient use medicine obtain regulatory approval new medicine vaccine maintain trust patient healthcare professional patient safety priority evaluate benefit risk medicine stage research new product approve sale commit transparency disclosing result clinical research recognise biomedical research raise ethical concern include relate use emerge technology stem cell research animal research clinical trial standard storage use human tissue protection personal information research participant aim address concern open approach participate discussion research practice regularly engage academic scientist regulator policy maker stakeholder issue guide research understand patient need focus patient programme help bring patient gsk site speak directly team specific healthcare need corporate responsibility report home research practice despite advance healthcare disease cure new treatment vaccine need prevent transmission help patient well control symptom focus effort area great patient need advance science offer good opportunity discover new medicine generate commercial return aim new treatment provide value currently available treatment patient payer significant investment year spend billion expenditure pharmaceutical remainder vaccine consumer healthcare research come government rank company investment world gsk deliver generation medicine hear chairman gsk deliver generation medicine world gsk review year pipeline glance earlystage pharmaceutical research activity focus biopharmaceutical dermatology specialised dermatology company stiefel immunoinflammatory disease infectious disease metabolic pathway neuroinflammation degeneration oncology ophthalmology respiratory disease vaccines rare disease latestage pipeline include product target autoimmune disorder infection form cancer metabolic cardiovascular disease neurological disease respiratory disease end product latestage development pipeline asset approve indication read pipeline progress product approval expenditure annual report strategy develop new medicine improve return focus area science high probability success announce formation new standalone unit focus treatment rare disease box research rare disease involve area science reduce time develop new treatment instance identification disease clear cause mutation single gene easy clinical trial assess impact new treatment change earlystage neuroscience research activity cease research select area depression pain focus neurology research effort identify develop treatment neurodegenerative neuroinflammatory disease include alzheimer disease multiple sclerosis parkinson disease new treatment option need advance science offer great prospect successful development new medicine department business innovation skill scoreboard rare disease rare disease identify few currently treat present significant unmet medical need part world despite rarity separate condition number disease mean overall population affect rare disease increase scientific genetic understanding researcher able identify rare disease likely respond therapeutic intervention provide significant impetus discover develop new medicine establish gsk rare disease group concentrate finding deliver new treatment rare disease group integrate development commercialisation believe integration suit rare disease small number specialist physician institution see treat relatively small number patient rare disease gsk rare disease benefit dedicated resource access cuttingedge science entire gsk organisation explore new molecule platform technology develop apply treat thousand rare disease group focus development medicine treat disease time select factor prevalence severity disease potential treatment help manage disease complication new group look bring new treatment patient pipeline partnership license deal disease investigate result recent alliance include duchenne muscular dystrophy develop nucleic acid base therapeutic collaboration prosensa hunter syndrome fabry disease gaucher disease alliance jcr pharmaceutical japanese developer manufacturer bioactive product obtain global right enzyme replacement therapy ada severe combine immunodeficiency know bubble boy disease exclusive licence fondazione telethon fondazione san raffaele develop commercialise investigational gene therapy currently phase iii alliance provide gsk codevelop application technology potential correct genetic abnormality range rare disorder new rare disease group world gsk review year reference wwworphanet portal rare disease orphan drug wwwfdagov analysis approve therapy know rare disease rare disease understand public health priority european organisation rare disease november wwworphanet portal rare disease orphan drug collaborative gsk large pool scientist recognise monopoly research good science form alliance accelerate discovery new medicine vaccine share scientific understanding ultimately improve patient care main area collaboration include research improve drug discovery biotechnology neglect tropical disease identify patient safety issue rare disease fund basic medical research conduct outside gsk increase understand human body impact disease type research frequently foundation future advance diagnosis treatment prevention disease example new ongoing collaboration contribute include initiative national institute health research university manchester examine impact human biological clock inflammation lung disease chronic obstructive pulmonary disease copd participation cochair newly establish copd biomarker qualification consortium cbqc consortium government agency academic institution pharmaceutical company pool information chronic obstructive pulmonary disease copd aim identify validate biomarker copd lead improvement disease monitor expedite development new therapy contribute environmental protection agency epa toxcast programme develop new laboratory computer method predict compound toxicity human toxcast screening fail chemical common factor toxicity identify gsk pharmaceutical company provide information fail drug candidate enable epa compare toxcast screening datum human clinical datum toxicology study toxcast potential identify toxicity issue early drug discovery process involve innovative medicine initiative imi publicprivate partnership europe involve pharmaceutical company small bioscience company academia stakeholder regulator patient group aim imi develop improve method predict safety efficacy new medicine currently lead project participate read collaboration patient safety seek contribute body scientific understanding finding collaborative research accessible publicly available scientific journal gsk scientist list coauthor collaborative research publication form research alliance seek work organisation principle align communicate policy partner collaboration agreement include clause require partner comply principle academic collaboration novel innovative research take place academic institution agree research collaboration universities academic institution globally include fund university research leadingedge academic research project provide support science student fellowship award support help advance scientific understanding capability give access expertise activity outside company expand potential recruitment pool train scientist academic collaborator benefit technology transfer access research facility expertise announce new alliance university nottingham create chemistry degree module medicinal chemistry skill pharmaceutical industry run collaboration university nottingham school chemistry new module introduce chemistry student medicinal chemistry skill pharmaceutical industry requires enhance knowledge transfer industry academia gsk medicinal chemistry module design option chemistry student year year msci course allow student select university pursue laboratory active research programme molecular target pharmaceutical company develop corporate responsibility report home research practice patient need patient need guide research essential understand patient need focus patient programme bring patient gsk site speak directly team specific healthcare need help well medicine inspire employee help improve patient live gsk site host patient seminar people include gsk employee healthcare professional patient patient advocacy group representative come discuss range topic include chronic lymphocytic leukaemia duchenne muscular dystrophy lupus macular degeneration metastatic melanoma myasthenia gravis psoriasis sarcopenia recording seminar available intranet enable employee benefit discussion interview patient recently diagnose rheumatoid arthritis expand knowledge condition impact early stage aim use type interview frequently inform drug development programme read effort understand patient work patient group corporate responsibility report home research practice emerge technology emerge technology emerge technology help expand boundary scientific understanding research capability stem cell genetic research provide new opportunity discovery innovative treatment disease well way evaluate benefit risk medicine develop example advance genetic research beginning enable identification patient likely experience certain effect use medicine use emerge technology research work develop recognise research emerge technology rise ethical concern outline approach use cloning technology stem cell research genetic research corporate responsibility report home research practice emerge technology cloning technology stem cell research cloning technology stem cell research cloning technology gsk use cloning technology replicate molecule cell research technology fundamental component medicine discovery development provide well way evaluate compound enable great insight benefit risk potential medicine gsk clone animal use cloning technology intention reproduce entire human being medical research case read position statement cloning technology stem cell research stem cell research recent advance stem cell research significant potential produce human tissue transplantation treatment disease include parkinson disease alzheimer disease diabete spinal cord injury gsk involved effort identify medicine activate patient stem cell regenerate cell lose result disease example pancreas cell diabete brain cell parkinson disease use adult human stem cell currently form integral instance use foetal stem cell human embryonic stem cell discovery medicine disease stem cell biological property reproduce adult stem cell use subject approval gsk chairman position statement cloning technology stem cell research outline view use stem cell medical research set stringent standard apply collaborate research organisation stem cell research announce new strategic alliance italian fondazione telethon fondazione san raffaele specialise research rare genetic disorder develop novel treatment condition gene therapy carry stem cell take patient bone marrow agreement develop investigational gene therapy adenosine deaminase deficiency severe combine immune deficiency adascid rare lifethreatening disorder affect approximately child worldwide codevelop stem cell therapy treat rare disorder read new group gsk rare disease collaboration include fiveyear partnership harvard stem cell institute hsci support research neuroscience heart disease cancer diabetes musculoskeletal disease obesity found member stem cell safe medicine scsm initiative bring pharmaceutical company public sector organisation scsm aim develop bank human cell line use early medicine discovery help identify eliminate potential toxicity issue medicine test people scsm investigation focus use stem cell generate cardiac liver cell corporate responsibility report home research practice emerge technology genetic research genetic research genetic variation underpin aspect human health people certain disease age disease develop fast progress respond drug recent breakthrough dna analysis lead discovery variety genetic marker people susceptible common disease collaboration academic group gsk contribute identification susceptibility gene variety condition include alzheimer disease asthma coronary artery disease diabete hypertension sleep disorder finding significant potential diagnosis common disease future discovery innovative medicine anticipate breakthrough result novel technology allow largescale sequence human genome rare disease cause genetic defect gsk establish group dedicate research development commercialisation innovative therapy patient rare disease genetic research form significant new unit activity read gsk rare disease genetic variation affect patient respond variety medicine gsk scientist emerge genetic information particularly field oncology study medicine differentiate suit group patient different genetic characteristic understand patient experience effect genetic research collaboration collaborate academic partner regulatory agency pharmaceutical company share genetic research information example cosponsor international adverse event consortium isaec aim improve patient safety genetic research share research data dbgap national institutes health database contain result study explore association specific gene medical condition genetic component alzheimer disease share genetic research finding select academic organisation include cambridge imperial oxford university michigan university university north carolina collaborate analyse result develop new statistical method genetic analysis begin collaboration develop novel stem cell treatment rare genetic disorder read stem cell research work rare disease respond concern genetic research recognise people concern application standard genetic research aim address concern transparent conduct genetic research genetic analysis undertake gsk clinical trial seek obtain informed consent participant procedure include provide information purpose scope research access genetic research datum read inform consent inform genetic research activity refer guidance national international group european medicine evaluation agency food drug administration council international organisation medical science corporate responsibility report home research practice animal research animal research approach animal study remain small vital research case method demonstrate effect potential new medicine living body test human animal research provide vital information cause disease disease develop safety regulation require test new medicine animal evaluate clinical trial vaccine test animal time new batch produce recent vaccine cervarix rotarix synflorix develop alternative approach use animal accept regulator animal necessary research commit act ethically provide animal health wellbee practise good animal welfare revise strengthen policy care welfare treatment animal performance detail approach ultimately gsk like important benefit research achieve applied human need animal testing believe achieve foreseeable future goal use animal scientifically necessary use scientifically feasible minimise pain distress senior management review strategy work animal annual basis animal quality council oversee effective application high quality welfare standard gsk animal testing worldwide head animal research responsibility develop embed coordinate strategy gsk business unit find nonanimal alternative improve animal welfare ensure progress goal chief animal welfare veterinary medicine position create responsible oversee humane responsible use animal pharmaceutical helping develop relevant policy respond stakeholder question gsk animal research laboratory europe asia north america animal research conduct external contractor behalf represent total animal use animal gsk rodent mainly rat mouse use rabbit dog nonhuman primate fish ferret chicken pig goat nonrodent account number animal list order magnitude use scientist apply principle find nonanimal alternative improve animal welfare biomedical research replace research animal nonanimal alternative specie low possible phylogenetic order reduce number animal provide information give precision example obtain information large study refining technique minimise pain distress maximise welfare animal animal research proceed propose study undergo scientific ethical review assess study design incorporation ethical review conduct independent internal committee base site country research place ethical review committee include veterinarian scientist person scientific background include specialist laboratory animal science engage regulator help ensure regulatoryrequire animal testing incorporate development encourage culture gsk regular training staff involve care use animal raise awareness encourage good practice communicating advance gsk medicine discovery development team recognise employee outstanding advance implement animal welfare award read recent gsk advance replace reduce refining animal use nonhuman primate animal use nonhuman primate voluntary commitment long perform research great ape common nonhuman primate species research macaque use nonhuman primate species appropriate study example instance human nonhuman primate affect respond potential medicine vaccine read position statement use nonhuman primate research ensure high standard research facility commit high standard animal welfare animal study carry behalf gsk facility contract external laboratory follow core principle ethical care welfare treatment laboratory animal legal regulatory requirement engage external expert refine improve programme animal care goal gskowne animal facility accredit association assessment accreditation laboratory animal care international aaalaci private nonprofit organisation promote humane treatment animal science achieve maintain aaalaci accreditation organisation follow national academy sciences guide care use laboratory animal revise rigorous review aspect animal care use include policy animal housing management member aaalaci council train professional staff year communicate approach people hold strong view animal research testing believe important explain need animal research transparent engage regularly animal welfare expert investor contribute public debate laboratory host visit external group include animal welfare organisation investment group politician scientist school talk pupil role animal pharmaceutical research protest accept right lawful protest animal research free society condemn use violence intimidation oppose animal use performance policy revision revise strengthen policy care welfare treatment animal gsk clarify conduct contract sponsor support animal study great ape conduct animal testing product primarily medical healthcare benefit conduct contract sponsor support testing animal product design primarily improve appearance individual aesthetic beautifying purpose product aesthetic healthcare use classified cosmetic regulator animal testing permit require regulator primary use marketing claim relate healthcare benefit product ingredient example nutritional product animal testing permit require regulator order marketing claim related health benefit progress develop central database regularly update track different type animal study conduct gsk design help gsk researcher worldwide share experience refine animal use care information collect database provide baseline measure future progress progress include refining blood sampling technique enable multiple sample take single mouse reduce total number mouse require certain study reduce number mouse require carcinogenity testing update methodology refining rodent model experimental autoimmune oveoretinitis represent human sightthreatening inflammatory eye disease mouse strain develop milder form disease reduce pain distress adapt rodent model influenza enable researcher anticipate finding disease apparent trial animal reduce pain distress review refining model inflammation rat allow use historical datum reduce number rat require anticipate finding symptom relatively mild number animal number animal laboratory low activity increase significantly period reduction use factor include change research priority few batch vaccine require testing animal release continue focus initiative compare few animal decrease combination application principle closure animal research programme croatia italy decision stop neuroscience research follow ethical review animal terminate research programme house completion ongoing study transfer new site company research use possible euthanase estimate proportion animal gsk research conduct external contractor compare animal gsk mouse rat guinea pig rodent rabbit include animal external contractor behalf animal external contractor behalf cent rodent rabbit change activity compare change number animal gsk figure normalise level chart datum include animal research conduct external contractor behalf activity combine budget vaccine sale main driver animal use use baseline year comparison year start compare datum gsk legacy company glaxowellcome smithkline beecham animal welfare reviewing size animal enclosure location world ensure site align good practice principle animal housing welfare follow review housing dog work external primate behaviour expert refine housing strategy macaque monkey new housing provide macaque great comfort stimulation include increase forage opportunity humananimal interaction begin review training offer work animal ensure consistent standard site appoint fulltime training manager complete review enhance training curriculum necessary analyse ethical review propose animal study perform company publish internal guidance ensure review consistent site worldwide gsk animal welfare award internal animal welfare award recognise advance real difference animal experimentation conduct gsk animal routinely care award give employee go high standard expect gsk involve animal testing give award research group adapt method originally develop human bile sample dog past bile collect dog invasive surgery potential discomfort complication new method involve dog swallow string absorb bile animal intestine withdraw animal mouth switch technique significantly reduce number dog need undergo surgery engagement collaborate promote use example encourage european partnership alternative approach animal testing epaa traditionally advocate replacement animal research focus reduction refinement subsequently adopt epaas theme year plan support initiate collaborative experiment refine methodology potential alternative ocular irritancy testing rabbit currently require regulatory agency conduct research collaboration contract research organisation european centre validation alternative method ecvam interagency coordinate committee validation alternative method iccvam lead educational seminar update food drug administration present safety work party european medicine agency use dry blood spot dbs technology method reduce need analysis reduce number animal require participate work group run national centre replacement refinement reduction animal research ncrs sit national academy sciences council institute laboratory animal research serve board americans medical progress national association biomedical research scientist center animal welfare revise legislation use animal research read position new directive aaalaci accreditation accredit facility cover animal house gsk laboratory accredit facilities belgium canada spain work extend accreditation small facility france hungary conduct animal research small facility china present use lease facility plan new building occupy design obtain aaalaci accreditation interim confident standard lease facility comparable facility corporate responsibility report home research practice human tissue research human tissue research research human tissue human biological sample fundamental discovery development safety monitor gsk medicine vaccine commit conduct research manner respect right research participant meet legal ethical obligation global policy gain appropriate consent ethical approval human tissue research conduct sponsor support fund gsk ensure comply human tissue act apply ethical requirement research human biological sample take place establish global human biological sample management governance board provide unified governance approach consistent oversight gsk business undertake research human biological sample read approach stem cell research corporate responsibility report home research practice maintain confidentiality research participant maintain confidentiality research participant medical information collect research protect maintain confidentiality individual participant use variety procedure protect confidentiality research participant datum example use datum code encryption restrict access research database require party handle research datum behalf comply relevant data protection legislation standard collect retain information individual relevant research study include medical information health status medical condition include occasion genetic data treatment condition ethnic origin inform research participant medical information collect study explain collect describe type party work perform study participant withdraw consent future collection medical information time read inform consent process vast majority case collect store information directly identify individual initial name address personal identification number information identify individual specific instance require law regulation relate pharmacovigilance ensure accuracy reporting facilitate followup participant retain medical research datum duration reasonably necessary meet regulatory legal research need read global privacy principle corporate responsibility report home research practice medical governance medical governance medical governance system principle policy accountability ensure apply recognise principle good medical science integrity ethic standard discovery development marketing gsk product protect patient interest ensure patient safety gsk fundamental operating principle ahead commercial interest research conduct objective scientific ethical manner protect inform patient prescriber payer promotional practice information provide product ethical accurate balanced meet legal regulatory ethical obligation support appropriate use product maximise benefit minimise risk patient medical governance ensure safety ethical compliance issue identify clinical research market product medical information promotional practice deal quickly effectively possible step take correct root cause issue medical governance framework medical governance framework apply gsk focus particular clinical research involve human subject safety patient clinical trial participant information provide product clinical trial promotional activity overall responsibility medical governance sit chief medical officer cmo senior physician gsk cmo support medical governance executive committee mgec establish medical governance policy ensure medical governance system standardise gsk identify new risk establish medical governance board report mgec ensure consistent effective efficient operation medical governance model business market board responsible educating employee involve human subject research report medical governance policy approach framework require external collaborator adhere medical governance standard gsk read patient safety governance framework medical governance training develop training programme design educate employee medical governance framework policy good practice include guidance employee question concern medical governance end employee involve clinical trial safety communication product trial finding receive training continue raise awareness medical governance ensure employee understand individual responsibility act integrity apply high ethical standard report safety concern corporate responsibility report home research practice conduct clinical trial conduct clinical trial clinical trial healthy volunteer patient enable assess compound potential new medicine medicine approve marketing evaluate effect medicine approve use assess potential use obtain additional safety datum conduct clinical trial accordance good clinical practice gcp guideline develop international conference harmonisation ich principle contain world medical association declaration helsinki ethical principle medical research involve human subject trial protocol review ethic committee independent gsk gsksponsore clinical trial conduct ethical standard irrespective place read conduct clinical trial develop world contract research organisation cro contract carry trialrelate activity behalf example monitoring study centre datum quality management require apply high standard study conduct read audit cro successful clinical trial programme usually phase trial effect potential medicine compare currently available medicine case inactive substance know placebo ethic conduct placebocontrolle trial question patient group receive placebo provide active treatment placebocontrolle trial carry compelling scientifically sound methodological reason risk minimise reasonable relation knowledge gain patient receive placebo subject additional risk irreversible harm safety clinical trial participant paramount importance evaluate safety phase clinical trial programme trial begin gsk work ethic committee investigator establish informed consent process explain research participant detail study benefit risk gsk employee involve conduct trial receive train regulatory requirement gsk policy trial audit internal audit department external regulator read clinical trial process corporate responsibility report home research practice conduct clinical trial plan approval planning approval clinical trial develop protocol set purpose research explain trial conduct result analyse include detail dosage supply duration treatment number participant require define measurement evaluate medicine safety efficacy describe procedure follow participant wish withdraw study protocol review ethical review committee independent gsk lay people medical professional scientist power reject stop clinical trial committee review approve material relate trial include information provide inform consent process instance trial protocol review government regulatory agency corporate responsibility report home research practice conduct clinical trial work healthcare professional work healthcare professional gsk conduct clinical research partnership healthcare professional possess unique medical insight knowledge critical development new medicine vaccine care ensure interaction conduct ethically reflect good interest patient clinical trial participant policy govern interaction gsk staff healthcare practitioner require clinical trial investigator select solely qualification conduct good quality clinical research history gsk product take account decide include exclude trial investigator payment practitioner govern contract compensation reflect fair market value work perform service provide payment offer influence judgement enrol maintain research participant clinical study gift permissible healthcare professional involve research project gsk commitment disclose research payment healthcare professional institution commence payment healthcare professional institution research study begin january onwards annual disclosure half capture payment phase medicine discovery development include clinical trial outside continue work disclosure individual payment disclose payment healthcare professional research institution aggregate basis commencing publication payment read payment healthcare professional organisation corporate responsibility report home research practice conduct clinical trial inform consent inform consent potential clinical trial participant voluntarily confirm willingness participate informed study benefit risk know informed consent inform consent clinical trial involve read sign consent form wide process communicate essential information trial include purpose treatment procedure potential benefit risk alternative participation provision datum protection confidentiality participant right include voluntary nature participation right end participation aim provide information potential trial participant nontechnical style lie person understand write document opportunitie facetoface conversation potential participant member research team discuss trial answer question use feedback patient group improve information provide prospective participant read able speak understand local language impartial witness present inform consent process confirm write necessary information accurately explain potential participant able ask question give consent voluntarily inform consent ongoing interactive process person decide participate trial research team update new information affect want continue potential new effect participant opportunity ask question raise concern trial special case obtain informed consent possible instance potential participant age legal consent seek consent allow provide local law regulation corporate responsibility report home research practice conduct clinical trial posttrial treatment posttrial treatment recognise continue treatment clinical trial participant nationally license medicine end trial require continued care patient general responsible funding nationally license medicine trial responsibility government provider national healthcare system begin trial disease condition continue completion trial assure healthcare system able provide responsibility continue care patient exceptional circumstance nationally license medicine fund gsk trial available trial participant derive measurable medical benefit continue fund medicine fund normal healthcare infrastructure patient long derive medical benefit circumstance compelling medical rationale patient continue receive gsk investigational medicine clinical trial case posttrial treatment provide clinical trial expand access programme enable appropriate oversight report adverse event circumstance gsk fund investigational medicine long patient benefit compound approve license country read public policy clinical trial develop world corporate responsibility report home research practice conduct clinical trial clinical trial develop world clinical trial develop world gsk clinical trial carry conduct high standard develop country need additional step ensure trial conduct accord good clinical practice gcp guideline necessary match objective inform consent local culture instance involve local leader family member gsk provide training ensure healthcare professional necessary skill knowledge conduct clinical trial behalf benefit gsk enhance skill healthcare professional way bring last benefit community conduct clinical trial country know outset intend pursue registration product available use country read position statement clinical trial develop world corporate responsibility report home research practice conduct clinical trial clinical trial child clinical trial child child number important physiological difference adult mean respond differently medicinesclinical trial child vital develop safe effective medicine child present lack medicine approve child commit development medicine child consider children need new medicine development programme read public policy paediatric medicine conduct clinical trial child carry practical ethical challenge example difficult recruit trial participant few speciality centre paediatric research compare adult extra step need obtain inform consent parent legal representative child child care occasionally necessary recruit child care clinical trial example child hivaid develop world lose parent disease care trial involve child care present ethical concern parental protection child vulnerable additional step ensure high ethical standard follow approval obtain chief medical officer child care recruit gsk clinical trial institutional review board ethic committee oversee trial explicit approval inclusion child corporate responsibility report home research practice conduct clinical trial training auditing training auditing training clinical trial employee involve design conduct recording reporting gsksponsore clinical research study receive train good clinical practice gcp guideline develop international conference harmonisation ich employee complete required training undertaking role detailed employee training record routinely request regulatory authority inspect gsk clinical research trial work regulator organisation continually improve quality compliance clinical trial provide training clinical researcher conduct clinical trial behalf gsk sponsor audit clinical trial risk management compliance framework include independent audit assessment conduct clinical trial audits assessment cover gsk system process external clinical research organisation cro investigator conduct clinical research behalf conduct trial asia latin america reflect business growth region reorganise quality assurance management structure provide additional audit compliance support region trial select audit assessment base risk risk factor include complexity study patient population location study previous audit history unusual finding conduct study report audit result quarterly compliance board annually risk oversight compliance council audit committee gsk board director read corporate governance section annual report concern issue identify fully investigate appropriate corrective action take gsk staff corrective action include development new training programme retrain individual concern severe case clear breach policy occur appropriate disciplinary action take include dismissal external investigator gsk retrain investigator stop work significant noncompliance impact patient safety integrity datum identify investigative site report trial datum regulator include exclude site provide rationale exclusion cro gsk require cro conduct additional training personnel enhance clinical andor quality assurance system significant noncompliance identify gsk promptly secure compliance discontinue association cro consider available site inspection report publish regulatory agency information debarment disqualification warning letter disciplinary action issue investigator help avoid stop investigator meet quality standard time begin audit new drug application nda report submit food drug administration fda drug approval process help confirm safety datum report include information clinical trial complete thirdparty audits regulatory authority carry independent inspection gsk investigator clinical research organisation cro use conduct clinical trial inspect independent ethic committee institutional review board ensure safety trial participant quality datum conduct trial accord good clinical practice guideline thirdparty audits occur increase frequency grow focus clinical trial emerge market market example africa latin america authority begin conduct audits time standard set regulatory authority stringent essential maintain sufficient oversight clinical trial conduct behalf system place ensure quality safety training clinical trial training activity relate good clinical practice gcp represent successful completion elearning module instructorle course relate gcp employee contractor audit clinical trial conduct audits assessment focus investigator site conduct gsksponsore trial represent approximately investigator site participate pivotal clinical trial trial provide primary datum regulatory approval base gsk system process clinical research organisation carry clinical trial gsk behalf gsk local operating company involve clinical research activity new drug application nda report submit fda addition investigation conduct response suspect irregularity investigator site fully investigate process investigate concern issue identify take appropriate corrective action box regulatory authority perform inspection gsk investigator use conduct clinical trial work research organisation ensure compliance routine visit research organisation conduct clinical trial behalf course visit aware area noncompliance regulation requirement include deficiency contractor monitor quality assurance process inform organisation finding immediately acknowledge nature issue identify implement action correct situation ensure happen research organisation develop robust quality assurance process agreed immediately begin conduct prequalification visit investigator site significantly increase number frequency routine monitoring visit site measure greatly improve organisation ability verify demonstrate compliance requirement standard auditor follow organisation check progress agree timeframe corporate responsibility report home research practice public disclosure clinical research public disclosure clinical research approach pharmaceutical company legally require disclose relevant data clinical trial appropriate regulatory authority seek approval new medicine provide update safety information clinical trial approval read patient safety safety efficacy information provide doctor prescribe information approve regulator gsk commit public disclosure clinical research irrespective result perceive positive negative medicine believe fundamental advance medical science inform prescriber patient scientific finding relate medicine clinical study register clinical study register website launch serve resource researcher medical professional public access datum gsksponsore clinical trial supplement locally approve prescribing information publication scientific literature figure end indicate site receive visitor month register include protocol summary ongoing study summary result complete clinical study compound subsequently market medicine summary result observational research study medicine normal medical practice metaanalyse combine analyse result previously conduct study evaluate medicine summary result study terminate medicine compound long develop help inform scientific community nonproductive area research reduce unnecessary exposure study participant similar compound clinical trial name principal investigator participate clinical research aim disclose trial result summarie new medicinal product register time approval month terminate development medicine trial complete product approve marketing aim disclose result year trial completion publication journal believe pharmaceutical company commitment seek publication result clinical trial paper scientific journal journal undergo independent peer review provide context interpretation research datum gsk policy prohibit ghost write journal manuscript require authorship acknowledgement scientific publication consistent requirement international committee medical journal editor icmje help meet commitment journal publication publication practice establish embed requirement gsk scientific publication medical scientific significance responsibility project physician scientist external author involvement gsk commercial staff read way work clearly separate nonpromotional scientific dialogue legitimate commercial promotional activity support license product study publish journal example perceive journal sufficient interest journal reader provide context interpretation result clinical study register help user interpret datum read position statement disclosure clinical trial information read principle work healthcare professional conduct research performance end clinical study register include protocol summary actively recruit gsk clinical trial medicine total post new result summary clinical study register year bring total chart study post internal target timeline number result summary gsk clinical trial gsk clinical study register medical publishing insight practice initiative make progress gsk found member medical publishing insight practice mpip initiative mpip bring pharmaceutical industry member medical publication professional society promote trust transparency publishing industrysponsore research mpip help improve understand issue challenge face journal publish industry research identify potential solution promote effective partnership raise standard expand access data mpip significant progress recognise communiqu trust reputation award issue pharmaceutical industry communication specialist group award recognise pharmaceutical initiative enhance industry trust reputation line association british pharmaceutical industrys trust initiative mpip publish author submission toolkit practical guide get research publish journal current medical research opinion toolkit aim help raise standard improve efficiency medical publishing highlight good practice manuscript development submission toolkit develop collaboration mpip cosponsor editor publisher lead journal introduce annual meeting international society medical publication professional mpip roll toolkit series industry training session november mpip host roundtable event journal editor focus editor view industrysponsore research paper credible goal close credibility gap output meeting set recommendation enhance credibility industry research include ensure clinical study publication address clinical business question publishing datum include negative result adverse event improve disclosure author conflict interest corporate responsibility report home research practice patient safety patient safety ensure safety medicine medical device critically important health wellbeing patient success business medicine potential risk benefit take medicine experience effect important identify evaluate minimise safety concern ensure overall benefit medicine outweigh risk strive serve patient interest promptly detect potential safety issue product communicate regulator appropriate decision action take product safety assess clinical trial product approve marketing adverse event possible effect detect approval product large number patient policy governance framework place help detect act adverse event dedicated team scientist healthcare professional world specific role monitor communicate safety issue regulatory authority work government official industry partner policy maker enhance safety system medicine vaccine read patient safety governance framework collect report safety datum corporate responsibility report home research practice patient safety patient safety governance framework patient safety governance framework global safety board gsb make decision product safety issue board chair chief medical officer compose senior physician scientist gsbs remit ensure safety focus product development review safety gsk product go market decision guide need ensure medicine vaccine favourable benefitrisk profile activity include oversee safety investigational market medicine vaccine consumer healthcare product approve administration investigational medicine human define condition use medicine vaccine minimise safety risk include special safety monitoring dose duration treatment consider safe approve progression investigational medicine pivotal trial trial provide primary datum regulatory approval base assess issue relate patient safety arise product development marketing central department responsible recording investigate evaluate adverse event report relevant regulatory authority example food drug administration fda european medicines agency ema global clinical safety pharmacovigilance team gcsp research organisation responsible safety evaluation pharmaceutical device gsk biological clinical safety pharmacovigilance department vaccine business responsible safety evaluation gsk vaccine consumer healthcare product safety group consumer healthcare business responsible safety evaluation consumer healthcare product require gsk staff immediately report issue relate safety quality medicine read expectation code conduct read medical governance benefitrisk management assess balance benefit risk particular medicine life cycle early development clinical trial product market evaluate document available safety information build detailed benefitrisk profile product use information develop benefitrisk management plan identify way improve product benefit minimise risk review update plan regularly clinical development period product approve marketing corporate responsibility report home research practice patient safety collecting report safety datum collect report safety datum requirement receive information adverse event possible effect source include unsolicited report healthcare professional patient postmarkete trial observational study investigator submit clinical study report regulatory authority medical scientific literature newspaper medium gsk employee require report adverse event aware outlined policy adverse event report annual business ethic certification programme employee confirm compliance policy add adverse event report button intranet site report easy employee adverse event report gsk record global safety database clinical trial database investigate clinical pharmacovigilance team report potential safety issue regulatory authority regularly regulator country publish information adverse event internet example data product market available medicine healthcare product regulatory agency mhra safety datum available canada food drug administration fda information database accessible public publish quarterly report potential safety issue investigate read medical governance gsk position statement pharmacovigilance respond adverse event adverse event affect benefitrisk profile product corrective action need minimise risk include carry clinical trial modify prescribing information communication physicians healthcare provider establish specific method minimise risk example highlight warn prescribe information product subject limited distribution programme prescription specialist doctor certain case appropriate stop clinical trial withdraw product market global labelling committee review approve prescribe information medicinal product ensure update appropriate read response question diabete product avandia product contain long act beta agonist labas improvements innovation continue improve patient safety system safety database monitoring process example develop sfetywork software tool enable rapid review safety information observational data source partner regulatory agency observational medical outcomes partnership omop understand well detect safety issue associate product observational database enhance process identify manage safety signal example establish system provide real time alert sudden change number adverse event report receive month particular product adapt system collate adverse event report facilitate electronic upload adverse event report compliance international regulatory standard allow efficient way process safety datum read collaboration patient safety new capability science benefit risk evaluation medicine enhance approach patient safety establish new clinical science evaluation team specialist team physician scientist focus increase expertise evaluation safety efficacy medicine development approve use patient team draw late research area population science clinical medicine help assess great detail patient respond medicine ultimately enable provide detailed information patient physician benefit risk medicine aim establish network external expert gsk collaborate develop science benefit risk assessment new scientific regulatory standard activity lead recent appointee gsk expert field population science health outcome research chair lead american medical school senior role report directly chair join global safety board corporate responsibility report home research practice patient safety collecting report safety datum respond question avandia respond question avandia avandia rosiglitazone treatment type diabete subject debate associate increase risk myocardial infarction european medicine agency ema fda take individual regulatory decision action september follow review avandia european union ema suspend marketing authorisation rosiglitazonecontaining medicine avandia avandamet avaglim ema state suspension remain place convincing datum provide identify group patient benefit medicine outweigh risk rosiglitazonecontaine medicine avandia avandamet avandaryl remain available additional safety labelling restriction use fda require risk evaluation mitigation strategy rem programme additional measure ensure safe use medicine fda suspend operation tide trial primary concern continue patient type diabete follow decision worked ensure physician europe information need help understand regulatory decision affect patient revise label medication guide rosiglitazonecontaine medicine withdraw product market govern ema continue believe avandia important treatment patient type diabete work fda implement remain fda requirement risk evaluation mitigation strategy rem programme ensure doctor patient aware restriction independent readjudication endpoint report cardiovascular safety study record work closely regulatory agency comply decision rosiglitazonecontaine medicine gsk voluntarily cease promotion avandia country operate continue respond request information support healthcare professional patient avandia resource centre late information corporate responsibility report home research practice patient safety collecting report safety datum development concern safety product contain long act beta agonist labas development concern safety product contain long act beta agonist labas longacte beta agonist know labas daily controller medicine relieve help prevent airway constriction airway constriction main component asthma labas treat main component asthma inflammation treat type daily controller medicine call inhale corticosteroid ics labas include gsk product serevent treatment persistent asthma lead treatment guideline recommend labas appropriate patient asthma combination ics gsk make product contain laba salmeterol seretideadvair combination salmeterol ics fluticasone serevent contain salmeterol june long period regulatory review include advisory committee meeting focus issue potentially increase risk asthmarelate death outcome gsk implement update labelling labacontaine product accordance fda direction labacontaining product indicate use treat asthma update labelling includes strengthen risk information recommendation intend promote safe use patient asthma fda approve new risk evaluation management strategy serevent advair include medication guide use patient gsk communication plan educate prescriber strengthen risk information recommendation intend promote safe use patient asthma fda require clinical research potential approach explore march advisory committee meeting consultation fda appropriate trial design continue corporate responsibility report home research practice patient safety collaboration patient safety collaboration patient safety work government official industry partner policy maker enhance safety system medicine vaccine cofounder international adverse event consortium isaec nonprofit collaboration partner include pharmaceutical company academic institution regulatory body work improve patient safety identify genetic variant predict adverse event gsk scientist cochair isaec scientific management committee seat board director isaec initial research focus reaction consider discontinue medication druginduce liver injury druginduce skin rashe stevensjohnson syndrome toxic epidermal necrolysis gsk contribute patient sample scientific expertise study europe gsk industry lead patient safety project innovative medicine initiative project protect publicprivate partnership aim improve process assessment benefitrisk profile new medicine partner food drug administration fda pharmaceutical company healthcare professional academia develop new system detection adverse event explore effectively communicate write information medicine patient example participate fda initiative improve patient medication information participate critical path institute predictive safety testing consortium independent nonprofit organisation bring scientist industry academia share validate safety testing method guidance fda european medicines agency ema member executive scientific oversight committee cardiac safety research consortium launch fda critical path initiative memorandum understand duke university use principle critical path initiative focus improve evaluation cardiac safety development new medicine read collaboration ensure improvement innovation collect report safety datum corporate responsibility report home ethical conduct introduction ethical conduct build strong ethical culture gsk develop robust policy recruit right people equip information need ethical decision put patient core principle ethical healthcare company failure uphold high standard ethical conduct carry significant business risk erosion trust gsk product include regulator doctor patient fine litigation result financial legal consequence damage gsk reputation code conduct set fundamental standard employee support employee guide business conduct help employee ethical decision emphasise gsk key value commit transparency respect people demonstrate high integrity conduct patient focus stress commitment performance integrity mean employee understand value stand policy procedure underpin approach internal compliance system design identify address breach code reinforce gsk value continual external pressure enhance system compliance oversight audits help drive change fully investigate suspect breach appropriate disciplinary action include dismissal ethical risk review diligence process acquisition bureau verita assure ethical conduct section report recommendation improve approach report take recommendation account improvement policy process ethical compass employee guide business conduct include ethical compass help employee deal ethical issue difficult resolve faced situation encourage people ask question legal ethical consistent gsk policy code conduct consistent gsk mission spirit explain family friend comfortable appeared newspaper encourage employee seek guidance ask question certain making right choice corporate responsibility report home ethical conduct key policy key policy code conduct gsk code conduct apply employee contractor states conduct business honesty integrity professional manner protect gsk good public image reputation build relationship customer vendor suppliers fellow employee base trust treat individual respect dignity conduct business familiar comply legal requirement gsk policy procedure avoid activity involve lead involvement unlawful practice harm gsk reputation image avoid actual potential conflict interest gsk appearance thereof transaction read code conduct employee guide business conduct employee guide business conduct build code explain employee meet requirement contain policy guidance ensure operate accord law maintain high standard ethical business behaviour guide emphasise good ethical conduct essential continued business growth ability improve quality life patient employee guide available language help employee understand policy align value include reallife scenario sample question employee guide business conduct question vendor offer pay weekend resort wife compensate time spend month evaluate vendor product finished assessment trip accept answer think look wife take trip people certainly reward payoff pick vendor unacceptable offer politely firmly refuse question information competitor mysteriously appear office mail return address indication come information include competitor plan price increase information answer review material place seal envelope immediately contact gsk legal department guidance respect company proprietary confidential information permit use information addition information receive relate competitor future price risk gsk competition law party code conduct introduce party code conduct gsk supplier set standard expect supplier meet cover ethical conduct labour practice environmental health safety standard management make exist supplier aware code routine interaction require new supplier sign statement confirm comply principle code business gsk help supplier understand interact appropriately gsk staff code include key principle employee guide business conduct policy receiving gift supplier agent engage activity subject gsk commercial practice policy govern sale marketing activity contractually require read certify compliance ethic policy initiate service gsk policy update available supplier online read gsk supply chain anticompetitive behaviour policy commit free open competition succeed company high quality competitiveness product talent commitment employee corrupt anticompetitive behaviour undermine fair competition inhibit economic development bad economy business people policy anticompetitive behaviour cover issue merger abuse monopoly power resale price maintenance predatory pricing restrictive agreement practice set standard behaviour expect employee agent prevent bribery corruption review strengthen approach prevent detect address bribery corruption prevent corrupt practice policy update launch dedicated antibribery corruption unit ensure consistent approach company gsk require compliance high ethical standard anticorruption law applicable conduct business value integrity transparency zero tolerance corrupt activity kind committed gsk employee party act behalf gsk unauthorised payment act create appearance promise offering give authorise payment prohibit policy tolerate mandatory risk assessment diligence procedure implement assess bribery corruption risk relate relationship party business development transaction contract template update include antibribery corruption policy change apply new contract exist contract renew apply policy practice comply antibribery corruption policy gsk employee carry appropriate check engage supplier party additional diligence require highrisk party include agent externalface consultant distributor party interact government official operate highrisk market diligence process help reduce risk business partner breach antibribery corruption policy assessment base diligence report provide dedicated inhouse team licensed research tool database supply external vendor look evidence negative news report warning sanction involve potential business partner association politically expose person present increase risk bribery corruption report raise concern employee discuss local compliance officer legal representative commission supplier case mean progress relationship party transaction employee read antibribery policy access antibribery handbook elearne module intranet training mandatory manager additional facetoface training develop employee involve selection payment oversight party business development interaction government official improve detection bribery corruption commission ernst young work antibribery corruption unit develop riskbase auditing monitor methodology use combination datum analytic traditional auditing forensic accounting technique change introduction party code conduct support compliance new bribery act foreign corrupt practice act anticorruption law example corruption prevention training anticorruption training introduce november design help employee understand comply antibribery corruption policy elearne module include example scenario employee encounter work example ask facilitation payment expedite processing visa application explain deal situation include report potential problem course available language complete mandatory gsk manager employee work function legal region high risk corruption course corporate responsibility report home ethical conduct key policy privacy privacy collect use personal datum number group people course business include employee consumer customer participant clinical research aim open transparent personal information collect use share party require practical provide processing information individual obtain individual inform voluntary consent process personal datum case necessary appropriate develop set global privacy principle ensure personal datum collect process transfer store securely appropriately line legal requirement helps maintain trust gsk establish datum privacy centre excellence global privacy office oversee privacy process communicate good practice gsk raise awareness gsk employee launch campaign reminding importance protect personal information refresh relaunche global privacy policy ensure reflect key legal requirement gsk value develop deploy datum privacy training support global privacy programme continue develop indepth training employee involve handle personal datum regular basis corporate responsibility report home ethical conduct key policy acquisition diligence acquisition diligence gsk expand presence emerge market acquire new business enter new joint venture region enter joint venture acquire new business look organisation share value diligence process potential acquisition take account ethical risk integrate ethic compliance requirement standard practice newly acquire business work embed value policy risk management analysis internal communication framework month new acquisition integration process new business include compare new company compliance programme identify area nonalignment develop action plan address roll global anticorruption policy employee training implement code conduct compliance training aligning gsk transparency initiative disclosure grant payment healthcare professional implement key compliance control monitoring process deliver performance integrity training look number company possible collaboration joint venture acquisition case choose pursue deal diligence process raise concern difference ethical standard company standard gsk type issue identify include insufficient regulatory datum support claim marketed product sale product meet gsk ethical safety standard certain case conclude acquisition discontinue sale product safety ethical reason introduce significant relabelle corporate responsibility report home ethical conduct marketing product marketing product market prescription medicine vaccine healthcare professional hospital government country advertise medicine directly consumer specialist sale representative meet regularly doctor pharmacist inform medicine approve use believe sale representative play important role provide uptodate information doctor product benefit risk patient recognise marketing pharmaceutical product raise challenge issue people concern marketing pharmaceutical company exert undue influence doctor sale representative doctor information potential effect promotion unapproved use medicine occur global marketing code forbid practice unethical conduct provide regular training sale team monitor compliance important gsk actively engage scientific debate communication outside company enable participate fully development scientific understanding benefit knowledge lead external scientist practitioner patient apply good science development medicine vaccine avoid activity construe promotion product new use product authorisation market support implement clear standard way work emphasise distinction nonpromotional scientific dialogue legitimate promotional activity support license product new standard apply scientific medical interaction external group include healthcare practitioner payer government patient group medium view scientific activity appear way promotional credibility undermine lose trust stakeholder standard support role trust value scientific partner develop medicine vaccine enhance patient care marketing code practice sale promotion pharmaceutical product highly regulate government medical agency addition gsk global code promotional activity interaction healthcare professional regional marketing code set consistent standard employee agent work behalf commit promotional practice ethical responsible principled patientcentred prohibit kickback bribery inducement healthcare professional hcp government official promotion unapproved use medicine regional code reflect difference market structure national healthcare system regulation stringent global code region country restrictive gsk support effort strengthen marketing standard pharmaceutical industry benefit patient support appropriate treatment help ensure company operate high ethical standard competitive disadvantage help improve reputation pharmaceutical industry marketing code practice summary information marketing promotion base valid scientific evidence accurate balanced fair objective unambiguous date information provide approve use medicine item healthcare professional educational assist patient administration treatment management condition reflect local custom accordance local law regulation industry code item give inducement prescribe medicine medical professional retain consultant gsk hospitality meeting gsk host meeting venue reasonably perceive lavish extravagant business meeting programme venue hospitality offer attract delegate attend gsk invite delegate guest accompany pay guest cost grant decision grant medical education review qualified medical scientific personnel grant donation charitable contribution inducement reward prescription product global practice employee regularly interact healthcare professional complete annual business ethic certification process confirm understand compliance employee guide business conduct update policy engage public official include healthcare professional acting capacity doctor serve ministry health government policy generally prohibit gsk employee sponsor funding government official attend educational meeting congress generally prohibit gift government official implement additional control prevent market research hcp disguise promotion pharmaceutical product market research study review approve medical governance department united states continue work resolve number longstanding legal matter light case fundamentally change procedure compliance marketing sell farreache policy procedure place guard inappropriate promotion hcp seek ensure breach regulation occur report government strengthen training compliance programme eliminate past practice adopt new measure relationship hcp enhance practice medicine approach reflect gsk commitment honesty integrity focus good interest patient update commercial practice policy cpps support marketing code sure fully align value language policy simplify easy employee understand sale marketing practice meet exceed phrma code interaction healthcare professional comply applicable federal healthcare programme fda requirement addition requirement global code policy practice include state reporting system payment healthcare professional hcps line legislative requirement states requirement gsk grant healthcarerelate group include patient advocacy group physician association exceed cent group annual income speaker evaluation process hcp sponsor gsk compliance team external supplier evaluate highfrequency speaker provide feedback effectiveness compliance speaker programme policy conduct speaker evaluation question doctor offlabel use product refer medical information department number type referral individual sale representative monitor help ensure representative promote offlabel use sale force remuneration reinforce requirement behaviour field sale staff consistent value change way incentivise representative date variable pay dependent volume prescription gsk product sale territory put place system reflect factor representative bonus pay assessment scientific business knowledge feedback customer region include demonstration gsk value overall performance business unit support shift focus generate prescription provide information support customer want programme fully implement july continue medical education grant implement new standard fund continue medical education educational activity help hcp maintain develop increase knowledge skill professional performance reduce number education provider support restrict fund academic medical centre professional medical association long fund medical education programme offer commercial medical education provider new approach help focus support education programme great potential improve patient health europe update european marketing code clarify provision gift state item provide use gsksponsore medical educational meeting pen paper pad brand gsk logo productspecific brand logo medical educational item permit enhance responsible use medicine gsk therapy area carry product branding value europe code practice interaction hcp reflect european federation pharmaceutical industry association code promotion specify use consultant gsk employee responsible select consultant expertise authority evaluate consultant suitable meet identify business need provide service real value gsk consultant require declare consultancy arrangement gsk speak publicly relate issue sample product sample give limit number limit time reference local standard hcps familiarise new product grant donation make grant financial donation health organisation involve grant donation receive service return grant donation give response unsolicited request purpose healthcare research offer give understand recipient prescribe recommend product permit health organisation individual phase clinical study conduct phase study study conduct medicine approve marketing use follow principle study commission inducement prescribe supply recommend medicine clear scientific healthcare research purpose contract institution undertake research study conduct accordance gsk policy study result distribute investigator line publication policy asia pacific japan emerge market revise promotion marketing code region implement requirement include hcp fee country set annual maximum limit cap fee pay individual hcp country grant donation provide response unsolicited request hcp institution provide offer exchange prescribing medicine commitment continue prescribe medicine grant donation give institution association hospital individual hcp gsk assure valid purpose grant donation involve detail receive service return sample sample provide inducement prescribe maximum number sample hcp maximum time period set national code define local standard operating procedure market research market research collection method unbiased nonpromotional subsequent use statistic information promotional local guidance available development market research material base code doubt material review medical department ensure research process constitute promotion clinical study market research study clearly identify potential participant medical education hcp invite attend gsk medical education event country meeting hold country clear compelling reason hold location gsk invite guest accompany invitee pay cost associate individual accompany invite hcp corporate responsibility report home ethical conduct grant donation healthcare organisation grant donation healthcare organisation gsk regularly ask grant donation healthcare organisation support range activity healthcare organisation mean private public sector organisation association healthcare professional hcp patient support research provide information hcp patient grant monetary contribution give organisation fund attendance organisation hcp medical scientific meeting cover expense grant provide support research gsk directly involve activity support independent medical education programme donation define gsk nonmonetary contribution example provide equipment bone densitometer medical textbook benefit patient healthcare organisation gsk assign monetary value donation order track activity separately community investment grant product donation include disclosure community investment gsk solicit request grant donation involve detail grant donation assure valid purpose grant donation benefit patient public health standard marketing code set requirement make grant donation include individual hcp purpose healthcare research gsk receive service return give understand recipient prescribe recommend product publish grant donation grant patient advocacy organisation cover section patient advocacy charitable donation include disclosure community investment start publish quarterly report grant donation february achieve country challenge system place uniquely identify healthcare organisation collate datum multiple market currency need write permission recipient organisation disclose purpose value grant donation continue work disclosure individual healthcare organisation grant donation publish aggregate payment commercial operation pharmaceutical consumer healthcare outside end corporate responsibility report home ethical conduct payment healthcare professional payment healthcare professional healthcare professional bring expert knowledge perspective clinical healthcare management experience share healthcare company gsk healthcare professional support improvement patient care service valuable improve patient health gsk believe professional fairly compensate provide service expertise gsk make payment healthcare professional hcp follow circumstance sponsorship financial support provide healthcare professional participate scientific conference support limited payment registration fee reasonable travel meal accommodation speaker service pay hcp speak meeting conference gsk product disease therapy area relevant payment hcp reasonable reflect time spend speak gsk behalf advisory panel convene advisory panel hcps example learn unmet medical need improve science develop new therapy conduct research read engage healthcare professional conduct medical research behalf clear standard set work hcp pay support provided inducement reward prescribing product interest external healthcare professional work receive excessive funding gsk work detract significantly time spend patient conduct research reduce professional credibility value independent source current medical expertise payment healthcare professional fair market value account individual speciality area level expertise time spend provide professional service standard schedule fee hcp vary accord speciality hcp local regional international expert fee determine research base information national wage survey introduce policy state speaker transparent gsk support attendance conference content education programme influence gsk publishing payment hcp speak advisory service commit publishing payment hcp achieve country challenge system country need aligned help uniquely identify hcp collate datum multiple currency personal information need obtain permission hcp disclose continue work disclosure individual healthcare professional payment take account complexity cultural challenge publication payment present country gsk implement datagathering system enable reporting fee consistently company process company amend contract hcp include clause allow individual datum closure publish quarterly report payment hcp speak advisory service available website january reduce limit payment hcp speaker advisory fee restrict maximum year individual hcp hcp consultant receive fee total year continue work disclosure payment individual hcp publish aggregate payment commercial organisation pharmaceutical consumer healthcare outside end corporate responsibility report home ethical conduct directtoconsumer advertising directtoconsumer advertising approach legal advertise prescription medicine consumer television print advertisement know directtoconsumer dtc advertise new zealand bangladesh south korea allow limited dtc advertising market allow limited advertising vaccine dtc advertising prescription medicine permit market promote use prescription medicine directly consumer raise concern critic believe encourage people request unnecessary treatment add burden healthcare system believe responsible pharmaceutical advertising useful source health information patient helps increase knowledge condition educate patient treatment option patient consult physician condition appropriateness prescription medicine obtain consent receive medicine prescription medicine dtc communication policy base phrma guiding principle direct consumer advertisement prescription medicine detailed approval process dtc advertising include review legal regulatory medical specialist appropriate train marketing employee dtc policy new dtc television advertisement submit food drug administration fda review comment prior broadcast member public healthcare professional send comment complaint dtc advertise phrmas office accountability report comment response company fda principle dtc advertise policy require commit appropriate time educate healthcare professional new medicine indication launch dtc advertising state dtc advertising design educate public medicine condition prescribe accurate support evidence include information risk benefit treatment provide information treatment option diet lifestyle change reference prescribe information product target audience cent adult overthecounter medicine consumer healthcare product advertising overthecounter medicine oral healthcare nutritional product govern national regulation code practice advertising overthecounter medicine promote pharmacist doctor dentist sale team belong consumer healthcare product association comply code advertising practice nonprescription medicine gsk consumer healthcare advertising review copy review committee large market medical legal personnel small market publication ensure meet standard diseaseawareness campaign market fund diseaseawareness campaign design increase understand disease promote specific gsk product campaign place coincide launch new product market raise awareness disease positive impact public health create commercial benefit gsk diseaseawareness campaign form television print advertisement direct mail mention specific gsk product people aware treatment available condition encourage doctor policy place ensure diseaseawareness campaign conduct high ethical standard example campaign govern dtc policy campaign material brand indicate produce gsk advertising child guideline advertising child prohibit advertising design appeal target child legally mandate minimum age example comply guideline buy advertising space children medium supply vend machine primary school sport star sponsorship important brand lucozade sport guideline state people set appropriate example sponsorship appeal solely child age performance pharmaceutical business receive notice violation fdas division drug marketing advertising communication ddmac ddmac response express concern draft promotional material submit review case violation immediately review withdraw material retraining provide employee involve develop material april ddmac write astellas pharma inc vesicare website gsk copromotion partner vesicare copy letter ddmac find website false misleading contain unsubstantiated superiority claim overstatement efficacy vesicare vesicare website immediately suspend amendment employee alert use vesicare promotional material review april gsk receive warning letter journal advertisement arzerra ddmac find advertisement mention arzerra clearly point product find advertisement false misleading omit important information safety effectiveness arzerra letter state gsk fail submit copy advertisement fda review gsk take step deem advertisement unbranded arzerra material use promptly review employee instruct discontinue related arzerra advertising april ddmac write gsk promotional material altabax find material contain misleading information broaden indication altabax unsubstantiated superiority claim minimise important risk information altabax response team promptly review active material instruct sale representative speaker stop write healthcare professional hcp receive promotional material provide corrective information issue raise ddmacs warning letter direction provide fda seriously develop new standard operating procedure help ensure fda requirement reflect future advertising violation country gsk use dtc advertise corporate responsibility report home ethical conduct training awareness train awareness train awareness programme help employee understand importance ethical conduct apply policy practice hire new recruit carry preemployment check ensure share gsk value include question ethic integrity guide employee interview expect employee live gsk value reinforce employee guide business conduct senior leader meeting employee broadcast communication training help employee understand apply value decisionmake process key ethic integrity message include profit principle short live gsk unwavere commitment conduct business integrity compliance law gsk employee personally professionally responsible help gsk maintain organisational integrity good reputation face difficult ethical situation refer ethical decisionmake model corporate ethic compliance intranet community contain link company policy ethic compliance train new recruit ethical decisionmake model ethic quiz useful example connection key training programme antibribery corruption party oversight audit assurance contact detail compliance officer freephone number global confidential reporting line integrity helpline employee advice guidance manager human resource legal department local compliance officer champion read reporting channel ethical issue new employee complete induction training gsk code conduct available intranet site train new general manager site director compliance responsibility monitor compliance arrangement annual business ethic certification programme require manager employee interact healthcare professional confirm comply ethic policy manager access elearning module ethical leadership company intranet specialised training provide employee work manufacturing sale market additional regulatory requirement train employee work sale marketing include induction training testing marketing code practice detailed training sale representative medicine promote disease design treat regular refresher course hold year regular management update risk management compliance board type unethical conduct detect disciplinary action take provide extra training guidance employee commit minor breach prevent commit breach future ethic training practice ethic training help employee right decision apply policy practice run ethical decisionmake training employee leader explore ethical dilemma face work provide guidance help understand appropriate response example ethical dilemma startup company approach work small project consultant work weekend evening use extra money time available work accept offer know occur outside workplace consider personal talk manager compliance officer gsk legal department offer decide reject offer take second job create conflict interest good answer situation different discuss implication make decision corporate responsibility report home ethical conduct training awareness lead example lead example senior manager expect lead example comply company policy support staff reinforce annually formal business ethic certification manager confirm understand compliance company policy contain employee guide business conduct programme cover manager worldwide extend include employee regularly interact healthcare professional bring total employee annual business ethic certification promote awareness gsk ethical standard company policy emphasise important role manager play embed ethical culture ensure employee understand apply policy certification statement understand gsk commit principle performance integrity particular ensuring activity comply applicable law receive copy access gsk code conduct polgsk standard conduct stdgsk gsk corporate policy corporate policy index accessible corporate ethic compliance community read understand employee guide business conduct accessible corporate ethic compliance community comply applicable law regulation gsk corporate local policy procedure understand responsibility promptly report actual suspect violation law regulation gsk corporate local policy procedure report actual potential compliance issue aware concern legal requirement company policy understand gsk commit principle performance integrity particular ensuring activity comply applicable law follow statement applicable supervisor personnel management responsibility people supervision receive copy access gsk code conduct applicable gsk policy inform responsibility place appropriate measure ensure people supervision comply applicable law regulation gsk corporate local policy procedure work behalf gsk new hire employee supervision complete schedule complete gsk corporate ethic compliance new hire train programme gsk induction corporate ethic compliance community read understand shall comply fully policy procedure specify learn activity understand fail company finds act unethically deal accordance relevant local national disciplinary policy procedure result action take include termination employment belgium france germany business ethic certification wording adjust comply local law corporate responsibility report home ethical conduct training awareness train awareness performance training awareness performance training awareness activity include refresher training promotion marketing code pharmaceutical sale marketing staff perform leading integrity train new employee communicate gsk value describe ethical decisionmaking model provide information help corporate ethic compliance department employee communication update policy explain change reflect gsk value compliance refresher training employee contractor employee present variety scenario customise business area ask discuss response well reflect gsk value manager employee complete selfcertification process review acceptance gift entertainment policy supplement reallife example help employee understand requirement united states pharmaceuticals business appoint integrity champion help raise awareness compliance embed gsk value managerlevel employee select demonstrate ability consistently apply value quarter provide training material help promote discussion compliancerelate topic business pharmaceutical marketing employee complete halfday workshop deliver growth good decision help apply ethical decisionmake model work workshop facilitate ethic compliance department marketing management team europe european pharmaceuticals business launch new compliance programme call know include number different initiative new training help employee improve awareness understand policy guideline new senior management team lead commercial senior vice president regularly review audit compliance result help learn mistake information pack compliance officer help understand focus priority issue business regular know bulletin information update current compliance initiative facetoface discussion compliance team general manager regional head discuss approach ethical issue division annual management meeting president pharmaceuticals europe restate businesss commitment performance integrity encourage employee report concern fear recrimination corporate responsibility report home ethical conduct monitor compliance monitor compliance monitor compliance manager ensure compliance company policy area responsibility oversee seek advice corporate ethic compliance department promote effective compliance programme address compliance issue report problem progress senior management board corporate ethic compliance department monitor track allegation suspect legal ethical policy infraction ensure allegation appropriately investigate disciplinary action include dismissal report relevant external authority take necessary violation policy report audit risk committee board compliance officer senior manager direct access gsk corporate executive team source expertise question ethic gsk policy corporate compliance officer report directly ceo dedicated compliance officer business unit manufacturing biological vaccine pharmaceuticals europe pharmaceutical emerge market asia pacific japan consumer healthcare corporate north america pharmaceutical additional compliance representative market fulltime regional compliance director commonwealth independent state cis include russia latin america middle eastnorth africa asia pacific china subsaharan africa south asia include india appoint deputy compliance officer support compliance officer help drive valuesbased culture gsk consult gsk brand sale team centre ensure compliance embed business integrate core process development marketing plan enhance integration compliance audit assurance function compliance officer contribute oversee comment business unit assurance report deliver audit risk committee board director highlight significant risk associate risk mitigation plan integrate compliance business establish senior compliance committee cochaire president north american pharmaceuticals division north american compliance officer committee report monthly commercial leadership team clt compliance action committee senior representative business unit establish assist risk management communication risk management risk oversight compliance council rocc oversee risk management internal control activity rocc support gsk corporate assurance department corporate ethic compliance department gsk corporate compliance officer chair rocc regularly report significant risk cet audit risk committee board information risk management corporate governance section annual report corporate responsibility report home ethical conduct monitor compliance monitor sale marketing monitoring sale marketing sale representative supervise manager regularly monitor educational event visit doctor expense use riskbase approach determine frequency check different team individual sale representative example monitor number activity identify prevent offlabel promotion include monitor sale representative receive enquiry physician offlabel use gsk product representative solicit offlabel question refer medical information department respond enquiry medical information letter frequent medical information letter request sale representative indicate employee promote offlabel use monitor sale representative provide product information sample inappropriate healthcare professional example provide information sample paediatrician gsk product approve use minor indicate offlabel promotion stop monitor sale note sale representative visit healthcare representative corporate responsibility report home ethical conduct monitor compliance reporting channel report channel employee encourage seek help ethical issue report concern suspect case misconduct line manager corporate ethic compliance department compliance officer compliance champion gsk human resource legal department global confidential reporting line integrity helpline global confidential reporting line available globally different language report concern employee relate compliance policy code conduct employee report anonymously leave message native language translate english integrity helpline provide advice caller outside company report channel employee report concern offsite post office box email reporting channel promote employee guide business conduct gsk intranet training raise awareness global confidential reporting line company intranet provide clear access key information linkage relate function commit protect employee raise concern good faith form retaliation prohibit disciplinary action include termination manager supervisor employee engage retaliation retribution harassment employee report compliance concern good faith employee report concern remind commitment protect retaliation investigation process interview people remind gsk zero tolerance retaliation share complainant employee investigation absolutely necessary usually whistleblower receive note compliance officer business unit head thank raise concern remind gsk nonretaliation policy settle longstanding legal issue relate investigation company manufacturing facility cidra puerto rico include settlement employee work briefly cidra plant gsk strongly reject initial claim employee fire whistle blow claim subsequently drop lawsuit corporate responsibility report home ethical conduct monitor compliance monitor compliance performance monitor compliance performance contact ethic compliance channel include enquiry request information guidance allegation misconduct line manager compliance officer confidential integrity helpline offsite post office box address misconduct employee discipline policy violation dismiss agree leave company voluntarily know separation disciplinary action include document warning disciplinary action include case employee breach sale marketing code case result dismissal separation company case result document warning addition appropriate discipline employee stay company receive retrain increase monitoring case retrain extend employee colleague prevent make similar mistake main type violation year include marketing promotional activity good manufacturingdistribution practice falsification document travel expense claim code conduct issue increase number policy violation compare tighten control address code conduct issue good manufacturing practice use company resource communicating requirement supplier breach policy involve supplier gsk employee case identify involved gsk manager accept excessive hospitality vendor include holiday wife manager colleague report situation confidential reporting line disciplining gsk manager meet senior legal compliance representative vendor remind gsk policy accept entertainment gift require train staff policy require change account team gsk gsk accept gift nominal value overnight travel entertainment reputation respect deal gsk risk staff acceptance entertainment gift favour intend perceive influence business judgement breach external code collect information centrally breach external industry government promotional code breach define sale marketing infraction violation law obligation code standard result fine censure gsk government agency industry association aim continually improve process ensure compliance industry code government regulation find breach external code time time decrease attributable change strengthen policy align commitment focus patient fully investigate breach external code step prevent reoccurrence include retrain corrective action include disciplinary action plan review internal control framework compliance programme assess opportunity improvement corporate responsibility report home supply chain introduction supply chain patient rely provide uninterrupted supply medicine manufacture highestquality standard effective responsibly manage supply distribution system essential highquality product right place right time supply distribution chain complex encompass material service buy supplier buy include manufacture warehouse distribution wholesaler retailer hospital government agency thirdparty payer gsk spend total billion external supplier billion spend active ingredient chemical intermediate package component material directly require manufacture product spend supplier country worldwide regional distribution total spend external supplier ingredient material purchase thirdparty supplier feed network manufacturing site country manufacture different gsk presentation produce billion package annually include tablet cream ointment inhaler injection liquid people work global manufacturing supply gms division outsource term production cost product manufacture thirdparty manufacturer provide finish partfinishe product meet patient need vital protect supply chain distribution system disruption establish maintain contingency stock active pharmaceutical ingredient finish product important product especially medically critical product additionally periodically assess supply chain risk appropriate ensure obtain key raw material ingredient alternative supplier necessary product ready work distribution company ship customer country product store correctly handle carefully distribution destination ensure patient benefit protect reputation provider highquality effective medicine vaccine include appropriate cold storage facility product vaccine biopharmaceutical product addition plan unexpected disruption air transport system affect volcanic ash cloud episode extreme weather gsk product leave warehouse temporarily store secure control facility fully compliant good distribution practice gdp requirement section focus relationship thirdparty supplier explain standard set aim source company maintain high standard quality labour environment protect employee human right standard explain quality ehs human right clause supplier contract report effort maintain product quality security supply anticounterfeite programme manufacture quality cidra plant puerto rico settle longstanding legal issue relate investigation company manufacturing facility cidra puerto rico regret operate facility manner inconsistent current good manufacturing practice cgmp requirement gsk commitment manufacturing quality gsk manufacturing division strong track record quality compliance current gmp requirement average inspection year site locate country manufacture issue facility take place nearly year ago commitment compliance cgmp demonstrate fact receive fda warning letter cgmp issue plant cidra facility cite july gsk resolve fully manufacture issue cidra facility time closure decline demand medicine site acceptable compliance status fda commit continuous improvement manufacturing process improve quality system gsk manufacture network improve selfinspection process find resolve potential issue mandate site director quality director totally transparent issue bring bear resource company resolve potential issue spend million year update improve equipment ensure state art patient come quality priority list corporate responsibility report home supply chain supplier standard supplier standard supplier standard ethical conduct labour practice protection human right ehs management system interaction gsk employee define new party code conduct launch march code align pharmaceutical supply chain initiative psci pharmaceutical industry principle responsible supply chain management roll new code gsk business global supply chain require new supplier sign statement confirm comply principle code business gsk procurement team engage exist supplier raise awareness code reinforce ethical principle contain gsk procurement contract template contain ehs requirement base global ehs standard human right clause base international labour organization convention universal declaration human right company agree requirement include supplier train new procurement employee standard requirement ehs human right emphasise importance role promote supplier compliance key procurement employee include procurement manager receive ongoing training topic maintain quality product material buy essential impact safety patient success business agree specification product ingredient packaging material supplier conduct quality audit relevant supplier site use riskbase approach determine frequency audit read effort improve environmental performance supplier focus critical supplier focus majority engagement monitor effort critical supplier include contract manufacturer supplier pivotal business critical supplier represent approximately supplier spend consider follow factor define critical supplier present high risk gsk regulatory compliance requirement relevance supply essential medicine threat continuity supply value affect product gsk hazards associate manufacturing process material environmental impact develop longterm relationship critical supplier conduct regular monitoring support uninterrupted supply highquality material service gsk corporate responsibility report home supply chain supplier standard human right clause human right clause supplier contract contain human right clause base international labour organization convention un universal declaration human right amend exact wording clause negotiation supplier translation suit local law change reduce contractual impact intent clause gsk standard contract clause ethical standard human right require prohibit law supplier warrant good knowledge relation supply good service term agreement employ engage use child labour circumstance task perform child labour reasonably foresee cause physical emotional impairment development child use force labour form prison indenture bond employee require lodge paper deposit start work provide safe healthy workplace present immediate hazard employee housing provide supplier employee safe habitation supplier provide access clean water food emergency healthcare employee event accident incident supplier workplace discriminate employee ground include race religion disability gender engage support use corporal punishment mental physical sexual verbal abuse use cruel abusive disciplinary practice workplace pay employee minimum wage fair representation prevail industry wage whichever higher provide employee legally mandate benefit comply law work hour employment right country operate respectful employee right join form independent trade union freedom association supplier agree responsible control supply chain shall encourage compliance ethical standard human right subsequent supplier good service supplier perform obligation agreement supplier shall ensure ethical human right policy appropriate complaint procedure deal breach policy gsk reserve right reasonable notice inspection cause case notice shall necessary enter supplier premise monitor compliance supplier warranty set clause supplier shall subject compliance law furnish gsk relevant document request gsk relation thereto subsection require general right audit agreement corporate responsibility report home supply chain supplier standard choose supplier choose supplier critical supplier meet minimum standard work select critical supplier conduct audit environment health safety ehs performance human right record addition conduct audit quality standard new supplier environment health safety assess potential new critical supplier ehs standard meet certain criterion join supply chain provide assurance manage basic ehs risk reduce likelihood significant incident harm people environment disrupt supply essential medicine potential new supplier meet requirement receive feedback encourage develop implement improvement plan case offer advice support help improve place supply agreement potential supplier achieve minimum gsk ehs standard addition audits critical supplier conduct preaudit assessment potential supplier emerge market large number company country fail meet minimum standard preaudit assessment enable identify supplier likely meet standard subject audit supplier unlikely initially meet standard capability improve supplier unlikely meet standard give feedback necessary improvement human right audit tool include question help assess potential supplier performance human right clause include supplier contract ask supplier information policy practice relate age limit employee discrimination employee local population prevention abuse individual wage benefit work hour meet legal minimum right worker organise recognition worker organisation inadequate response question reason progress business supplier result gsk inform appropriate authority finding read audit programme ensure compliance quality standard quality conduct quality audits potential supplier prequalification process enable identify company meet standard work necessary improvement dedicate quality team country include emerge market brazil china india pakistan south africa responsible ensuring standard apply consistently local knowledge help meet challenge associate gsk growth region team member share information global quality database example collaborate supplier china improve product quality supply gsk despite fail meet minimum quality standard prequalification supplier show potential improve standard meet need chinese quality team educate supplier good manufacturing practice show improve product process quality followup visit week later supplier prove meet standard subsequently approve supply gsk pass quality inspection european union food drug administration develop education programme ingredient packaging supplier emerge market raise awareness issue range good manufacturing practice contamination control run workshop suppliers china india malaysia provide participant training material use site plan run workshop market include indonesia african market corporate responsibility report home supply chain supplier standard monitoring engagement monitoring engagement procurement quality ehs staff monitor performance standard routine interaction supplier include global regional supplier review meeting senior gsk manager interact supplier key issue environment health safety conduct periodic audits exist critical supplier check continue meet standard ehs risk impact manage ethically effectively gsk supplier audits critical supplier conduct internal audit assurance function independent global manufacturing supply gms function audits evaluate supplier facility ehs standard meet certain criterion demonstrate acceptable performance continue supply gsk audits identify gap ehs performance breach human right clause supplier immediately develop implement improvement plan completion date agree gsk follow monitor progress terminate supplier contract improvement plan address gap agree timeframe introduce issuespecific audits look depth particular highrisk issue audit conduct large critical supplier provide additional assurance manage significant risk effectively result improvement plan enable supplier understand manage ehs risk well help ensure security supply audits help build close relationship supplier conduct pilot audits box extend approach supplier encourage supplier review audit ethical standard ehs human right performance company supply chain raise awareness ehs risk provide contract manufacturer information eh risk associate gsk material produce handle supplier booklet work gsk production supplier guide reiterate gsk expectation supplier operate high ethical standard act responsibly comply law industry guideline quality use riskbase approach determine frequency audits quality standard receive batch ingredient packaging material gsk site sample test quality specification additional measure maintain quality supply chain prevent contamination include use dedicated transport tamperevident seal work improve supply chain collaborate industry example pharmaceutical supply chain initiative psci supplier information need meet industry expectation labour ethic ehs management system investigate opportunity psci member company adopt share audit programme enable great oversight pharmaceutical supply chain increase resource burden individual pharmaceutical company reduce time supplier spend duplicate audit activity enable operate efficiently gsk industry consortium agree industrywide standard quality audits product ingredient supplier easy supplier understand expectation industry company standard longterm goal share quality audit model lowerrisk supplier supplier number company audit multiple time result share purchasing company consortium begin audit supplier behalf member increase efficiency audit process member work agree common standard auditing packaging material supplier fair treatment supplier foster good supplier relationship characterise mutual trust respect aim treat supplier fairly gsk support impartiality phase procurement cycle standard payment term supplier minimum day receipt invoice corporate responsibility report home supply chain supplier standard supply chain performance supply chain performance environment health safety audit audit exist potential supplier audits assess supplier asia supplier audit exist potential supplier americas europe asia africa total number audits number type supplier audit exist potential supplier type supplier america europe asia total primary raw material intermediate active pharmaceutical ingredient contract manufacture pharmaceutical formulation consumer healthcare excipient active raw material eh audit score key supplier exist supplier high average score america europe contrast low average score asia largely related maturity ehs management system support legislative framework enforcement region broad range score asia region upper score reflect higherperforming supplier generally longterm intervention gsk low score contrast relate supplier undertake initial audits find significant deficiency ehs management risk control significant audit finding current potential supplier occur mainly develop market include poor fire risk management emergency response capability absence fundamental risk control process safety poor control exposure hazardous substance poor waste management environmental control gap compliance regulation need terminate supplier contract result audit finding case deem supplier performance risk security supply bring additional supplier base analysis audit finding continue develop information assist supplier understand gsk ehs requirement help well understand common significant issue improve ehs management system potential supplier seven potential supplier audit fail meet minimum requirement preaudit assessment identify potential supplier unlikely meet minimum requirement believe potential supplier capability commitment improve interest offer advice monitor improvement programme audit undertake ensure supplier meet gsk criterion establish commercial supply quality audits conduct quality audits ingredient packaging material supplier compared increase related grow activity emerge market quality standard high acquisition new business sizeable supply chain corporate responsibility report home supply chain supplier diversity supplier diversity small company own woman people belong minority group underrepresented supply chain large company gsk believe small diverse business significant potential meet procurement need recognise value bring community job creation revenue generation source diverse supplier benefit gsk help comply regulation market encourage innovation expose new perspective fresh idea provide opportunity small diverse business supply good service work build capability expand business compete global contract gsk multinational company supplier diversity programme lead support procurement team worldwide gsk procurement employee responsible support diverse supplier possible assessed supplier diversity goal annual performance evaluation supplier spend diverse supplier supplier diversity outsourcing gsk outsource management global facility security specialised source company objective improve efficiency achieve overall cost reduction require company continue small diverse supplier contracting check supplier diversity plan share commitment supplier inclusion development procurement team work closely thirdparty source manager ensure objective implement correctly relationship small diverse supplier develop thrive addition gsk believe partnership form outsource relationship yield great return diverse supplier relationship offer diverse supplier opportunity gain exposure corporation turn enable diverse supplier build capacity allow line grow programme supplier diversity team create opportunity diverse supplier work gsk activity include support procurement develop supplier diversity strategy evaluate develop solution key prime supplier ensure supplier diversity inclusion provide support enable diverse business leader attend executive programme tuck school business kellogg school management sponsor attend national local outreach business conference host workshop enable diverse supplier understand business requirement organising matchmaking forum roundtable event box diverse supplier opportunity meet key senior executive buyer gsk advocate supplier diversity gsk business partner set supplier diversity goal monitor spend diverse supplier progress target report supplier diversity achievement government year roundtable give small diverse supplier chance shine traditional network matchmaking forum design diverse supplier opportunity showcase company key senior executive buyer gsk oneonone matchmaking session team go traditional internal network matchmaking forum design roundtable event provide value business diverse supplier hold different type event know roundtable help diverse supplier win business gsk allow value meeting event provide company information help tailor sale pitch include detail need challenge concern past supplier relationship result diverse supplier able provide bespoke information come roundtable prepared answer question demonstrate ability form successful partnership award contract supplier attend event plan host roundtable forum excellent expectation logistic procurement team provide far exceed forum participate ample time meet emmett walker walker international llc valley stream outside global supplier diversity initiative outside include sponsorship global link programme help diverse supplier world develop partnership local business expand capability access new technology membership minority supplier development council msduk launch january council link multinational corporation minority business aim increase procurement development opportunity october attend msduk conference corporate responsibility report home supply chain sustainable source sustainable source aim purchase raw material packaging sustainable source help ensure security supply business protect environment help gsk procurement team understand mean sustainable source think environmental implication product material gsk purchase explanatory video detailed training guide company intranet explain position link sustainable source issue climate change water use begin engage supplier sustainable source presentation tool explain approach role survey large supplier resource use material source policy collate information well picture sustainability supply chain continue develop sustainable source strategy aim establish set sustainable source target share sustainable source good practice supplier lowcarbon blackcurrant boost ribena sustainability work grower produce ribena blackcurrant reduce climate change impact fertilise crop nitrogen fertiliser use account agricultural greenhouse gas emission highly energyintensive manufacturing process apply subject loss leach loss atmosphere nitrous oxide greenhouse gas nearly time potent issue affect fertilise crop blackcurrant grower explore approach reduce impact use slowrelease fertiliser formulation nutrient supply closely match requirement crop evaluate possible increase utilisation efficiency produce yield fertiliser use legume fix nitrogen atmosphere grow alongside blackcurrant bush row legume cut plough blackcurrant use store nitrogen supplementary source nutrient research support fund gsk blackcurrant grower gsk contribute long term find low carbon solution help reduce greenhouse gas emission successful technique crop corporate responsibility report home supply chain security supply security supply ensure continuous supply highquality medicine essential patient depend product success business vital security supply compromise stage distribution chain prepare major incident disrupt supply range largescale theft product natural manmade disaster near facility gsk global manufacturing supply business implement contingency plan medically critical product define product medically critical lifesaving available patient likelihood detriment health know alternative plan define productbyproduct basis include hold sufficient stock product active pharmaceutical ingredient work critical supplier encourage implement contingency plan highrisk country set joint venture ensure maintain control distribution chain global supplier deliver good border gsk manufacturing site gsk distribution centre conduct regular highlevel operational review include focus security include security requirement contract road air freight carrier good distribution centre market corporate responsibility report home supply chain counterfeiting counterfeiting approach accord world health organization pharmaceutical product sell develop country counterfeit develop world figure high country counterfeit medicine vaccine healthcare product crime cause harm patient consumer vast majority counterfeit drug subject quality control hygiene standard test ingredient monitor product specification equipment come variation contain legitimate active ingredient active ingredient reduce subtherapeutic amount completely different andor inappropriate active ingredient impuritie unapproved colourants microorganisms packaging falsify product description expiry date gsk global anticounterfeiting strategy involve investigate suspect incident counterfeit collaborate authority legal action seize counterfeit good forensic analysis counterfeit product provide evidence legal proceeding corporate security legal packaging design technology security team heavily involve activity use finding investigation build picture counterfeit take place distribution route counterfeiter enable target effort problematic region provide information relevant authority support work gsk country manager require identify product likely counterfeit develop training sale representative sale representative worldwide play important role helping discover counterfeit product constant contact detailed knowledge market outlet counterfeit product likely sell add anticounterfeiting feature product packaging include hologram security seal complex background pattern difficult photocopy scan wide variety covert identifier add print technology sophisticated marker help identify counterfeit gather evidence offender gsk work closely wide pharmaceutical industry investigate case counterfeit raise awareness government internationally press strict law severe penalty gsk found member pharmaceutical security institute psi coordinates information collection investigation industry internationally help shape anticounterfeite policy national government international organisation performance report case counterfeit gsk product increase case likely number factor include improved interaction custom authority great external internal awareness report economic downturn fuel demand counterfeit particularly consumer healthcare product report case result raid authority suspect counterfeiter arrest raid take place illegal manufacturing facility wholesaledistribution outlet factory represent criminal operation capable mass produce counterfeit medicine healthcare product raid facility undoubtedly prevent significant amount counterfeit product enter legitimate market world anticounterfeiting practice conduct number successful anticounterfeiting operation example provide information chinese authority lead police raid illegal factory shenzhen city guangdong province authority seize manufacturing equipment pack counterfeit zentel arrest suspect counterfeit product destroy counterfeiter subsequently sentence month imprisonment fine impose helped identify source counterfeit alli purchase internet consumer test sample indicate presence stimulant drug manufacture gsk food drug administration issue public safety warning charge people illegally import counterfeit alli china contribute investigation lead indian police raid illegal factory patna seize counterfeit actife tablet manufacturing equipment raw material arrest counterfeiter help maltese custom detain container counterfeit aquafresh toothpaste contain pack destine algeria gsk anticounterfeite activity number report case counterfeit number raid number arrest corporate responsibility report home environmental sustainability introduction environmental sustainability gsk commit integrate environmental sustainability business responsibility contribute meeting environmental challenge opportunity compelling business case save energy water material align gsk strategic priority simplification develop revise environmental sustainability strategy ambitious goal operation value chain raw material product disposal longterm goal value chain carbon neutral short medium term set demand target reduce carbon footprint material use impact include reduction water use value chain zero waste landfill continue progress previous target area reduce water use exceed annual reduction target exceed fiveyear target wastewater quality waste mass efficiency emission volatile organic compound meet target reduction energy greenhouse gas miss cumulative energy greenhouse gas emission target investment early fiveyear period start deliver benefit final small amount ozonedamage cfc piece cool ancillary equipment remove meet goal elimination performance page report target progress summary summary data table highlight revise environmental strategy focus carbon water environmental stewardship value chain ambitious new target develop global carbon footprint time gsk entire value chain carry life cycle assessment product technology packaging option identify sustainable alternative develop framework procurement team integrate sustainability begin measure supplier performance annnounce important partnership singapore economic development board commit million million funding support research green sustainable manufacturing gsk company achieve global certification carbon trust standard corporate responsibility report home environmental sustainability environmental sustainability strategy environmental sustainability strategy revise environmental sustainability strategy building strategy originally introduce set ambitious goal gsk impact entire value chain objective significantly benefit environment engage employee tackle key issue benefit gsk financially believe reduce annual cost million reduce energy material distribution cost analysis gsk impact include carbon footprint value chain show need concentrate main area carbon dioxide emission contribute climate change water use environmental stewardship cover impact product use material generation waste need act operation carbon footprint result supply chain derive propellant customer use inhaler great impact work life cycle product simply concentrate direct impact longterm vision operation product carbon neutral ambitious target mean net greenhouse gas emission manufacturing distribute dispose product include source raw material support vision set specific goal key impact year include cut carbon dioxide emission answer achieve goal project contribute underway jurong factory future singapore feature box solar power installation york pennsylvania jurong factory future comprehensive environmental sustainability strategy turn site jurong singapore factory future site strategic objective include achieve tangible benefit investment green chemistry jurong appoint director operational excellence sustainability lead site team work closely gsk sustainable manufacturing centre excellence target step change environmental performance energy water mass efficiency chemical oxygen demand wastewater volatile organic compound release air site identify major improvement manufacturing lamivudine active ingredient hiv combination therapie new process increase mass efficiency reduce water solvent recovery operation litre lamivudine cut chemical oxygen demand wastewater previous level enable sustainability environmental sustainability strategy lead corporate executive team cet senior vice president human resource overall accountability new gsk sustainability steering team senior executive member cet identify sustainabilityrelate target include specific sustainability goal business plan environmental sustainability centre excellence support business drive improvement work business provide specialist expertise support individual programme identify step change achieve sustainability goal central fund available addition normal spending increase capability business share financial risk environmental sustainability investments singapore partnership create gsksingapore partnership green sustainable manufacture tenyear programme aim foster innovation green chemistry manufacturing partnership million fund gsk set singapore economic development board education research green manufacturing chemistry public health policy research award grant singaporean researcher grant award area chemical transformation physical transformation area biotransformation corporate responsibility report home environmental sustainability manage environmental sustainability manage environmental sustainability review organise achieve broad environmental sustainability goal continue improve direct impact energy water use environmental sustainability centre excellence coe responsible develop strategy set standard provide expert support business work executive responsibility sustainability business provide expertise programme datum management helping identify step change sustainability business functional area procurement packaging respond appropriately contribution gsk goal sustainability priority example pharmaceutical manufacturing set sustainable manufacturing centre excellence provide support direction improve site process reduce waste vaccine business create sustainability council senior manager climate change environmental priority platform technology science pt group develop sustainability strategy consumer healthcare develop bright green strategy cover key environmental sustainability area pharmaceutical pilot recycling scheme respiratory product inhaler similar pilot start governance overall responsibility sustainability environment rest corporate executive team cet formally review sustainability performance year new sustainability steering team senior executive oversee gsk sustainability plan programme meet quarterly review progress target identify emergent issue opportunity prioritise allocation funding revise detailed objective board subcommittee oversight respectively risk compliance audit corporate responsibility regularly review performance policy environmental sustainability key environment health safety sustainability ehss policy define aspiration global leadership excellence current policy approve cet cover ehss fundamental approach risk management ambition sustainability commitment transparency gsk ehss policy ehss policy define aspiration global leadership excellence outline broad scope plan achieve revise policy approve cet leader ehss performance protect environment community work enable healthy motivated employee fully engage success maintain culture continuous improvement ehs fundamental risk impact embe ehs fundamental fabric business implement management system ehs governance risk management practice address risk impact facility process contract research manufacturing organisation supplier sustainability integrate sustainability principle aspect healthcare business working stakeholder operate environmentally sustainable limit lower ecological footprint enhance social equity address future issue open ehss communication open transparent stakeholder effort address ehss responsibilitie ehss performance corporate executive team cet ensure risk track mitigated communication significant risk escalate business management structure commensurate risk impact involve cet ensure effective management involvement staff clearly assign accountability responsibility management system gsk comprehensive set internal standard environment sustainability issue accessible operation intranet use management system align recognise international standard iso base structured framework building vision policy support standard guidance material tool train recognition audits help business manage issue target set fiveyear period originally currently develop detailed target support revise environmental sustainability strategy use internal audit team assess system manage risk impact compliance legislation performance standard audits assess appropriate management system use integration business process scientist use environment health safety milestone align process ehs map integrate sustainability everyday activity help identify address issue new product development supply activity ehs map help scientist understand principle impact manage identify opportunity improve ehs impact procurement acquisition gsk procurement activity support sustainability environmental goal choose energyefficient equipment renewable recycle material working supplier manage sustainability environmental risk supply chain diligence process acquire divest business ensure sustainability environmental issue consider contract negotiation adequate management system place work acquire company align sustainability environmental health safety practice gsk emergency response crisis management discovery development manufacture pharmaceutical consumer product involve use hazardous material process site incorporate emergency response crisis management programme management plan programme ensure accident effectively manage occur impact business local community environment minimise site conduct annual review internal emergency response programme technical capability develop plan address area need improvement find health safety compliance remain vigilant stay compliance environmental law regulation incur environmental fine large exceeding acidity limit failure notify local authority upper merion sludge discharge associate new production activity fine site corporate responsibility report home environmental sustainability manage environmental sustainability plan target plan target approach complete year ehs plan excellence include fiveyear target set performance revise strategy develop increase focus sustainability translate ambitious goal priority area carbon footprint water environmental stewardship require measurement overall value chain especially carbon footprint target meet obligation downstream user chemical register supplier include review extend safety datum sheet implement necessary change risk management measure read public position paper reach regulation sustainability target target carbon reduction gsk overall carbon footprint value chain water reduction gsk operational water consumption reduction water consumption value chain environmental mass efficiency new pharmaceutical process stewardship reduction waste landfill operation reduction waste generate operation hazardous nonhazardous paper packaging sustainable source note reduction target absolute change compare exception mass efficiency packaging performance plan excellence include groupwide target improve environmental performance show table exceed fiveyear target water wastewater quality waste mass efficiency emission volatile organic compound meet annual target reduction energy consumption greenhouse gas emission miss cumulative target final small amount ozonedamage cfc piece cool ancillary equipment remove meet goal elimination target progress group target progress energy operation reduction unit sale reduce sale transport baseline cumulative climate change impact reduction unit sale reduce sale energy operation baseline cumulative transport mass efficiency new average transfer product average mass efficiency process period achieve transfer new product manufacturing product launch water annual reduction baseline reduce sale unit sale cumulative wastewater chemical annual reduction baseline reduce sale oxygen demand unit sale cumulative solid waste dispose non annual reduction baseline reduce sale hazardous unit sale cumulative ozone depletion elimination cfc process eliminate equipment air emission volatile annual reduction baseline reduce sale organic emission unit sale cumulative ehs audit score average minimum average achieve long requirement table note figure unit sale calculate constant exchange rate cer piece equipment contain cfc remain operation replace introduce new corporate audit process gsk include risk impact relate ehss data audits assurance information new audit process include approach provide overall audit opinion star rating base adequacy risk control relate management system replace previous audit scoring approach sgs verify corporate responsibility report home environmental sustainability manage environmental sustainability stakeholder engagement stakeholder engagement environment health safety stakeholder panel provide independent feedback companywide plan performance panel draw customer supplier regulator public interest group environmental organisation investor senior ehss representative gsk regularly participate gsk manager attend discussion specific topic panel facilitate environment council independent charity use feedback stakeholder panel inform environmental sustainability health safety programme panel review comment progress climate change water sustainable procurement life cycle analysis engagement take place nationally include partnership create singapore economic development board participate issuespecific engagement ceo water mandate initiative site engage stakeholder locally activitie open day newsletter community project corporate responsibility report home environmental sustainability manage environmental sustainability awareness recognition awareness recognition essential environmental sustainability goal engage employee level organisation new strategy provide framework individual clearly act contribution provide training orientation business leader understand issue well respond specific sustainability environmental training manage individual site relevant job role sustainability environment professional receive induction training undertake regular update ensure aware late technical information field need continue upgrade level competence site environmental staff ceo sustainability award programme recognise employee further gsk environmental sustainability agenda awareness raise employee awareness environmental sustainability intranet regular internal publication event publish articles sustainability environment spirit internal magazine brief news story internal web page number site bulletin functional newsletter carry article sustainability passive communication need develop interactive communication engage employee launch climate change microsite call climate change gsk site explain importance climate change need act gsk individual include item report action cut carbon dioxide emission business celebrate success area gsk intranet support sustainability environment include sustainability environment community site share news sustainability environmental programme group hold support material ehss framework policy standard guideline training material document use collect datum measure performance report result site celebrate earthweek raise awareness environmental issue encourage integrate environmental concern gsk culture personal lifestyles sustainability award ceo sustainability award programme recognise gsk team innovation create benefit society environment business creativity achieve genuine step change sustainability publicise innovative practice win award dedicate intranet site team gsk consider award sustainability environment centre excellence administer scheme internal review committee agree shortlist winner choose panel include expert academia government public interest group winner receive trophy select charity receive donation gsk entry country project honour winner category sustainable science technology chemical development stevenage project improve sustainability darapladib manufacturing develop new process route manufacturing heart disease treatment currently development achieve mass efficiency compare original saving emission tonne equivalent year reduce cost eliminate hazardous zinc waste stream environmental sustainability global manufacturing supply production procurement embed sustainability production procurement way work procurement team develop tool help staff select supplier production process sustainable tool identifie supplier sustainable material efficient manufacturing product sustainability heart organisation understand impact carbon footprint relation product process use training programme raise awareness understand issue stimulate change culture behaviour perspective workforce sustainability global manufacturing supply gurgaon india project nurture life achieve substantial improvement sickness safety horlick plant feature box health safety wellbeing section corporate responsibility report home environmental sustainability manage environmental sustainability life cycle assessment supply chain life cycle assessment supply chain gsk commit introduce sustainability concept product life cycle supply chain disposal product begin develop sustainable supply chain strategy align new environmental sustainability strategy life cycle assessment gsk commit assess minimise cumulative environmental impact footprint activity entire life cycle product include supply chain use disposal carry life cycle assessment lca key product carbon footprint entire value chain climate energy time lca evaluate environmental impact include climate change ozone depletion water pollution raw material extraction manufacture transport product use disposal recycling perform lca include assess footprint product compare packaging option technology alternative finding study integrate product device packaging development reduce environmental impact develop packaging device life cycle tool simplify webtool know fast life cycle assessment synthetic chemistry flasc chemist engineer gsk supply chain develop framework procurement team integrate sustainability line objective carbon water material source develop educational programme procurement staff provide new tool system process programme ceo sustainability award environmental sustainability begin measure supplier performance identify area improvement collect datum different material buy challenge especially material buy directly numerous supplier tier exist new supplier require complete request information provide great understanding awareness environmental social impact supply chain helping identify potential risk opportunity improvement survey large supplier ask resource use material source policy information help well understand life cycle impact associate gsk product aim establish set sustainable source target share sustainable source good practice supplier examine environmental footprint contract manufacturer initially target manufacture outsource active pharmaceutical ingredient intermediate evaluate resource consumption waste generation enable highlevel estimate environmental profile supplier datum available directly estimate refined information available supplier corporate responsibility report home environmental sustainability climate change energy climate change energy pharmaceutical industry create greenhouse gas emission contribute increasingly urgent global effort counter climate change gsk support effort agree international treaty legally bind target provide clarity business need regardless outcome global negotiation commit reduce impact set challenge energy carbon reduction target support business cut energy cost gsk sign caring climate initiative reflect commitment action climate change longterm goal include new environmental sustainability strategy entire value chain carbon neutral step reduction carbon footprint value chain carbon footprint undertake highlevel companywide exercise identify main contributor carbon footprint stage value chain datum study estimate total footprint million tonne main contributor material use process product propellant release inhal use analysis life cycle assessment individual product emphasise need work supplier site report carbon dioxide refer greenhouse gas equivalent specify gsk carbon footprint million tonne annum result highlevel carbon footprint input sustainability strategy establish priority programme plan refine carbon footprint vaccine business well estimate footprint material vaccine production available pilot carbon footprint select manufacturing site identify major opportunity reduce operational impact climate change programme programme reduce climate change impact propellant supply chain continue drive substantial energy emission reduction operation expect achieve substantial energy emission reduction make building equipment energy efficient instal onsite renewable technology biomass wind turbine photovoltaic panel feature box buying electricity produce renewable source reduce climate impact travel transport switch air sea freight road rail encourage use collaborative information technology reduce need business travel create central fund help finance carbon reduction energysaving project share financial risk business unlock great potential energy carbonsave opportunity example renewable energy project support fund rooftop solar array global data centre read introduce central financial support project support fund helped avoid tonne greenhouse gas emission big solar roof array york facility gsk consumer healthcare instal north america large rooftop solar array regional distribution centre york pennsylvania nearly solar panel generate approximately million kwh energy year completely meet building energy need gsk facility world power entirely solar energy save tonne year number renewable energy project investigate gsk collectively save tonne year complete progress gsk achieve carbon trust standard global certification company achieve recognition global excellence carbon management meet target reduction energy consumption greenhouse gas emission cumulative target investment early fiveyear period start deliver benefit energy consumption greenhouse gas emission operation transport fall respectively relative sale constant exchange rate short target performance information sgs verify corporate responsibility report home environmental sustainability climate change energy propellant propellant propellant inhaler asthma chronic obstructive pulmonary disease represent approximately total carbon footprint traditionally product contain hydrofluoroalkane hfas chlorofluorocarbon cfc potent greenhouse gas cfcs damage ozone layer meet goal eliminate use cfc product end replace hfas reduce emission associate inhaler product million tonne coe approximately million tonne increasingly supply dry powder inhaler use propellant patient find difficult use research programme find effective way reduce impact product include different valve meter dose inhaler require propellant release gas develop new drug molecule dry powder formulation require propellant search alternative propellant low global warming potential hfas investing programme recycle device patient finish take medication include recover residual propellant takeback scheme begin pilot scheme start corporate responsibility report home environmental sustainability climate change energy facility facility aim cut energy emission facility energyefficient renewable energy central fund available help finance energysave investment project select complete project potential saving tonne emission continue acceleration investment reflect improve progress energy reduction target sgs verify energy use manufacture supply pharmaceutical consumer product manufacturing function global manufacturing supply gm large emitter greenhouse gas group target reduction energy use gms achieve reduction significant improvement come heating ventilation air conditioning gms kaizen sitewide continuous improvement campaign approach originate japan identify energy efficiency measure gms complete kaizen project identify potential energy saving average combine heat power system generate electricity steam efficiently grid supply electricity gas instal site past month memphis cut energy use year memphis consumer healthcare site cut energy use save tonne year project contribute achievement include improvement heating ventilation air conditioning warehouse light site exhaust heat air compressor preheat combustion air boiler saving pipeline work start end improve air dehumidification polident denture clean manufacturing process instal variable speed drive site air conditioning system lighting improvement include lead light save energy solar power instal year appoint dedicated site energy manager instrumental achieving improvement support energy champion product stream monthly energy team meeting frequent communication progress maintain drive cut energy renewable energy grow gsk energy climate programme include biomass wind solar improved energy efficiency renewable reduce emission replace fossil fuel source wind solar power generate renewable site belgium germany india singapore south africa site country instal solar water heating system solar panel cut emission gsk global datum centre gsk datum centre upper providence pennsylvania contribute tonne saving year follow installation solar panel roof investment support funding gsk climate change energy reduction programme state federal grant tax incentive generate kwh year replace power grid solar energy save site year director datum center operation facility say make upper providence site green possible guide design principle begin add large global datum centre require great deal energy power cool thousands computer contain photovoltaic installation example commitment design sustainable operation emission trading gsk site participate european union emission trading scheme ets collectively site emit specify allowance generate surplus carbon credit proceed sale carbon credit invest energysaving project site participate government voluntary climate change agreement programme provide discount climate change levy site meet agree energyefficiency target participate gsk site comply climate change agreement gsk participate uks carbon reduction commitment crc scheme gsk house london qualify scheme mean gsk site affect crc regulate ets climate change agreement place preparation crc gsk obtain certification carbon trust standard site globally instal continuous energy monitoring equipment site affect corporate responsibility report home environmental sustainability climate change energy transport travel transport travel estimate transport product sale fleet employee business air travel account approximately direct greenhouse gas emission operation transport come equally transport product manufacture plant distributor business air travel sale fleet product transport logistics group set target tonne save distribution product worldwide achieve switch transport mode air sea practical optimise european road freight network improve vehicle load configuration maximise use available capacity result few vehicle road warehousing improvement reduce number external warehouse cut travel site warehouse instal intelligent lighting control energy efficient lighting consolidation refrigerate storage unit reduce electricity refrigeration energy efficient forklift truck charge unit use air freight product short shelf life switch air sea freight airtoocean programme pharmaceutical consumer healthcare manufacturing switch route ocean freight saving tonne emission achieve tonne saving change transport mode initiate airtosea mode change significant saving route evreux france japan tonne annum zebulon north carolina australia tonne annum sgs verify plan logistics group target save tonne transport switch air sea contribute saving continue improve european road distribution network investigate opportunity use european rail network benefit improve pallet loading thank product simplification packaging improvement major project look efficient distribution reduce transport emission include multi market warehouse asia pacific region allow transport mode change majority distribution chain market serve travel green travel plan number site encourage employee reduce environmental impact travel work significant investment videoconferencing system videoconference room country technology include teleconference desktop personal videoconference unit web conferencing staff select appropriate system need depend number participant objective meet drive desire reduce unnecessary employee travel cost environmental impact increase use videoconferencing compare distance fly fall million nearly few single flight compare reduce emission tonne reduction sgs verify corporate responsibility report home environmental sustainability climate change energy climate change energy performance climate change energy performance total energy emission global warming potential energy transport inhaler use note emission patient use inhaler calculate retrospectively sale datum climate change impact operation transport inhaler use longterm trend show sharp fall emission begin replace cfc gas meter dose inhaler climate impact level begin fall energysave investment show positive result climate change impact include operational energy travel transport direct source plus use inhaler patient million tonne low include million tonne patient use inhaler exclude manufacture use inhaler climate change impact operation energy transport scope target fall million tonne million tonne energy use operation transport decrease million million salesrelate data target base emission energy consumption operation transport million sale sale adjust constant exchange rate normalise emission decrease energy use million sale fall cumulatively cut normalise emission energy use miss target measure climate change impact operation energy transport energy use operation transport explanation trend emission level launch new energy programme initial progress slow performance begin improve investment pay past year gsk climate change emission fall absolute term close number facility balance acquisition growth reduction emission mainly drive investment project support climate change programme addition decrease transport emission cause reduction distance drive sale force employee air travel significant acceleration performance demonstrate achieve ambitious target new environmental sustainability strategy note figure include target restate constant exchange rate cid cid cid cid cid cidcidcidcidcidcidcidcidcidcidcidcidcid corporate responsibility report home environmental sustainability water water approach fresh water finite vulnerable resource increase demand water source result population growth rise urbanisation increase affluence effect climate change mean area waterstresse world population expect suffer severe chronic water shortage damage ecosystem quality human life recognise need strategic approach water use reflect complex interaction human population growth climate change disease pattern change biodiversity stress address water issue help business increase water security improve manufacturing efficiency strengthen reputation relationship stakeholder approach element continue reduction water use make water quality improvement maximise water efficiency minimise risk impact assess direct indirect supply chain water use collaboratively manage share water risk community operate reduce human health impact cause water scarcity target reduce pollution potential wastewater site discharge measure chemical oxygen demand cod oxygen require chemically oxidise compound water direct operation supply chain require clean water manufacture process product cool cleaning general site use drink food service sanitation action reduce consumption focus site area water scarcity waterintensive product develop sitespecific target facility area water scarcity account site identify site world business council sustainable development global water tool supplement local watershed information intelligence assessment total water use direct indirect primary product category identify waterintensive product help develop productspecific water strategy economic commodity model estimate direct indirect water use associate energy agriculture chemical packaging product estimate total water use embed supply chain recognise virtual water associate material buy represent major water footprint engage supplier assess awareness exposure plan mitigate water risk use information grade supplier drive improvement target reduce water consumption annum unit sale reduce water consumption exceed target cut consumption total example progress pharmaceutical consumer healthcare manufacturing site agbara nigeria save overall water consumption remove old inefficient washing equipment improve inspection maintenance water pipeline sources minimise loss parma italy save overall water consumption water reduction programme focus cool water resin replacement water softener steam discharge autoclave zebulon save recycled water municipal treatment work community engagement community health local ecosystem link watershed conduct global assessment site gauge local awareness water scarcity status local watershed level community engagement result develop site communication plan raise awareness provide guidance engage local community example consumer healthcare turn tap campaign launch italy encourage people use water brush tooth estimate litre water save education awareness campaign responsible use water everyday life health impact waterborne disease gsk address waterborne disease example rotarix vaccine commitment disease develop world continue support phase simple handwash programme launch teach hundred thousand child reduce spread infection particular diarrhoeal disease engagement government organisation endorse united nations ceo water mandate line support global health programme community initiative improve access medicine guide integrate water policy stewardship global healthcare commitment strategic element mandate foundation approach water stewardship commitment demonstrate recognition water valuable natural resource business play positive role manage endorse mandate pledge improve water sustainability direct operation supply chain work organisation government encourage sustainable policy practice engage site local community provide education support water sanitation accurate transparent reporting waterrelate issue section water constitute communication progress accordance mandate reporting requirement performance water consumption chemical oxygen demand wastewater gsk worldwide water use total billion litre billion litre water consumption unit sale low cumulatively water use unit sale fall ahead annual reduction target explanation trend water consumption fall site closure range water save initiative business reduction offset business growth particularly consumer healthcare biopharmaceutical manufacture vaccine wastewater generate billion litre wastewater high baseline chemical oxygen demand cod wastewater fall cod million sale fall reach cumulative baseline put ahead target decrease year explanation trend wastewater volume increase new expand operation particularly vaccine biopharmaceutical business quality wastewater discharge measure cod closely relate type material produce manufacture active pharmaceutical ingredient apis consumer product decrease year low production waterintensive process manufacture apis number cod reduction project project include segregate offsite treatment high cod waste stream pharmaceutical manufacturing site instal new effluent treatment plant site bangladesh introduce new plant remove solid toothpaste factory work improve manufacture efficiency continue decrease wastewater pollution future note figure include target restate constant exchange rate sgs verify corporate responsibility report home environmental sustainability environmental stewardship environmental stewardship aim operate responsibly input material packaging efficiently safely minimise waste avoid harm human environment raw material typically contributor overall environmental impact pharmaceutical operation read life cycle assessment material sustainably require change business process consume few resource generate waste remove hazardous substance possible eliminate waste persistent toxic bioaccumulative routinely evaluate environmental footprint product process explore way minimise impact manufacturing operation use fast life cycle assessment synthetic chemistry flasc webbase tool helps identify sustainable process material currently expand flasc assessment include ecofootprint tablet formulation process launch enhance solvent selection guide double number solvent cover include simplified version early manufacturing stage begin develop reagent selection guide different chemical transformation tool help scientist select material reduce environmental impact waste solvent reuse process raw material industry achieve know cradletocradle approach instance site manufacture active pharmaceutical ingredient recover solvent reuse pilot plant send solvent ethyl acetate ethanol external recovery reuse biodiversity support effort conserve biological diversity convention biological diversity use biological material develop new medicine vaccine production process unusual biological material natural form active component pharmaceutical operation supplier impact local habitat gsk ehss standard require impact assessment include impact ecosystem affect biodiversity site support protect habitat use wastewater support native species gardens procurement group analyse potential supplier impact understand priority ensure biodiversity cover responsible source approach involve number project remediate site land contaminate past handle practice chemical identify site site require remediation waste disposal site gsk responsible party gsk heritage company spend million cleaning site year involve continue work figure include datum verification corporate responsibility report home environmental sustainability environmental stewardship potential hazard potential hazard continuously examine use material concern phase development determine identify replace development instance new manufacturing route epilepsy treatment eliminate use highly hazardous oxidize agent peracetic acid chlorinate solvent highly odorous sulphur reagent sulphur waste read project runnerup ceo sustainability science technology award metric tonne material concern tonne increase drive undertaking manufacturing support late stage development product need high volume product clinical trial seven solvent account volume solvent waste production destroy incineration recycle pharmaceuticals environment portion active pharmaceutical ingredient apis substance medicine work eventually enter environment mainly excrete patient disposal unused medicine discharge manufacture current scientific consensus pharmaceutical residue present environment pose risk human health working identify potential impact environment continue monitor issue contribute work group research inform stakeholder discharge limit apis wastewater manufacturing site assess process waste concentration level treat wastewater necessary achieve safe level information read public position statement pharmaceutical environment genetically modify microorganism gmms use gmm research development new therapeutic agent manufacture certain medical product vaccine produce product contain viable organism routinely undertake research development involve cultivation genetically modify plant specie gmms help identify genetic target cause disease develop new antibiotic drug condition heart disease diabete depression use number different gmms predominantly harmless organism disabled strain bacterium ecoli eukaryotic cell culture manufacture number product derive gmms hepatitis vaccine manage use gmms body site institutional biosafety committee genetic modification safety committee line national local regulation require gmms inactive waste stream ensure safety human health environment publish policy statement genetically modify microorganism environment health safety nanomaterial investigate opportunity use nanomaterial material atomic molecular scale programme currently product market contain deliberately engineer nanomaterial read public position paper use nanomaterial reach compliance activity eus registration evaluation authorisation restriction chemical reach requirement fully embed manufacture procurement operation continue implement reach legislation identify substance buy require register mitigating risk supply request confirmation intent register supplier approximately chemical purchase registration deadline develop communicating use condition exposure scenario substance buy submit registration dossier highvolume substance manufacture import gsk require registration november potassium phenylacetate aminopenicillanic acid register new substance manufacture import volume great tonne year review candidate list substance high concern implement substitution plan phthalate musk xylene develop procedure manufacture site meet responsibility downstream user chemical meet obligation downstream user chemical register supplier include review extend safety datum sheet implement necessary change risk management measure read public position paper reach regulation classification labelling meet european union deadline december implement un globally harmonize system classification labelling chemical ghs adopt regulation world implementation require update publishing intranet revise gsk safety datum sheet sds ghscompliant format reclassify substance accord ghs criterion submit classification label information european chemical agency inventory approximately hazardous substance supply gsk site import develop elearne poster employee train new hazard warning symbol label introduce gh produce ghscompliant hazard label manufacture site change format sds comply reach annex requirement corporate responsibility report home environmental sustainability environmental stewardship mass efficiency mass efficiency approach pharmaceutical industry typically tonne material tonne active pharmaceutical ingredient api produce pharmaceutical process complex usually require large amount solvent raw material process obtain right pharmaceutical purity necessary finalise production process quickly avoid delay drug approval production originally set target double average mass efficiency process new product achieve increase target additional increase efficiency new product launch set target manufacture site achieve mass efficiency product launch aspiration new environmental sustainability strategy achieve efficiency specific project achieve mass efficiency target launch gsksingapore partnership green sustainable manufacture process design redesign effective process design essential minimise environmental impact determine chemical process manufacturing impact production waste develop sustainability strategy achieve mass efficiency sustainability aspiration operational sustainability team work process development team incorporate ehss considerations process design material source help scientist select material environmental impact identify potential sustainability ehss risks manufacture expand solvent selection guide double number solvent cover include simplified version early stage medicinal chemistry simplify life cycle assessment tool operational sustainability team recognise american institute chemical engineer industrial practice award sustainable engineering institute cite work embed sustainability manufacturing ecodesign toolkit manufacturing assess potential improvement new product transfer exist product project jurong redesign process exist compound improve mass efficiency redesigning process save material money redesign manufacturing route albiglutide product development upper merion pennsylvania improve overall yield reduce water consumption half increase mass efficiency improvement reduce cost raw material initiative second place ceo science technology award performance mass efficiency average chart show range mass efficiency average process stage manufacturing process develop demonstrate improve mass efficiency compound development stage early stage process achieve mass efficiency stage process transfer manufacturing average mass efficiency period exceed target period mass efficiency new product transfer target start report mass efficiency performance new product transfer manufacture corporate responsibility report home environmental sustainability environmental stewardship waste waste approach production research sale activity produce waste production hazardous waste solvent chemical nonhazardous waste include packaging quality control laboratory small amount chemical include product intermediate break glassware plastic office paper standard commercial waste maintenance building renovation produce nonroutine waste obsolete equipment office furniture structural material significant proportion waste classify hazardous mainly contain solvent chemical manufacture active pharmaceutical ingredient nonhazardous waste general material office waste paper kitchen waste nonhazardous substance manufacturing aim eliminate waste reduce eliminate reuse material possible recycle waste dispose remain material sensitively require disposal contractor comply requirement local regulation site audit waste contractor hire consultant carry audits apply waste hierarchy solvent main hazardous waste work improve mass efficiency reduce waste volume choice reuse recycle solvent recover purify site reuse original manufacturing process sell commercial reprocess company reuse recycle possible solvent usually incinerate energy recover possible regulation vary widely world work hierarchy manage waste way meet exceed regulatory expectation target refer nonhazardous waste send offsite disposal wasteperformance new environmental sustainability strategy set target hazardous nonhazardous waste generate aim cut total waste aim zero waste landfill gsk site exclude office send waste landfill cut waste source significantly reduce waste supply clinical trial tackle waste source improve planning simple network distribution depot optimise supply chain avoid produce medicine test trial initiative begin reduce excess production active pharmaceutical ingredient apis tablet save package excess production need avoid result incineration unused material estimate improvement save tonne manufacturing tonne api roughly previous level make million few tablet million few plastic bottle pack clinical trial material performance nonhazardous waste nonhazardous waste dispose destination nonhazardous waste datum include nonroutine waste construction demolition rubble similar material relate daytoday operation nonhazardous waste dispose fall low baseline tonne waste million sale low year substantially year improvement target build performance new ambitious target target specific nonhazardous waste dispose measure total nonhazardous waste generate include waste recycle generate tonne nonhazardous waste higher previous year recycle dispose landfill incineration figure show improvement datum explanation trend increase nonhazardous waste generate high production manufacturing facility australia india manage increase percentage waste send recycle particular site australia india increase generation nonhazardous waste able significantly increase waste send recycling site australia increase recycling site india increase recycling addition site nigeria increase waste recycle overall gsk total recycling rate increase note figure include target restate constant exchange rate sgs verify hazardous waste hazardous waste dispose destination hazardous waste generate tonne hazardous waste reduction recycle incinerate energy recovery waste go landfill hazardous waste dispose tonne low waste dispose million sale fall level explanation trend decrease hazardous waste dispose continue effort manage recycle especially solvent decrease production product significant quantity solvent site responsible reduction hazardous waste generate waste reduce site scale production prior closure action site include installation new technology increase manufacture efficiency installation onsite treatment facility prevent need send waste offsite disposal hazardous waste dispose related type quantitie product solvent manufacture active pharmaceutical ingredient solvent waste hazardous waste generate reduction hazardous waste generate mainly action take main site use large quantity solvent note figure include target restate constant exchange rate sgs verify corporate responsibility report home environmental sustainability environmental stewardship packaging packaging substantial opportunity improve packaging profile work reduce environmental impact product packaging set target derive paper packaging sustainable source begin implement sustainable packaging strategy develop base table support new strategy begin update green packaging guide guide help designer manager benchmark new exist packaging design take account manufacturing impact mass choice material recyclability reusability evaluate ecofootprint series packaging option life cycle assessment carbon footprint analysis table show example example application principle focus example reduce mass material complexity redesign ventolin canister save life cycle footprint tonne aluminium tonne packaging year income dry powder inhaler component zebulon ship pallet box instead individual case save tonne tonne material year remove material sustainability ehs remove pvc tray nicoderm save issue tonne material tonne year reuse recycle material packaging reusing tray pallet drum save plastic subject regulatory requirement wood mean major challenge pharmaceutical recycle design recyclability move desiccant require niquitin bottle cap mean bottle recycle working supplier change carton material aquafresh fully recyclable alternative save tonne material tonne renew use material energy paperbase packaging increasingly buy renewable source material recover fibre reward improve environmental impact sustainability key element selection total gsk packaging supply continue management supplier form chain meeting need patient integral procurement framework customer consumer lower general way work cost respect use responsible supplier include social environmental requirement supplier selection process develop detailed criterion specific area example packaging improvement include new pack iodex pain relief ointment reduce material advair carton corrugate box material reduction save tonne year abreva clamshell packaging replace pvc recycle pet save gramme pack move glass polypropylene pet bottle horlick iodex crocin india save tonne year horlick carton reduction save tonne year corporate responsibility report home environmental sustainability environmental stewardship emission air emission air approach main emission gsk site apart greenhouse gas gases damage ozone layer volatile organic compound voc cause lowlevel pollution ozone depletion ozonedeplete substance odss damage ozone layer upper atmosphere expose people radiation cause skin cancer health problem recently cfc propellant gas meter dose inhaler mdi gas release patient use inhaler small escape production stop manufacture cfc inhaler gsk site contract manufacturing site use odss cool system ancillary use gsk facility release event leak maintenance progressively switch hydrofluorocarbon hfcs ammonia hydrocarbon cfc associate cool system ancillary use eliminate piece equipment remain service plan eliminate use cfc associate remain equipment end plan eliminate use hcfc cool system ancillary equipment end public position statement volatile organic compound volatile organic compound voc react nitrogen oxide presence sunlight create ozone low atmosphere result smog factor human respiratory illness emit vocs atmosphere mainly solvent manufacture active pharmaceutical ingredient pilot manufacturing plant target reduce voc emission unit sale year focus reduce voc site responsible threequarter voc release facility improve solvent abatement site include singapore india australia performance ozone depletion ozone depletion potential equipment production cfc equivalent release ozonedeplete substance odss patient use inhaler eliminate odss equipment production loss decrease compare follow similarly substantial reduction mean meet target eliminate loss cfc production equipment cfc service long present maintain register significant piece equipment contain refrigerant use track progress piece equipment contain kilogram cfc amount approximately total volatile organic compound volatile organic compound emission volatile organic compound voc emission decrease tonne emission fall voc release air million sale decrease mean achieve annual target continue trend reduction previous year take total reduction unit sale explanation trend emission voc air affect management solvent mix product year voc emission focus area concentrate emit site india singapore improvement mainly result improve solvent abatement site site australia reduce voc emission note figure include target restate constant exchange rate sgs verify corporate responsibility report home environmental sustainability datum audit assurance datum audit assurance section summarise key datum provide fiveyear trend contain internal audit external assurance report basis report environmental datum collect pharmaceutical consumer healthcare nutritional healthcare manufacturing site vaccine site pharmaceutical consumer healthcare site headquarters building office distribution centre target performance normalise sale base constant exchange rate rate mean normalise figure previous year different show year report datum vary slightly early report error find datum prior year correct use greenhouse gas protocol calculation emission energy use use late country factor electricity publish international energy agency iea update factor climate change emission propellant refrigerant wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring project report page geneva switzerland chapter corporate responsibility report home environmental sustainability datum audit assurance datum summary datum summary table summary year environmental performance breakdown component metric datum detailed data table energy consumption operation transport million gigajoule climate change impact thousand tonne operation transport inhaler use patient total climate change impact water use million cubic metre wastewater volume million cubic metre cod thousand tonne hazardous waste generate thousand tonne dispose recycling nonhazardous waste generate thousand tonne dispose recycling otherwaste generate thousand tonne dispose recycling volatile organic compound emission thousand tonne ozone deplete substance release tonne production refrigerant release patient use inhaler total od ozone deplete potential refrigerant equipment tonne value include estimate datum december actual datum available time publication external assurance gsk response assurance energy climate change impact travel transport air land sea calculate greenhouse gas protocol measurement base distance travel directly fuel use year collect category freight transport employee business travel employee air travel capture route globally individual booking usa group booking product logistic capture route globally air sea road collect usa canada climate change impact calculate equivalent greenhouse gas protocol develop world resources institute world business council sustainable development year review factor update datum year appropriate use factor climate change emission ozone depletion potential wmo world meteorological organisation scientific assessment ozone depletion global ozone research monitoring projectreport geneva switzerland chapter year review refrigeration equipment inventory year estimate incomplete datum calculate probable release factor british refrigeration association collect inhaler production volume allow accurately calculate climate change ozone depletion potential impact use depletion potential impact inhaler use recycle water include total water consumption focus collection wastewater chemical oxygen demand datum primarily major contributor primary manufacturing operation pilot plant coating activity sterile operation sanitary wastewater stream include separate production wastewater stream significant chemical oxygen demand cod measure water pollution measure wastewater leave site follow onsite treatment focus collection volatile organic compound emission major contributor primary manufacturing operation pilot plant coating activity sterile operation consider waste hazardous property define basel convention radioactive bioengineere biohazardous basel convention property include flammability explosivity water air reactivity corrosivity oxidise potential acute chronic toxicity ecotoxicity infection biological waste render nonhazardous treatment consider nonhazardous waste focus collection hazardous waste major contributor primary manufacturing operation pilot plant coating activity sterile operation sgs verify corporate responsibility report home environmental sustainability datum audit assurance internal audit internal audit regularly audit operation contract manufacturer key supplier assess system manage risk impact compliance legislation performance environment health safety sustainability ehss standard audits assess appropriate management system place improve performance maintain compliance internal auditor certify lead auditor iso standard ehss audit team integrate gsk audit assurance function provide independent audit assurance capability separate ehss management organisation ehss audit team use gsk audit assurance function standardise riskbase audit process audit management environmental risk audit strategy include audits theme operation prevention major release propellant gas hfc tetrafluoroethane manufacture meter dose inhaler frequency audit operation determine level risk impact site performance manage risk audit site cover key risk performance ehss standard general performance relate management environmental risk good critical finding indicate lack proper management risk potentially consequence concern environment number positive performance area include general management reduction environmental impact number finding raise mainly relate aspect management waste emission containment read supplier audits supply chain section certification site continue certify international standard iso ohsa potential benefit follow review conclude certification equally benefit site certification focus need significant improvement site require robust management system include selfaudit system encourage certify formal requirement end site certify iso corporate responsibility report home environmental sustainability datum audit assurance external assurance external assurance fifth year sgs review data environment section health safety page corporate responsibility report independent view process valuable adopt suggestion year improve process site select review gsk business site visit special focus site contributor environmental emission previous year relatively new site visit sgs datum verification site difficulty submit datum timely manner sgs assurance statement assurance statement sgs united kingdom ltds report environment health safety datum glaxosmithkline corporate responsibility report nature scope assurance sgs united kingdom ltd commission glaxosmithkline gsk conduct independent assurance environmental health safety datum corporate responsibility report scope assurance base sgs sustainability report assurance methodology include datum contain follow section report environmental sustainability health safety wellbeing plan target performance climate change safety programme driver safety ergonomic energy water waste emission air human factor climate change energy emission saving health safety performance climate energy performance health safety datum table water performance waste performance emission air performance datum audit assurance detailed data table environment health environmental datum summary safety information gsk report presentation responsibility director management gsk sgs united kingdom ltd involve preparation material include report responsibility express opinion datum graphs statement scope verification intention inform gsk stakeholder financial datum draw directly independently audit financial account check source assurance report assure moderate level scrutiny protocol evaluation content veracity assurance comprise combination interview relevant employee documentation record review seven gsk location end reporting year follow interim site visit october november australia port fairy france marlyleroiuk coleford weybridge usa marietta zebulon interview eh director management team global manufacturing supply biological pharma november end year site visit january corporate health safety environment performance function london site select include submit high proportion key data part gsk business statement independence competence sgs group company world leader inspection testing verification operating country provide service include management system service certification quality environmental social ethical auditing training environmental social sustainability report assurance sgs united kingdom ltd affirm independence gsk free bias conflict interest organisation subsidiarie stakeholder assurance team assemble base knowledge experience qualification assignment comprise auditor assuror register irca iema emas verifiers assurance opinion basis methodology describe verification work perform satisfied environmental health safety datum contain gsk corporate responsibility report reliable provide fair balanced representation gsk environmental health safety activity assurance team opinion report reporting organisation stakeholder summary finding minor area improvement datum collection submission manipulation identify assurance process address incorporate improvement report improvement opportunity outline enable review establish need system process change future reporting cycle early deadline compilation datum estimate datum final month reporting period require update actual figure site implement improvement monitor measurement certain datum voc cod improvement reliability consider site emission datum calculate base small number sample case know release od equipment include equipment register methodology collate od datum equipment amend enable specific know release include addition good practice note follow area increase comment explanation site inputte datum explain significant change estimation calculation analysis data corporate level ongoing improvement include detailed review report illustrate significant change anomalous datum sitebysite basis include review conflict trend request site detail explanation introduction graphical display illustrate yearonyear trend kpi include contribution performance possible view individual site gsk business unit gsk group introduction automate report generation improve evaluation analysis submit datum include generation report double entry late entry submission estimate entry recommendation future datum verification process include interview ehs director gsk business unit find effective method gain overview expect data trend project contribute achievement target opportunity improvement process conduct ehs director interview early report cycle enable direct evaluation relevant project undertake site visit datum verification sign behalf sgs united kingdom ltd jim weaver systems service certification business manager february wwwsgscom corporate responsibility report home environmental sustainability datum audit assurance gsk response assurance gsk response assurance please site improve submit complete accurate datum include comment explanation trend timely fashion commit continue improve ultimate goal provide accurate datum public website real time datum corporate responsibility report site improve management environmental programme health safety programme addition endofyear datum analysis conduct midyear evaluation datum encourage site track progress assist management environment health safety sustainability welcome sgss finding good practice recognition improvement data collection analysis note sgs find value engage ehs director discuss anticipated performance trend gsk business arrange eh director interview early year new ehs project implement evaluate subsequent site visit response specific area recommend sgs improvement follow estimate datum final month reporting period requires update actual figure report deadline site bring forward enable gsk report available public early possible datum obtain invoice energy consumption dependent external supplier provide datum timely fashion final datum available require site provide estimate review estimate datum ascertain estimate reasonable sure datum update actual figure end quarter current year improvement reliability consider site emission calculate basis small number sample recommendation relate site relatively low level discharge sample infrequent case site require measurement local regulator local regulator specify low frequency sampling work site ensure sample quarter unexpected discharge event occur increase frequency sampling discharge return normal level methodology collect od data equipment amend enable specific know release include register hold information od content equipment use calculate fugitive emission include additional loss spillage report separately introduce new record system collect accidental release refrigerant gas corporate responsibility report home people introduction people gsk employ people country worldwide want gsk know great place work employer choice talented people background attract retain good people confident achieving mission improve quality human life enable people feel well live long employment practice design help create right workplace culture gsk employee feel value respect empower inspire important element approach include value behaviour commitment inclusion diversity support flexible working practice regular twoway communication employee respectful fair treatment employee change company leader set tone employee role play maintain culture ask adopt company value behaviour work box return aim provide great employee experience gsk include highquality training development opportunity include focus leadership development highpotential employee competitive reward package commitment protect employee health safety wellbee value behaviour feel strongly realise achievement important achievement company value guide gsk employee conduct daily work ask commit transparency respect people demonstrate high integrity conduct patient focus ensure contribute successful responsible gsk employee patient flexible thinking enable change well continually monitor improve performance embrace training development opportunity offer build strong relationship customer corporate responsibility report home people inclusion diversity inclusion diversity approach aim inclusive diverse company empower employee show value respect contribution good business bring different knowledge perspective experience working style gsk gsk permit harassment discrimination relate race colour religion belief gender sexual orientation gender identity expression age national origin genetic makeup disability chronic health condition protect employee privacy confidentiality recognise human right revise inclusion diversity strategy help create workforce reflect global presence community serve provide flexible framework adapt local culture legislation different market communicate change employee continue raise awareness approach nominate president european pharmaceuticals business new corporate executive team cet sponsor inclusion diversity responsible ensure right initiative place raise awareness senior management business work cet ensure increase focus inclusion diversity talent management process renew commitment equal pay career opportunity introduce new framework flexible thinking relation working practice inclusion diversity support mentor programme future leader encourage mentor coach different background global hivaids policy discriminate prospective current employee base hiv status require medical testing prerequisite employment maintain medical confidentiality time provide staff information training hivaids prevention address problem stigma relate disease offer hivaids test voluntary counselling treatment programme include free antiretroviral employee family country easily available government healthcare programme approach disability work ensure people disability access range recruitment career opportunity gsk example partner employer forum disability aim disability confident organisation strive workplace create culture inclusion remove barrier access make adjustment enable individual disability contribute employee customer partner hold tick symbol jobcentre plus demonstrate commitment employ people disability example partnership serme spain specialist integration disabled people workforce serme help create employment opportunity disable people human resource response centre flexible thinking relation working practice think flexibly way work include formal arrangement flexible hour parttime working job share informal arrangement work different location empower employee help optimise effectiveness well balance work need commitment encourage flexibility provide meet broad need business develop new global framework encourage manager assess employee team productivity performance simply presence office way implement approach vary business location accord local need culture employee resource group employee resource group provide forum people similar interest background meet discuss share experience work help gsk inclusive workplace resource group provide gsk manager view insight diversity help medium marketing team well understand diverse customer stakeholder gsk employee resource group include asian african american hispanic group cancer support group gay lesbian bisexual transgender midcareer multifaith group enhance religious understanding veteran family friends young early career professional woman group executive sponsor help set achieve goal obtain resource champion objective group base gay lesbian bisexual transgender group council young professional group council country include australia brazil china india information commitment relate employee customer stakeholder diversity find website performance gender diversity despite continue period change maintain percentage woman working level management gsk management position globally hold woman please steady progress year gender diversity management position hold woman svp director manager total currently woman corporate executive team change increase role lead major commercial operation consumer healthcare business significant increase woman represent corporate executive team ethnic diversity report ethnic diversity market united kingdom ethnic minority account employee proportion record context ethnic minority account population england wale census classification ethnic minority base commission racial equality definition encompass identify white british include people identify white irish north american european measure diversity count number employee define nonwhite employee nonwhite compare united states minority define black hispanics asians pacific islander american indians alaskan native minority comprise workforce compare maintain level despite substantial workforce reduction compare workforce datum north american industry classification system naic pharmaceutical medicine manufacturing industry identify area address gsk workforce africanamerican comparable naic industry figure gsk workforce latino asian compare industry figure respectively ethnic minority employee ethnic minority employee ethnic minority corporate responsibility report home people employee engagement employee engagement approach aim gsk employee feel engaged work colleague understand business objective performance communicate regularly workforce provide update progress goal change business listen feedback stimulate innovative idea use variety communication channel ensure reach employee possible include facetoface communication include team briefing company meeting conference web broadcast live record reach large geographically disperse team global intranet site connectgsk provides update company industry news act repository information resource employee email cascade system keep senior leader inform company news example late financial result spirit internal magazine news feature article gsk product people program available print intranet biennial employee survey open gsk separate survey run individual business unit induction programme provide new starter overview gsk resource available employee communication senior executive andrew witty ceo talk regularly employee global forum broadcast ceo advisory board comprise employee representative company act informal sound board idea intranet myceo give staff chance pose question andrew members corporate executive team cet cet member hold web broadcast blog page team inform consultation recognise trade union consultation collective bargaining country worldwide europe additional mechanism consult employee significant development changes business staff work council meet regularly provide employee chance speak directly company management employee representative country participate european employee consultation forum work alongside national consultation process forum meet annually receive business update senior gsk executive subcommittee employee representative meet quarterly management representative receive update discuss restructure proposal performance engage online launch new intranet portal connectgsk feature new social medium network tool enable employee collaborate share information connect easily introduce idea engine online tool allow employee submit idea recommendation vote suggestion colleague january ask employee idea simplify company procedure reduce bureaucracy nearly employee visit site receive recommendation april follow weeklong session explore result employee survey employee ask comment think response specific issue positive negative recommend action help improve employee participate feedback result number change example increase commitment think flexibly work practice employee survey nearly employee worldwide take december workforce survey survey ask question gsk demonstrate company value engage workforce empower individual develop employee skill overall survey result indicate people proud gsk clear accountable empower feel trusted job understand constitute ethical behaviour area identify improvement include need great transparency raise bar employee empowerment continue provide opportunity personal development consultation june hold annual european employee consultation forum eecf munich germany discussion cover topic include building trust reputation research development evolution vaccine market gsk ambition growth pharmaceutical business europe corporate responsibility report home people development training development training want employee access highquality training development opportunity career gsk right training development help employee improve performance feel engaged work progress career individual identify personal development need support manager performance appraisal process introduce degree feedback increase number employee work specialist external organisation conduct indepth assessment senior leader certain employee include member department external expert interview relevant individual use finding develop clear picture experience capability robust personal development plan development opportunity agree influential research center creative leadership highlight adult learn work report learning occur key process job development challenge project developmental relationship mentors formal development training programme research mind opportunity available gsk employee include action learning project offer employee opportunity new challenge work different colleague gain new insight secondment department gsk enable individual company work different angle workrelate training course cover subject inspirational leadership financial skill offer training course language gsk employee country mentor senior leader help employee improve performance think future career coach highperforming employee potential gskrsquo future leader employee volunteering help gsk employee gain new experience skill case acquire deep understanding patient need time support community charity gsk give employee pay day year volunteer community pulse programme offer chance employee spend month work nongovernmental organisation corporate responsibility report home people develop leader develop leader good leadership good succession plan vital successful sustainable implementation business strategy expect leader demonstrate value behaviour inspire team succession plan effective robust succession planning ensure suitably experience candidate fill senior management critical role gsk identify potential future leader gsk develop equip capability need run company encourage successor key role gain experience outside home country broaden outlook gain new skill measure readiness succession plan twice year identify gap look bring external talent enhance leadership skill gsk senior leader degree assessment receive feedback performance supervise colleague manager assessment help leader identify area improve provide exist future leader focus training development include assignment responsibility design stretch enhance learning capability provide train nearly gsk leader worldwide level leadership develop training programme future senior leader senior executive implement provide leader coach design help reach personal business goal coach include manager train coach internal approve external coach companywide mentoring programme expect senior leader mentor individual mentor opportunity pass advice knowledge programme help employee feel engaged management company identify employee mentor talent review process encourage employee set mentoring arrangement resource mentor mentee available intranet site support effort inclusive diverse company encourage mentor support different background corporate responsibility report home people reward recognition reward recognition rewarding employee contribution company recognise achievement help attract retain motivate good people offer competitive salary base industry benchmark incentive acknowledge employee good performance annual objective actual company performance benefit include share ownership scheme open gsk manager worldwide employee market pension provision healthcare vacation childcare support employee car ownership programme recognition specific project demonstrate high performance day job share ownership scheme help create culture ownership employee gsk manager worldwide eligible participate share programme reward package country employee opportunity share high level participation example employee participate share reward scheme corporate responsibility report home people restructure restructuring time time undertake restructuring programme improve effectiveness productivity operation ensure longterm sustainability gsk include outsource site closure staff reduction present streamline operation develop market grow operation emerge market line change shape business conscious effect restructure employee possible aim achieve organisational financial goal preserve job consult employee representative implement measure affect workforce local regulation allow speak affect employee work council trade union employee representative appropriate event redundancy affect employee receive wide range support include competitive severance package assistance find alternative employment career counselling retraining work hard maintain morale employee gsk restructure corporate responsibility report home people health safety wellbee health safety wellbee keep employee contractor healthy safe business priority reflect gsk core value respect people essential responsible employer contribute business performance improve engagement productivity reduce healthcare business disruption insurance cost health safety integral part broad environment workforce sustainability strategy reduce risk harm employee help remain healthy productive energise section report focus performance health safety aspect workforce sustainability strategy focus improve health safety culture address key health safety risk expand highimpact global programme read management environment health safety sustainability ehss nurture life campaign deliver healthy result programme call nurture life involve employee site director contractor staff horlick plant india address aspect healthy work living participant tackle wide range issue machine safety work culture include personal health empower employee charge health see tangible improvement reduction sickness absenteeism site greatly improve safety behaviour especially machine safety occupational health safety target reduce reportable injury illnesse ergonomic injury illness year exceed annual target annual reduction fiveyear period improvement total rate musculoskeletal rate read performance reduction reportable injury illness continue important goal drive reduction gsk pilot health safety indicator warn risk result injury corporate responsibility report home people health safety wellbee health safety culture health safety culture manage health safety integrate environment health safety sustainability ehss management system review update system align recognise international standard iso ohsa read management ehss conduct review health safety strategy ensure align gsk evolve business model ensure gsk continue effective sustainable health safety governance review enable allocate resource line health safety risk set new performance target occupational health safety datum independently assure ehss assurance process safety build maintain site risk assessment control process construction contractor safety programme capital project ehs review process emergency response programme monitor performance internal audit conduct integrate ehss audits site assess system manage risk compliance legislation performance global standard overall find aspect system manage safety health risk implement weak performance newly acquire site improvement plan address gap ensure good level risk control improvement plan monitor ensure timely progress read overall ehss audits living safety living safety programme design embed strong safety culture gsk identifie strength gap team large unit health safety culture establishe behaviour expect demonstrate everyday work important element programme focus behaviour employee contractor display establish everyone responsibility health safety management system responsible report potential risk encounter involve improve safety performance supervisor behaviour ensure gsk health safety standard understand implement maintain team include contractor supervisor champion compliance policy encourage team involve improve safety performance promote risk awareness manager attitude behaviour set tone lead high health safety standard communicate openly employee issue quickly address risk identify involve effort improve safety performance living safety currently deploy manufacturing organisation gsk site clear business benefit assess business health safety impact programme health safety learning culture gskwide mechanism learn external organisation event benchmarke internal near miss incident internal audits performance indicator review help create continuously improve health safety culture develop training framework identifie gap employee knowledge health safety provide inhouse external training course provide global training personal health risk management health safety standard programme process safety chemical exposure protection identify risk auditing ergonomic site develop conduct training base local need capability internal learning tool commercially available programme material safety health professional share knowledge good practice teleconference intranet community training programme discussion forums november launch new micro site gsk intranet share ehsrelated training material focus increase ehs professional skill staff site embark new qualification international nebosh diploma national examination board occupational safety health advance qualification occupational hygiene environmental management addition formal training learn opportunity raise awareness employee health safety issue announcement myehs community intranet site ceos sustainability awards programme health safety week celebration hold site level inspire employee address potential risk work home corporate responsibility report home people health safety wellbee address key health safety risk address key health safety risk risk assessment communication understand potential hazard pose material produce use research development manufacturing essential effectively manage health safety risk prevent damage environment hazard assessment help meet regulatory requirement registration evaluation authorisation chemical reach legislation globally harmonize system classification labelling chemical ghs conduct hazard assessment develop safety data sheet new material product progress development process ensure health safety information readily available employee contractor contract manufacturer customer handle transport dispose material product safely safety data sheet available multiple language website provide health safety environmental information nearly gsk material key manufacturing process chemical manage chemical exposure rigorous procedure control protect employee exposure chemical gsk site monitor air quality assess exposure hazardous compound implement control achieve respirator free goal goal exist operation handle hazardous compound free respirator end mean employee need wear respiratory protective equipment routine production task instead site install technology prevents release hazardous compound work environment situation possible respirator free employee remain protect appropriate respiratory equipment extend respirator free target date originally focus adapt operation high degree risk easiest adapt new facility respirator free start date operation respirator free process safety product begin formulation process hazardous material flammable solvent combustible powder scientist look opportunity eliminate use material green chemistry green technology programme substitution elimination option engineer use online system assess safety process plant design develop plant maintenance strategy share hazard information control strategy gsk focus execution longterm plan high risk area business begin detailed preparation implement process safety management principle low risk area business oversight effort maintain process safety steering committee comprise senior operation eh management representation relevant business area process safety incident include significant overpressure incident thane manufacturing facility india carry technical management system investigation incident implement detailed response plan thane support staff second gsk site plan share gsk learn incident concentrate risk reduction measure process conduct site process safety review external consultant complete underway primary technology site include desktop review gsk process safety management system driver safety sale representative spend significant amount time drive risk involve road traffic incident drive accident common cause fatality include death injury lose time motor vehicle accident fatality injury data health safety performance section aim reduce risk road traffic accident global driver safety programme include instruction guideline driver training vehicle selection risk assessment distraction drive accident reporting motorbike rider safety manual employee country provide motorbike scooter conduct driver safety audits high risk country turkey india egypt audits find progress implement global driver safety programme reduce risk example improve training maintenance vehicle country ergonomic human factor musculoskeletal illness repetitive strain injury lead cause time away work good workplace job design help employee job effectively reduce risk musculoskeletal illness injurie ergonomic human factor apply properly reduce illness injury work performance error lose time seventy crossdisciplinary ergonomic improvement team work identify risk develop solution share good practice globally ergonomic intranet site addition train facilitator help manage computerbased ergonomic risk assessment assessment employee opportunity discuss way reduce injury risk focus improve risk assessment reduce ergonomicsrelate injury illness establish simplified ergonomic risk assessment nonoffice environment use site ergonomic team completely redesign ergonomic intranet page stimulate interaction learn site community discussion area blog feedback continue countermeasure place manufacturing operation office example limit injury manual lifting provide sufficient adjustability equipment result effort far exceed target achieve average annual reduction musculoskeletalrelate injury illness rate year musculoskeletal injury illness continue major cause worker ill health continue focus proactive reactive system improvement corporate responsibility report home people health safety wellbee health wellbeing programme health wellbeing programme gsk offer programme enhance employee health wellbee sustain employee energy engagement work contribute improved productivity performance global health programme focus prevent manage lead cause employee illness disability depression nonworkrelate injury heart disease stroke respiratory infection annual seasonal flu vaccination offer free gsk employee market seasonal flu vaccine centrally fund increase access travel health programme include medication vaccination help employee healthy productive travel business support global network employee health professional global programme address specific issue support employee wellbeing include flexible work option programme improve health employee family depend local need healthcare service assist employee suffer chronic disease support access appropriate longterm treatment help prevent disability absence work support safe timely return work gsk support key public health effort world aids day world health organization health day tobacco free day global handwashing day employee assistance programme begin introduce global employee assistance programme eap design provide emotional counselling evaluation support employee end country eap place introduce market employee country access free basic mental emotional healthcare include session counsel qualified health professional new life emotional issue arise year programme provide counsel emotional support time disaster crisis site downsizing personal team resilience increase pressure pace communication complexity global business emphasis need support team personal energy resilience pressure resilience ability successful highpressure fastpace continuously change work environment support good performance help prevent mental illness arise stress leading cause ill health disability work offer workshop individual team enhance build personal resilience help team manage source pressure lead ill health inefficiency personal resilience programme help people build skill increase focus energy confidence reduce tension anxiety fatigue employee participate start team resilience programme help employee manager identify act source pressure team lack workplace flexibility accountability programme complete employee country begin participant identify positive outcome successful team work efficient machine operation increase empowerment well sale performance study group engage team resilience programme find reduce perception workplace pressure increase pride gsk work motivation study involve interview people undertake team resilience process find sense great control influence team work improve communication energy performance high energy level help employee focus well work efficiently energy performance programme help employee build skill well manage physical mental energy effectively help people develop habit improve engagement work home employee participate workshops total employee country attend programme report significant improvement physical mental performance emotional energy participant find improved energy level month workshop analysis outcome datum graduate show increase score desire gsk behaviour notably develop people key empowerment helps improve wellbee performance health business continuity contingency plan place protect employee business event natural disaster manmade emergencies flu pandemic public health emergency rapid global spread influenza pandemic preparation help inform protect staff dependant key complementary worker country universal access seasonal flu vaccine provide legally permit antiviral medicine provide employee dependant give quick access medication ill flu increase cleaning disinfect work surface thorough hand washing rigorous absence procedure help reduce spread workplace base experience pandemic simplify strategy future pandemic response dedicated flu information website continue educate inform employee additionally crisis continuity management website provide information tool template gsk country site crisis team respond type business disruption corporate responsibility report home people health safety wellbee health safety performance health safety performance performance performance datum verify sgs fine penalty safetyrelate fine penalty injury illness rate main health safety measure reportable injury illness rate number incident hour worked measure number injury illness result lose day number day lose injury illness provide indication severity incident rough guide health safety target progress injury illness target progress reduce reportable injury illness rate year end average year reduce reportable musculoskeletal illness injury rate year end average year reduce lose time injury illnesse year end average year reportable injury illness rate set target reduce lose time injury illness year exceed year target achieve target continue good progress overall lose time injury illnesse reduce injury illness cause lead cause injury illness continue slip trip fall ergonomic injury mainly strain repetitive musculoskeletal injury road traffic incident mental ill health account illnesse case result high number day lose day case average address resilience programme leading cause injury illness cause injury illness total slip trip fall ergonomic road traffic incident machinery relate fatality injury road traffic accident fatality amputation gsk employee place hand equipment switch employee india kill motorbike collide truck operator remove fix guard attempt clear jam finger cut edge star wheel lead amputation leave index finger operator clear foil jam packaging machine cutter rotate unexpectedly result amputation middle finger right hand scope datum cover gsk employee contract worker directly supervise data contractor work gsk site supervise staff incomplete include injury illness datum collect pharmaceutical consumer healthcare nutritional manufacturing site biological site pharmaceutical consumer healthcare site headquarters site include office sale group million hour work small office distribution centre site report injury illness data sgs verify datum table table summary year health safety performance breakdown metric component detailed data table injury illness gsk employee hour work million fatality number injury lose time calendar day lose injury number illness lose time calendar day lose illness number injury lose time number illness lose time lose time injury illness rate reportable injury illness rate ergonomic lose time injury illness rate ergonomic reportable injury illness rate calendar day lose rate note data occupational health safety datum cover employee contract worker directly supervise gsk employee report snapshot injury illness performance year case add end year prior year change losttime injury illnesse workrelate injury illnesse result day away work rate hour work lose calendar day calendar day include weekend employee work workrelate injury illness help provide measure severity injury illnesse reportable injury illnesse lose time incident result time away work lose time aid result lose time sgs verify corporate responsibility report home human right introduction human right gsk commit uphold universal declaration human right oecd guideline multinational enterprise core labour standard set international labour organization signatory global compact voluntary global standard human right labour environment anticorruption believe government responsibility define enforce legal framework human right accordance international law agreement business responsibilitie work hard uphold human right sphere influence include employee supplier local community society broadly direct control human right operation recognise industry unique role play effort improve health worldwide develop safe effective treatment ailment affect patient health strive medicine vaccine widely available possible running business sustainable way approach include research partnership disease develop world flexible pricing product affordable develop country safeguard place ensure human right people take clinical research protect include inform consent process procedure protect patient privacy especially careful protect right child involve clinical trial recognise support role convention biological diversity cbd play provide framework conservation biological diversity protect right country community access share benefit arise read approach cbd use biological material maintain high standard human right benefit business help good employee support relationship community near site ensure supplier contract run smoothly provide reliable supply highquality product protect reputation information gsk human right human right relevant issue cover report section give overview approach information human right clause include contract supplier read supply chain read effort improve access medicine read investment local community read employment practice read inform consent process approach clinical trial involve child read position statement convention biological diversity corporate responsibility report home human right employee employee employment standard issue diversity equal opportunity health safety protect employee human right employer commit provide fair salary good employment condition commit provide healthy safe secure workplace employee contractor oppose discrimination work commit promote respect diversity commit promote personal development dignity employee respectful employee right join independent trade union freedom association oppose form slavery exploitative child labour work appropriate partner address problem responsibly encounter employee report concern supervisor line manager compliance officer compliance champion human resource legal department ethic compliance department use global confidential reporting line allege human right violation global confidential reporting line read employment practice policy inclusion diversity corporate responsibility report home human right supplier supplier buyer raw material manufacture good service world require supplier contractor business partner meet standard human right gsk human right clause include supplier contract introduce party code conduct apply supplier outline standard expect meet new supplier require sign statement confirm comply principle code business gsk exist supplier require comply term condition contract include element similar party code conduct highlight stand party code conduct routine engagement exist supplier aware code reinforce ethical principle contain issue arise work supplier close gap consider human right issue routine interaction critical supplier contract manufacturer supplier present great risk gsk key risk area environmental health safety ehs audits potential new exist critical supplier include question help identify potential breach human right clause supplier ask information policy practice relate age limit employee discrimination employee local population prevention abuse individual wage benefit work hour right worker organise recognition worker organisation knowingly use supplier responsible human right infringement identify human right issue recommendation supplier improve performance require supplier submit regular progress report undertake site visit ensure improve performance member pharmaceutical supply chain initiative psci industry collaboration set guide principle standard supplier cover human right labour issue psci look way improve supplier standard especially emerge market read supply chain corporate responsibility report home human right community community respect promote right people community near operation effort improve access medicine work help society broadly fulfil right health local community gsk aim good relationship community site operate way infringe human right seek minimise impact local environment operate site safely aim bring social economic benefit area presence read investment local community convention biological diversity cbd convention biological diversity provide framework conservation sustainable use biodiversity promote fair equitable share benefit arise use genetic resource include research development new medicine vaccine gsk support cbd role give diversity biological material way research development possible generalise role play biomedical research fundamental value material particular project product careful consideration need seek define implement monitor appropriate access genetic resource share benefit arise use gsk participate recent discussion international protocol access genetic resource fair equitable share benefit arise utilization end result agree conference party cbd nagoya october recognise compromise agreement leave issue open interpretation national implementation stage hope implementation local level ensure pharmaceutical company continue search new compound treat cure disease time protect interest country community genetic resource source gsk currently involve product development genetic resource collect cbd ratify currently look resource know bioprospecte result access benefitshare agreement place possible future undertake development work natural genetic resource indigenous particular country instance access resource obtain accordance cbd reflect local law ensure relevant party receive agree benefit use resource example monetary payment read position statement convention biological diversity corporate responsibility report home human right society society declaration human right state right standard live adequate health wellbeing family include medical care improve healthcare society great challenge particularly develop world gsk contribute healthcare worldwide discover new treatment vaccine wide range product affordable develop country preferential pricing voluntary licence agreement generic manufacturer make contribution develop country community investment project contribute improvement healthcare infrastructure patient assistance program improve access thousand uninsured patient engage government multilateral agency ngo pharmaceutical company help improve access medicine read approach access medicine work community corporate responsibility report home human right activity embargo country activity embargo country stakeholder concern gsk business activity country subject trade embargo burma myanmar north korea iran sudan share un belief people deny access medicine regime operate country aim provide medicine vaccine country need wish purchase observe sanction trading control apply country nation longstanding commitment presence predate introduction measure trade embargo period governmentimpose trade embargo ensure continuity supply subject specific legal restriction demand product embargo country country business support commit uphold universal declaration human right core standard set international labour organization observe local law regulation corporate responsibility report home public policy patient advocacy public policy patient advocacy pharmaceutical industry highly regulate government policy legislation regulation significant impact business important engage government stakeholder legislative policy process public policy activity work legislation policy encourage scientific innovation balance interest business stakeholder work patient group professional group help member voice healthcare debate believe conduct advocacy work responsibly valuable contribution debate issue impact business particularly relate research development use pharmaceutical healthcare aim increase stakeholder trust gsk transparent lobby public policy work address concern stakeholder pharmaceutical industry exercise inappropriate influence government publish key element public policy activity year website report trade association membership federal institution lobbying expenditure publish information work patient group include detail funding provide gsk political contribution provide information approach work healthcare professional research practice ethical conduct section report corporate responsibility report home public policy patient advocacy approach external affair approach external affair employee involve public policy work abide employee guide business conduct base principle partnership commit working government regulatory authority stakeholder constructive way communication view account concern external audience enable assess improve business practice integrity base public policy work research analysis fact respect opinion look constructive solution external affair work line code conduct relevant policy include related competition law prevent corrupt practice political contribution external affair team major region business unit monitor propose legislative reform policy development stakeholder concern meet regularly government official stakeholder multilateral organisation ngo explain view public policy issue tailor approach suit different culture political tradition country engage public policy process ensure position fully consistent gsk policy public policy statement ensure standard set guide business conduct apply globally lobby issue affect pharmaceutical consumer healthcare industry conduct trade association hire professional lobbyist support public policy work trade association gsk member trade industry organisation include association british pharmaceutical industry abpi association european selfmedication industry aesgp bioindustry association bia biotechnology industry organization bio british pharma group bpg confederation british industry cbi european brands association aim european cosmetics association colipa european federation pharmaceutical industry association efpia intellectual property owner association ipo international chamber commerce icc international federation pharmaceutical manufacturer association ifpma japan pharmaceutical manufacturers association jpma national association manufacturers nam organization international investment ofii organisation pharmaceutical producers india oppi pharmaceutical research manufacturers america phrma rdbased pharmaceutical association committee rdpac important lobbying conduct trade association reflect policy value work member set policy attend industry association meeting government stakeholder share view particular issue member trade association trade association adopt public policy position agree participate advocacy activity relate subject senior gsk manager sit board majority industry trade association member raise concern particular advocacy position corporate responsibility report home public policy patient advocacy public policy activity public policy activity engage government stakeholder wide range issue affect industry publish position key issue relate corporate responsibility include access medicine ethical conduct research development intellectual property environment public health competitiveness pricing reimbursement market access counterfeiting healthcare product key issue engage healthcare reform access healthcare disease prevention regulation relate research practice patient safety intellectual property corporate responsibility report home public policy patient advocacy public policy activity advocacy healthcare reform advocacy healthcare reform activity march president obama sign law patient protection affordable care act aca significantly change access funding healthcare service gsk support effort congress obama administration increase access improve quality reduce cost growth health system new law present pharmaceutical industry financial challenge form expand rebate new fee offer opportunity health system direction embody threepart approach advocate achieve lowercost higherquality healthcare increase prevention improve treatment accelerate research well treatment chronic disease triple solution healthy america focus interpretation implementation aca priority ensure legislation implement way reflect good interest patient preserve environment value medical research development innovation believe reform improve quality care save cost focus prevention personal responsibility remove barrier access coordinate care improve management chronic disease health reform position paper offer outline gsk stand issue relate health reform read advocacy increase investment chronic disease prevention treatment triple solution healthy america increase access expand discount organisation engage congress white house industry association involve phrma bio gsk position aca include expansion rebate discount medicine purchase government medicare medicaid programmes gsk commit change help increase access medicine citizen participate programme begin implement previously patient eligible medicare pay cost medication cost reach certain eligible assistance member phrma beginning gsk provide cent discount brand medication coverage gap require aca government pay cent leave patient pay remain cent law fully implement industry support provision aca help cover cost increase expansion medicaid government programme pay health insurance include prescription drug child lowincome individual pharmaceutical industry contribute newly establish health fund stipulate aca helps offset cost associate healthcare reform approximately million citizen expect gain health insurance coverage time aca fully implement result provision seek improve access affordability healthcare read gsk work increase access medicine regulatory pathway fda approval biosimilar organisation engage congress white house industry association involve bio phrma gsk position aca create regulatory pathway food drug administration fda approve biosimilar version biological medicine vaccine call followon biologic similar innovator product gsk support development responsible approval pathway biosimilar biologic derive living organism include vaccine human insulin biologic effective target therapy tackle costly complex disease aca recognise importance medical innovation include year datum exclusivity date licence innovator product encourage appropriate balance desire enhance competition preserve incentive innovation gsk encourage fda require company new regulatory pathway provide clinical datum safety efficacy biosimilar sufficiently similar innovator product establish pharmacovigilance framework identify evaluate minimise safety issue regulatory approval future health reform implementation aca year continue support effort address rise healthcare cost approach call triple solution healthy america focus prevention intervention innovation focus area potential dramatically change way healthcare fund deliver especially consider comparative effectiveness research cer comparison treatment option healthcare delivery strategy health information technology hit use technology manage individual group patient data quality standard measure healthcare quality base nationally recognise practice guideline believe implementation payment delivery system reform consider spectrum healthcare service cost place limit expenditure area result increase patient morbidity mortality increase health cost area continue demonstrate value expenditure prescription drug support numerous study improve adherence medication reduce overall healthcare cost read previous advocacy cer corporate responsibility report activity asia healthcare reform china organisation engage chinese government pharmaceutical industry business china member state government european commission academic chinese think tank industry association involve bpg efpia rdpac phrma uschina business council china pharmaceutical enterprises association cpea chinese pharmaceutical association cpa china medical doctor association cmda gsk position chinese government invest rmb billion billion cent gdp improve country healthcare system narrow current ruralurban healthcare gap plan healthcare reform include expand basic medical insurance cover cent population establish network local clinic improve service public hospital government establish essential drug system require healthcare institution purchase certain medicine ensure available public appropriate dosage form affordable price gsk welcome ongoing healthcare reform help ensure well access medicine vaccine chinese patient particularly rural area commit work chinese authority meet objective reflect pricing market access policy ensure well access innovative medicine vaccine china increase investment china include expand activity china establish commitment discover medicine china currently conduct research severe disorder multiple sclerosis parkinson disease alzheimer disease establish innovation centre beijing subsidiary gsk china sinoamerican tianjin smith kline french laboratory tskf ensure product increasingly tailor need chinese patient gsk china establish clinical research centre development project conduct collaboration medical school hospital gsk speed partnership domestic biopharmaceutical company locally produce flu vaccine paediatric vaccine investment help improve chinese patient access innovative drug vaccine gsk engage partnership china improve access vaccine launch website information family vaccine china preventive medicine association cpma value vaccine public education project ccdc cpma partner ministry health improve treatment hepatitis unicef provide essential vaccine child rural poor area fast patient access new medicine taiwan organisation engage taiwanese government department health doh taiwan food drug administration tfda bureau national health insurance bnhi pharmaceutical industry industry association involve international researchbase pharmaceutical manufacturers association irpma european chamber commerce taipei ecct american chamber commerce taipei amcham gsk position gsk work regulatory health authority taiwan encourage change registration reimbursement system new medicine currently reimbursement application product approve marketing delay patient access new medicine gsk advocate overlap parallel review process tfda bnhi evaluate innovative medicine time reduce time span marketing approval decision national coverage payment accelerate patient access new medicine create incentive investment reduce time return investment work ecct file position paper lead irpma stakeholder engagement issue gsk taiwan work local american chamber commerce taipei support gsk position meet authority corporate responsibility report home public policy patient advocacy public policy activity advocacy healthcare disease prevention advocacy healthcare disease prevention global activity safeguard timely unrestricted access influenza virus organisation engage world health organization develop develop country government institutions industry association involve efpia european vaccine manufacturer evm ifpma influenza vaccine iv phrma gsk positionthe influenza virus unstable mutate quickly government need remain vigilant emergence new strain virus share freely government enable development vaccine framework share influenza virus benefit establish intergovernmental meeting igm pandemic influenza preparedness pip run year indonesia stop share influenza virus insist benefit exchange access virus response international community include vaccine industry map way help develop country prepare pandemic response include product donation technology transfer tiere pricing discussion continue nature benefit industry provide return access virus mandatory voluntary gsk vaccine manufacturer support principle voluntary benefit choose individual vaccine manufacturer accord capability preparation meeting pipigm december vaccine manufacturer individual benefitsharing commitment ifpma meeting progress participant appear agree limit pip agreement pandemic influenza viruse vaccine exclude seasonal influenza virus benefit sharing discuss cochair pipigm instead discuss possible benefit directly manufacturer prior meeting april innovation disease develop world organisation engage world health organization government department international development department health intellectual property office commission government ngo industry organisation involve ifpma phrma efpia abpi bpg bio gsk position contribute development global strategy plan action gspoa research development relevant disease affect develop country disproportionately agree consensus world health assembly read report detail gsk continue pursue approach develop world healthcare align gspoa area work product development partnership pdps set patent pool share compound library differential pricing access medicine information gspoa call creation expert working group ewg look finance develop world provide input work ewg support report present world health assembly meeting create new consultative expert working group progress work ewg review option membership group agree executive board january gsk seek constructively engage new group directly ifpma appropriate securing financing establish delivery framework malaria vaccine organisation engage time african health minister roll malaria rbm department international development dfid parliament party malaria group special envoy malaria gsk position rtss gsk candidate malaria vaccine candidate furth advanced clinical development likely available malaria vaccine read access medicine section report development happen partnership pathmvi go general introduction rtss infant age week possible year vaccine file young child aged month early gsk state vaccine available price cover cost generate small return committed reinveste profit generation malaria vaccine product disease develop world second generation vaccine malaria neglect tropical disease work multilateral partner ngos foundation stakeholder create supportive policy environment introduction vaccine ensure adequate financing place goal help healthcare system prepare invest necessary capacity infrastructure comprehensive programme control eventually eliminate malaria implementation start soon vaccine approve use activity investment chronic disease prevention treatment organisation engage department health human services congress white house state legislator governorsrsquo office state health agency partnership fight chronic disease industry association involve phrma gsk position chronic disease diabete heart disease lung disease account threequarter healthcare spend relatively little invest prevention chronic disease costly complication preventable increasingly manageable advocate threepart approach achieve lowercost higherquality healthcare increase prevention improve treatment accelerate research well treatment chronic disease healthcare provider need incentive promote preventative service address major cause chronic disease obesity smoking healthcare policy need reform well encourage reward medical research improve treatment costly unmet medical need alzheimerrsquos disease prevent well manage chronic disease reduce overall healthcare cost long term read triple solution healthy america european activity support government tackle obesity organisation engage national government european commissioneuropean parliament world health organization industry association involve european selfmedication industry aesgp pharmaceutical group european union pgeu standing committee european doctor cpme national association gsk position european health minister european commission set target reverse increase number overweight obese people europe promote healthy diet physical activity help prevent people overweight obese reduce associate social economic public health impact gsk believe additional complementary approach include overthecounter weight loss medicine alli consider policy maker reach target ensure overweight obese people support require manage weight live healthy life read overthe counter weight loss medicine urge policy maker consider healthcare professional include doctor pharmacist nurse come contact overweight obese individual good support sustain healthy weight loss review market weight loss product well enforce national law consumer confidence product appropriate scientifically robust evidencebase safety efficacy profile ensure consumer information tool need manage weight successfully advocacy work include campaign event raise awareness help change public perception influence policy funding decision include sponsorship firstever european obesity day event include awarenessraise picnic cooperation red cross run obesity healthy lifestyle information point city online petition set citizen express support obesity day charter encourage european commission action tobacco dependence cessation organisation engage european commission member states european parliament tobacco control community industry association involve association european selfmedication industry aesgp pharmaceutical group european union pgeu standing committee european doctor cpme national association gsk position member state introduce legislation require indoor environment smokefree believe help people stop smoke encourage government ensure national smoking cessation strategy provide smoker great support motivation stop support world health organization framework convention tobacco control fctc include guideline promote smoking cessation treat tobacco dependence advocacy event smoking cessation hold european parliament november bring tobacco control community policy maker scientist pharmaceutical industry discuss new guideline turn practice activity asia engage government religious leader use product muslim community organisation engage government indonesia european union united states embassy embassy belgium embassy indonesian islamic council mui indonesian halal certification agency lppom mui nahdlatul ulama academic research institute industry association involve ifpma phrma efpia gsk position indonesian islamic council issue fatwa forbid use meningitis vaccine mencevax indonesian government purchase mass immunisation pilgrim hajj mecca fatwa related use pork product ndash forbid consumption muslim ndash mencevax production process decree pose threat public health prevented pilgrim indonesian muslim receive vaccine general policy accordance customer need gsk process change possible use synthetic nonanimal origin material production vaccine include mencevax process new seed lot system develop production meningococcus polysaccharide base use culture medium free animalndashderive material include free bovine porcine material gsk begin work indonesian government government member state ensure muslim community indonesia comfortable mencevax invite muslim leader government representative health expert scientist visit manufacture site provide documentation manufacturing process confirm vaccine contain trace pork product effort indonesia successful countrys large muslim community organisation nahdlatul ulama issue halal decree meningitis vaccine corporate responsibility report home public policy patient advocacy public policy activity advocacy research practice advocacy research practice european activity european commission review clinical trial directive organisation engage european commission european parliament member states national regulatory agency industry association involve efpia european vaccine manufacturers evm european association bioindustrie europabio national trade association gsk position clinical trial directive outline procedure clinical trial investigator follow european commission begin review assess success directive implementation plan publish finding proposal revise directive advocate revision directive facilitate highquality clinical research achieving require clear legal framework avoid duplication regulatory effort unnecessary bureaucracy highquality scientific regulatory review approval process rapid reliable review approval timelines harmonise requirement implementation member state read conduct clinical trial advocacy revision variation regulation organisation engage european commission european parliament member states national regulatory agency european medicine agency industry association involve efpia evm europabio national trade association gsk position medicinal product approve marketing change example manufacturing process prescribe information consider variation handle accord complex regulatory framework define law variation regulation historical reason large majority product fall outside legislation subject divergent national rule procedure lack harmonisation place significant administrative burden industry national regulatory authority add unnecessary complexity objective revision variation regulation simplify legislative framework harmonise rule apply medicinal product gsk welcome revision advocate simple clear flexible framework variation reduce number regulatory event associate postapproval change associate regulatory burden enable predictability variation procedure timeline order beneficial change introduce timely manner provide legislative framework accommodate flexible regulatory approach outline ich guideline ich pharmaceutical development ich quality risk management ich pharmaceutical quality system introduce science riskbase approach manage postauthorisation change facilitate innovation continual improvement pharmaceutical manufacturing european commission adopt framework legislation recently finalise key support guideline intend ensure implementation manner consistent objective new legislation implement gsk provide european commission feedback experience apply guideline rapidly consistently nationally approve product advocacy european animal directive organisation engage european commission european parliament european member state industry association involve abpi efpia les entreprise mdicament france leem association francaise des sciences technique lanimal laboratoire afstal groupe interprofessionnel rflexion communication sur recherche gircorgrice laboratory animal veterinary association lava laboratory animal science association lasa federation european laboratory animal science association felasa home office liaison forum holos gsk position european animal directive directive eec originally introduce govern use animal experimental scientific purpose aim establish framework animal research activity september adopt revise european animal directive directive place great emphasis replace reduce refining use animal research gsk believe legislation animal testing ensure high animal welfare standard support environment allow research lead new medicine vaccine meet patient need welcome revise directive requirement integrate current practice work trade body ensure consistent transposition national legislation read use animal research support new approach pharmacovigilance organisation engage european commission european medicines agency government industry association involve abpi efpia gsk position gsk welcome new approach pharmacovigilance regulation approve european parliament september new regulation amend exist framework pharmacovigilance provide regulation directive fully implement july new regulation allow pharmaceutical company regulator focus evaluate product safety compliance unclear complex regulatory demand believe follow essential legislation advantage fully realise harmonise implementation europe soon possible launch fully functional eudravigilance database collate adverse event report europe single set rule gsk continue work trade association regulator appropriate facilitate advise publication clear unambiguous guidance pharmaceutical industry comply regulation corporate responsibility report home public policy patient advocacy public policy activity advocacy patient safety advocacy patient safety activity legislation prescription medicine import organisation engage department health human service food drug administration fda congress state board pharmacy state legislator governor office industry association involve bio phrma gsk position current law prevent prescription medicine import safety cost saving certification secretary health human service periodic legislative attempt remove safety saving certification requirement aim easy legally import medicine undermine fdas ability protect distribution system counterfeit unsafe medicine harm patient guarantee consumer save money department health human service find thirdparty payer insurance company likely benefit gsk support safe alternative help patient afford medicine partnership prescription assistance ppa example give access public private patient assistance programme patient lack prescription drug coverage read gsk patient assistance programme read advocacy healthcare reform european activity enhance patient safety harmonise serialisation pharmaceutical product europe organisation engage patient group european commission european parliament member states wholesalers pharmacists health insurer industry association involve efpia local pharmaceutical trade association association european selfmedication industry aesgp europabio gsk position pharmaceutical supply chain europe complex million pack move region year numerous wholesaler intermediary trader create risk counterfeit product enter legitimate supply chain make detect trace counterfeit medicine difficult world health organization identify trade involve intermediary free trade zone key driver counterfeit activity december european commission introduce proposal tighten supervision european supply chain mandate introduction safety feature aim trace authenticating pharmaceutical product key outcome commission proposal likely introduction serialisation unique product identification code apply prescription medicine allow tracking authentication prior dispense patient gsk welcome european commission plan work industry ensure element believe central enhance patient safety reflect final european framework need harmonised approach europe standardise approach identification verification medicine essential allow pharmacist member state check pack dispense help detect duplicate counterfeit product supply chain country origin standardisation identification verification system differ country make difficult identify product originating country million pack medicine currently parallel trade buy pharmaceutical company member state sell year system limited national scheme ignore crossborder nature counterfeit principle single market support serialisation system base datum matrix gsi standard datum matrix ecc currently efficient effective datum carrier available capable meeting need stakeholder pharmaceutical supply chain highly reliable quickly read enable large datum store small space compare method data carrier implement product year reasonable cost proposal vote european parliament council codecision procedure quarter gsk pharmaceutical industry continue advocate need harmonised implementation proposal europe read position statement counterfeit corporate responsibility report home public policy patient advocacy public policy activity advocacy intellectual property right advocacy intellectual property right global activity access benefit share disclosure obligation patent law organisation engage secretariat convention biological diversity cbd hoc work group access benefit share department environment food rural affair trade european commission national european government government world intellectual property organization world trade organization industry association involve bio bpg efpia icc ifpma phrma gsk position october party convention biological diversity cbd adopt nagoya protocol access genetic resource fair equitable share benefit arise utilization gsk support cbd objective provide fair equitable share benefit arise use genetic resource argue possible generalise role genetic resource play biomedical research value particular material particular project product view protocol go round negotiation careful balance need struck interest stakeholder take account far way society risk hamper search medicine vaccine treat cure disease cancer hivaid malaria far way legitimate interest country community genetic resource source undermine negotiate protocol recognise compromise agreement leave issue open interpretation government please negotiator mandate introduction disclosure obligation patent application disclose origin genetic resource invention obligation create major legal commercial uncertainty researcher company develop product genetic resource discourage innovation ultimately lead few benefit share gsk work ensure protocol implement balanced way country decide adopt activity patent system reform federal legislation organisation engage patent trademark office pto congress industry association involve bio coalition century patent reform phrma gsk position patent law framework provide business certainty long period promote investment essential researchbase pharmaceutical industry wide range manufacturer long lead time research market senate progress draft legislation provide meaningful patent reform preserve incentive necessary sustain innovation spur creation highwage highvalue job thoughtful compromise key issue include postgrant review damage allow bill legislative process gsk work coalition researchbase company manufacturer university small inventor promote patent reform stimulate investment research strengthen patent system support patent reform clear provide business certainty improve quality patent remove subjectivity litigation issue european activity creation patent box stimulate ukbased investment gsk organisation engage government treasury department business innovation skill industry association involve confederation british industry cbi group association british pharmaceutical industry abpi bioindustry association bia gsk position december labour government power announce introduce patent box provide cent tax rate income attribute intellectual property beneficially own idea create patent box come gsk support company trade association attractive location investment pharmaceutical manufacturing november coalition government announce proceed plan aim patent box effect april detail implementation discuss consultation gsk welcome government proposal establish patent box successful introduction enable new investment read press release detention patentinfringing product transit organisation engage european commission wto industry association involve efpia aim gsk position march european commission launch review custom regulation provision allow european custom official detain good include transit suspect infringe patent trademark implementation regulation historically highly controversial report incident product detain destroy return export country transit infringe patent export import country brazil india file complaint world trade organization regulation contravene international trading rule impede trade legitimate product gsk support objective regulation safeguard intellectual property right innovation brand protection believe effort take stop counterfeit healthcare product enter transit recognise public health argument support detention counterfeit product necessarily extend patentinfringing product object current transit provision relate patent remove regulation subject consideration regulation retain provision allow company record patent customs respond suspect patentinfringing product destine entry gsk record patent way year like retain option protect european patent infringement patent trademark holder able use information supply official relate suspect intransit good support infringement proceeding import export country require change regulation corporate responsibility report home public policy patient advocacy political contribution lobbying expenditure political contribution lobbying expenditure gsk corporate political contribution disclose voluntary political contribution employee political action committee federal lobbying expenditure cost cost lobby institution political action committee contribution gsk employee political action committee gsk pac facilitate voluntary political contribution eligible employee accordance federal election campaign act pac control gsk run govern board participate gsk employee company decision recipient contribution participate employee exercise legal right pool resource political contribution pac contribution voluntary contribution subject strict limitation example gsk pac contribute election individual candidate federal office require law pac contribution report federal election commission fec report state pac contribution line applicable state law gsk employee pac contribute percent republicans percent democrats percent unaffiliated party candidate run state federal office lobby expenditure europe gsk signatory european commission code conduct lobbyists voluntary register interest representative register interest representative declare cost associate lobby institution range include run brussels advocacy office salary external event travel accommodation consulting cost educational material figure take account proportion employee time spend interest representation report lobby expenditure congress accordance lobby disclosure act spend federal lobbying activity include cost salary benefit employee register lobby government use lobbying consultant support lobbying contact planning activity research run gsk washington government affair office support staff portion trade association fee associate federal lobbying report state lobbying expense line applicable state law contribution policy group gsk contribute group provide forum policy analysis debate include think tank number country organisation corporate responsibility report home public policy patient advocacy patient advocacy patient advocacy patient group nonprofit organisation found patient caregiver family member health professional provide member information condition guidance live disease engage healthcare provider government medium promote improve treatment service patient campaign change issue affect patient caregiver live carry vital research cause potential treatment specific condition patient group important stakeholder gsk engage commitment patientfocuse company share belief healthcare system focus prevent treat manage disease patient access quality medicine service information disease relationship patient group mutually beneficial help well understand patient need illness turn guide support help patient voice hear healthcare debate strengthen support patient illness diagnosis chronic treatment endoflife care support patient group disease area alzheimer disease asthma cancer diabete epilepsy hivaid multiple sclerosis provide funding support daytoday running cost oneoff donation help patient group conduct specific event activity example breast cancer awareness day offer educational support training staff management skill disease education work disease awarenessprevention project engagement design market product support public policy work managing engagement patient group establish new group responsible sharing good practice patient advocacy gsk new group seeks ensure consistency relationship patient group worldwide open new centre excellence dedicate coordinating engagement patient advocacy group professional association national regional state level involvement patient group involve funding relationship define write agreement specify group use contribution benefit member gsk employee work patient group relevant party follow patient advocacy guidance standard operating procedure sop box abide applicable law regulation europe gsk work efpia help update code work patient group revise code follow gsk commitment area include disclose funding patient group provide training employee understand requirement employee region learn patient advocacy activity access specific company intranet europe publish newsletter raise employee awareness internal external development relate patient group work patient group standard operating procedure state access medicine involvement patient organisation declare transparent gsk seek patient organisation endorsement medicine pay patient group endorse gsk service medicine promote patient organisation gsk create patient organisation sole funding sponsor patient organisation provide cent funding patient organisation exception allow circumstance encourage independence gsk seek direct return investment funding patient organisation information gsk pipeline compound factual nonpromotional provide patient organisation scientific dialogue acceptable gsk clinical trial medical personnel work patient organisation ensure optimal clinical trial recruitment consult clinical trial design protocols gsk directly sponsor patient organisation representative attend medical congress conference healthcare professional event exception include representative invite speak conference medical congress specific workstream design patient gsk sponsor representative attend nonmedical congress gsk pay modest honorarium speaker fee patient organisation advisory board member speaker represent party working gsk give project fully transparent relationship interact patient group project encourage independence believe patient group independent encourage seek financial support wide range organisation possible hold workshop funding application ensure funding patient group appropriate size guideline state gsk funding cent group overall income vast majority instance actual percentage lower allow exemption cent cap group support limited income small donation example exceed limit group difficulty attract funding nature activity example provide needle exchange drug user case approve general manager local operating company regional general manager head regional government affair corporate responsibility report home public policy patient advocacy patientadvocacy transparency transparency transparent support patient group help build trust stakeholder include group publish information work patient group europe asia pacific emerge market region information support patient group work globally include detail funding receive detail fund patient organisation pharmaceutical company publish level information go majority industry code practice require list group fund require nonprofit organisation seek gsk fund consider disclose gsk support voluntarily disclose funding support website update information quarterly ensure support compliance applicable law regulation include guideline standard set american medical association ama food drug administration ama pharmaceutical manufacturers america phrma code lead medical organisation detail information gsk australia canada find website corporate responsibility report home public policy patient advocacy patientadvocacy understand patient understand patient help well understand patient need set advisory board europe include representative wide range patient group advisory board independent chair meet regularly attend senior gsk manager board enable voice patient hear high level gsk allow access view patient group seek feedback subject clinical trial pharmacogenetic information provide patient ethical issue invite speaker patient group meet gsk employee include scientist researcher marketer discuss issue affect member improve understand patient need show gsk employee difference work people life read focus patient initiative help well understand patient need develop well medicine engage patient group patient advocacy leader summit pal bring patient advocate discuss health policy concern develop new skill andor way expand influence pal patient advocate opportunity learn gsk tell company well support work involve run total summit european country japan include national pal north carolina regional pal colorado michigan new england texas discussion pal meeting europe japan focus improve quality care netherlands clinical trial crossborder healthcare latvia value innovation germany clinical trial ehealth relationship patient group pharma industry switzerland provide accurate easy understand healthcare information japan discussion pal focus broad range issue include impact healthcare reform legislation health people minority group implementation patient protection affordable care act good practice mental health prevention wellness military personnel family use social medium technology reach people serve current healthcare system culturally sensitive appropriate way national pal meeting hold april focus health information technology participant state patient advocacy group discuss way technology improve access engagement empowerment speaker include president north american pharmaceuticals business lead national healthcare issue expert european patient forum gsk cosponsored european patient forum annual conference brussels healthcare company pfizer novartis amgen bring approximately patient group stakeholder europe exchange idea improve healthcare increase involvement patient organisation area health technology assessment hta hta type policy analysis examine medical economic social ethical implication value use medical technology healthcare corporate responsibility report home public policy patient advocacy patientadvocacy advocacy advocacy describe training support activity undertake partnership patient group work patient group clinical trial increasingly work patient group obtain input gsk clinical trial input patient help improve clinical trial design inform consent process enhance recruitment process include diverse population factor help support clinical trial recruitment retention collaborate patientpartner improve communication patient involve clinical trial professional run study train awareness patient group gsk introduce online training module patient group italy spain help local national patient group increase understand variety topic range access fund understand health technology assessment hta aim introduce online training country begin produce newsletter provide patient group germany useful information healthcare plan market external website inform patient advocacy community issue activity event affect involvement work party gsk member european work party aim strengthen patient voice healthcare debate genetic alliance month project examine patient family perceive balance risk benefit new medicine pharmaceutical company provide fund project gsk representative sit steer group industry perspective innovative medicine initiative joint undertaking imi unique paneuropean publicprivate partnership aim foster collaboration stake holder include large small biopharmaceutical healthcare company regulator academia patient gsk member efpia consortium associate propose education initiative aim enhance patient awareness pharmaceutical consortium member contribute educational activity help govern project eganefgcp patient roadmap treatment work party neutral paneuropean multistakeholder initiative help provide patient organisation train syllabus drug development emphasis clinical study inform patient colleague topic clinical study new treatment development include study result advise pharmaceutical industry protocol development study management experience patient clinical study improve community awareness continue work national football league team washington redskin help fan improve health raise awareness burden chronic disease programme focus collaborate local government school healthcare organisation prevent childhood obesity cardiovascular disease woman breast cancer lead team fan washington redskins quarterback health ambassador donovan mcnabb provide health message tackle chronic disease help save life low healthcare cost corporate responsibility report home work community introduction work community invest community partnership programme seek improve access medicine healthcare world aim real difference community work partner find innovative solution healthcare challenge believe business important role play society contribution community investment key element aim use resource deliver value community business support include donation time money expertise medicine investment specialist nonprofit organisation well place understand local community need target resource effectively partner support organisation goal objective reflect mission improve quality human life programme include strategic global initiative design tackle disease develop world multiple country support local programme tailor specific need challenge different market focus issue health education access medicine science education aim maximise benefit community investment select project relevant business enable use expertise resource benefit community investment strengthen business improve reputation boost employee morale help build relationship base mutual understanding range stakeholder improve access healthcare main priority community investment invest programme create opportunity education economic development support science education particularly important grow shortage science graduate market invest education help ensure longterm sustainability business commitment improve access medicine healthcare support small number art environmental initiative particularly health focus encourage employee involve benefit organisation charity support contribute employee personal development support reputation employee gsk entitle pay day year volunteer community run pulse enable highperforme employee share expertise learn ngo partner month placement want support bring longterm sustainable benefit set goal project ask partner report progress annually help community organisation plan time support finish help win funding source corporate responsibility report home work communitie global programme global programme approach develop country million people continue suffer die preventable treatable disease global health programme design improve health quality life people community provision medicine education advocacy investment disease prevention healthcare infrastructure global programme longterm commitment design scaleable replicable sustainable working partnership ngo lead health organisation believe possible achieve significant longlasting improvement healthcare section profile ambitious programme involve global alliance eliminate lymphatic filariasis partnership eliminate disfiguring debilitate tropical disease contribute world largestever drug donation focus global alliance eliminate lymphatic filariasis ambitious partnership hija village uyombo vituka morogoro region tanzania complete primary education afford attend secondary school able find work help support family change contract lymphatic filariasis debilitate disease lead severe swell limb breast genital regular attack fever walk difficult hija leave ill work new programme launch morogoro hija receive drug albendazole gsk mectizan merck administer drug donation programme eliminate tanzania take drug hijas symptom improve swell reduce suffer fever soon able walk help cultivate familys land earn money support family disease develop world hear parasitic disease transmit mosquito affect million people country community live tropical country effect devastating make hard attend school hold job result stigma discrimination sufferer prospect community improve significantly thank unique collaboration global alliance eliminate lymphatic filariasis alliance gsk partner hope completely rid world million people experience disable effect disease year launch alliance donate billion tablet albendazole hundred million people treat mass drug administration country effect far reach county include egypt togo zanzibar sri lanka dominican republic comoros pacific island complete treatment programme conduct evaluation confirm transmission eliminate area country recent research paper year programme million case prevent economic benefit equivalent billion achieve include saving health system avoidance loss income disable effect global alliance build partnership approach bring complex network ministry health lfendemic country organisation public private sector academia government body nongovernmental organisation gsk work particularly closely world health organization lead partner alliance responsible working endemic country government ensure drug deliver safely effectively mass administration programme partnership absolutely critical success landmark public health programme explain david molyneux emeritus professor liverpool school tropical medicine member alliance work overcome technical challenge exchange experience idea obtain support government endemic country secure financial support donor world gsk work different partner stage deliver drug teach lot wide barrier healthcare develop world poor physical infrastructure overstretch hospital network shortage train healthcare worker influence approach community investment give rise range programme design overcome barrier involvement global alliance mean major commitment resource manufacturing skill capacity logistic albendazole worldclass manufacturing condition dedicate line manufacture plant south africa india require team employee work day produce pack ship finish product world complex transportation arrangement require dedicated staff organise track delivery need place process oversight medical issue arise time time drug administer gsk factory manager cape town say give away drug community programme treat batch manufacture box ship professionally high standard going pay customer world commitment grow help prevent albendazole able treat intestinal worm know soiltransmitted helminth intestinal worm cause ill health schoolage child infection impede physical growth cognitive development programme additional positive impact community discussion health expert commit expand donation albendazole enable treatment schoolage children africa intestinal worm onwards new donation major impact children educational performance physical wellbee school attendance nutrition say david molyneux new commitment bring fresh challenge manufacture plant need produce significantly albendazole factory say nice problem think positive impact school education million child saving resource bring overstretch health system africa team power work scourge tackled head hija community prospect elimination real possibility effort soon join new programme relieve misery cause africas school child intestinal worm performance highlight key global programme outline information available website view programme region interactive map invest develop world healthcare infrastructure issue million people world develop country ldc lack access basic healthcare service gsk announce gsk commitment partner find solution healthcare delivery reinveste profit medicine consumer healthcare product develop country ldc local healthcare infrastructure amount base profit result date commit number project include support maternal child health sudan ethiopia democratic republic congo expand network nurserun clinic improve access essential medicine rwanda improve access water sanitation cambodia burma myanmar january announce global partnership amref save child care international build initial project aim establish regional healthcare infrastructure partnership hip profit invest goal hip strengthen health workforce ldcs focus frontline health worker rural marginalise community structure new initiative yemen niger sierra leone angola zambia mozambique bangladesh nepal cambodia prioritise implementation personal hygiene sanitation education programme phase issue year million people die diarrhoearelate disease children develop country gsk establish phase reduce diarrhoearelate disease encourage school child wash hand result phase reach million child country meeting goal reach million child highlight include fit school launch philippine combine phase campaign promote regular tooth brushing phase partner india participate global handwash day family mumbai slum receive visit school child convey importance hand washing phase uganda extend new district far help reduce school absence participate district african malaria partnership issue year million people affect malaria die subsaharan africa gsk african malaria partnership aim improve access treatment prevention malaria subsaharan africa education community training help community health volunteer diagnose case severe malaria result highlight partnership save child reduce risk malaria outbreak community affect flood northeast kenya include training help health professional improve malarial case management indoor residual spraying control malarial outbreak household school prison distribution longlaste insecticidetreate net recruiting train new community health volunteer disaster response issue natural disaster earthquake hurricane flood devastating effect community year gsk provide humanitarian assistance affect emergency natural disaster donate cash supply product humanitarian aid organisation experience respond quickly event result give help british red cross provide emergency safe water sanitation facility thousand people affect earthquake haiti give cash contribution support community affect earthquake pakistan donate medicine include dose hepatitis vaccine antibiotic analgesic dental hygiene kit support community affect earthquake chile corporate responsibility report home work community local programme local programme approach support community different country operate programme align goal support access medicine healthcare improve education design fit local circumstance culture local priority vary community community population population common challenge address improve maternal child health issue relevant developed develop country priority issue gsk help improve health mother family improve health economy community future generation focus gsk local programme aim improve maternal child health align support contribution key local programme summarise performance tab focus improve maternal child health chester county wealthy county pennsylvania assessment conduct major obstetric hospital close door note real disparity access care health outcome white woman black hispanic woman significantly poor birth outcome say pam breyer executive director maternal child health consortium work improve health family chester county maternal child health consortium threetime winner gsk impact award programme recognise local organisation measurably improve access healthcare disadvantaged group winner receive grant help continue extend programme support gsk donor able help thousand uninsured woman obtain health coverage provide proper nutrition family access mental health service support say pam breyer woman child disproportionately affect poverty lack access healthcare improve maternal child health priority share impact award winner help group knockon benefit family community contribute health wellbee future generation organisation work street sex worker impact award winner dropin centre outreach van mother baby house bristol provide practical emotional support help woman break cycle sex work substance misuse look child win award morale boost team vulnerable woman support say helen hill senior fundraising manager underfunde woman ask help award able replenish financial reserve positive medium coverage raise awareness need woman serve enhance credibility potential funder gsk commit give money increase number impact award winner benefit capacity building support management team receive leadership network fundraising skill train beneficial say helen hill capacity building like key component approach community investment help strengthen organisation support skill need operate effectively sustainably local programme help build skill capabilitie individual level example gsk support pro mujer programme northern argentina work lowincome woman access affordable financial service healthcare pro mujer provide train small loan help woman set business provide access affordable healthcare service estela carmen cuevas mother pro mujer year benefit loan time pro mujer develop business improve health say great achievement personal develop person build confidence improve maternal child health priority local community investment project current programme focus reduce number woman infant die childbirth example vietnam support training birth attendant rural village sudan fund motorcycle ambulance pregnant woman experience childbirth complication hospital work global policy level support effort reach un millennium development goal child mortality maternal health contribute development secretary general new global strategy womens children health mobilise resource private public sector commitment expand albendazole donation help tackle intestinal worm school children africa contribution strategy performance community investment programme majority country work small selection programme support breadth depth work group theme illustrate goal work community investment information available community section website view programme region interactive map investing skill build capability ensure patient develop develop country receive good care need improve skill knowledge capability people work healthcare system include professional doctor nurse people like community health worker people provide wide range service respite therapeutic treatment patient promote basic health education case study home nursing child greece issue child greece develop cancer year case attend hospital day medical care followup disrupt school attendance affect parent attendance work gsk work floga parent association parent child live cancer set homebased nursing programme greece help improve quality life child live cancer result progress speciallytraine nurse home visit improve treatment child reduce burden outpatient care public awareness advocacy campaign help secure donation company include free transportation nurse car hire firm avis example programme support wellchild support sick child family xintu centre health promotion reproductive health education programme migrant family shanghai china hole wall association medically base therapeutic camp child illness lifethreatene condition europe improve science education number young people choose study science subject fall student lack proficiency reading mathematic result country face significant skill shortage gsk longstande history support initiative promote science especially young people help improve scientific education case study opportunity scholarship issue difficult people experience adversity continue education achieve potential gsk opportunity scholarship people overcome adversity include physical sexual abuse illness personal loss pursue education mean change life scholarship available north carolina philadelphia provide financial support help people continue education result progress gsk award scholarship total recipient overcome adversity seek degree public health nursing engineering criminal justice business example programme support scientist sport inspire young people science runup london olympic games science summer free education programme design young people pittsburgh pennsylvania great philadelphia north carolina interested science read education programme invest healthcare infrastructure improve access medicine gsk invest programme build support healthcare infrastructure strive catalyst change actively seek new way deliver healthcare world challenging environment case study improve access vaccine mumbai issue third million people mumbai live slum health indicator adult child low immunisation coverage poor gsk work path ngo community group partner improve vaccine coverage people live mumbai slum month project work exist health system develop sustainable model delivery immunisation replicate area project result carefully evaluate help identify key factor improve immunisation programme poor urban environment result progress programme approve endorse local government implementation january number health post public health service delivery unit increase recruitment training programme manager field coordinator run project complete initiate baseline evaluation assess current healthcare provision immunisation practice example programme support pittsburgh mercy foundation operation safety net support healthcare outreach homeless travel pack provide essential medicine overthecounter product physician assist world poor people sabongiddaora vaccine project year peerreviewe project raise childhood immunisation nigeria provide vaccination service basic health education clinical care corporate responsibility report home work community community investment community investment global community investment million million compare million million value donation cost average cost good wholesale acquisition cost wac measure company accurate reflection true cost gsk belong uks london benchmarking group lbg committee encourage corporate philanthropy cecp lbg guideline report product donation cost cecp guideline report product donation market value benchmarking purpose report wac value donation total value give wac product million million compare million million give high expansion product donation patient assistance program albendazole lymphatic filariasis donation vaccine plus increase cash grant hiv aids reinvestment initiative develop country product donation figure million main programme value average cost good patient assistance program support lowincome patient total million humanitarian product donation total million donation albendazole tablet lymphatic filariasis elimination programme totalling million product donation figure include additional cost donate million dose vaccine pandemic flu world health organization use develop country read position statement product donation method give million breakdown cash give grant publish datum charitable grant patient group europe emerge market asia pacific business region charitable grant find grant retain communitymark ongoing work local national level large international programme company achieve mark outstanding investment community follow independent assessment communitymark company award threeyear period monitor ensure continue commitment excellence mark found business community endorse government voluntary sector leader employee involvement volunteer initiative launch gsk employee pay day year volunteer good cause continue employee support wide range charity project include work local school shelter homeless community garden nursing home aid community affect natural disaster gsk pulse volunteer partnership launch enable gsk employee difference community world pulse volunteer work fulltime partner nonprofit nongovernmental organisation ngo professional skill knowledge facilitate positive sustainable change organisation community serve experience volunteer address clear ngo need develop leadership capability pulse volunteer work country ngos pulse volunteer continue receive gsk salary month pulse assignment figure operating cost manage pulse programme represent total inkind donation million information volunteer available community section website corporate responsibility report home work community plan target plan target continue focus programme help increase access healthcare education plan include expand donation albendazole treat schoolage children africa soiltransmitte helminth intestinal worm addition annual commitment supply million tablet use global programme eliminate lymphatic filariasis launch global partnership amref save child care international improve healthcare infrastructure develop country ldc commitment reinvest profit ldcs medicine consumer healthcare product train community healthcare worker help build capacity local healthcare system expand personal hygiene sanitation education programme include oral healthcare handwash roll new programme gsk partnership olympic paralympic game include scientist sport education outreach programme inspire young people science work partnership lead university continue investment science technology engineering mathematic stem education program help ensure future workforce necessary qualification skill